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ABSTRACT 
The effects of high-dose anticancer chemotherapy (CT), total body irradiation (TBI), and age 
at SCT were studied in relation to tooth agenesis, microdontia, and root-crown (R/C) ratios of 
permanent teeth in 56 stem cell transplant (SCT) recipients. Developing a simple method to 
describe in one figure the overall quantity of the developmental dental disturbances studied 
was another objective. The study patients were children and adolescents transplanted at the 
mean age of 4.3 (range 1-9.4) years mainly because of a malignant disease and followed up 
for a mean period of 7.3 (range 1-20.6) years after SCT.  
 Developmental dental defects were assessed from panoramic radiographs. Agenesis was 
not confirmed before the age of 5 years in the first premolars, 6 years in the second premolars 
and molars, and 12 years in the third molars. Teeth were considered microdontic if the 
mesiodistal crown size was about half or less than half the expected crown size. The method 
to assess R/C ratios was developed, and its reproducibility was determined in a healthy 
population. R/C ratios of the SCT recipients were compared to the reference values obtained 
from the healthy population, by calculating standard deviation scores (SDSs). Dental variables 
were studied in reference to TBI and age at SCT. Finally, a one-figure defect score was 
calculated for each subject by a novel Individual Defect Index (IDeI) developed during this 
work. 
 Prevalence of tooth agenesis in the SCT recipients was 31% (66% with third molars 
included). Young age at SCT was a stronger risk factor for tooth agenesis than was TBI. The 
risk for tooth agenesis was especially high in children ≤ 2 years at SCT, but very rare 
(excluding third molars) after age 3.5. After TBI, the number of missing teeth was higher, the 
maximum number being 11 (third molars excluded). Prevalence of microdontia was 44% in 
the SCT recipients, with at most 12 teeth affected. Risk for microdontia was minimal if the 
anticancer CT was initiated after the age of 4 years (excluding third molars). TBI had no 
significant effect on microdontia. Some disturbances in R/C ratios occurred in all SCT 
patients and in 77% of teeth. Root growth was most severely affected at the SCT age of 3.0 to 
5.5 years, especially following TBI. When the defect points were added together with the IDeI 
(third molars excluded), the highest scores occurred in patients who were 2.0 to 4.5 years at 
SCT. TBI patients had higher mean IDeI scores, demonstrating worse tooth development 
compared to that of non-TBI patients.  
 In conclusion, in SCT recipients, the effects of high-dose anticancer CT and TBI on 
developing teeth were marked, since all patients and most teeth were affected. Young age (< 5 
years) at SCT was a risk factor for high defect scores, when tooth agenesis, microdontia, and 
deficient root development were added together. High-dose anticancer CT alone caused 
considerable damage to developing teeth, but with TBI, its amount and severity increased. 
The clinical implications of these dental aberrations in long-term follow-up at the moment 
remain unknown. Dentists should be aware of the possible adverse dental effects of anticancer 
therapy and consider their implications for treatment planning. 
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INTRODUCTION  
Numerous signal molecules that mediate communication between cells and tissues and 
determine the identity, size, and shape of teeth regulate tooth development from the oral 
ectoderm and the neural crest-derived ectomesenchyme (reviewed by Thesleff and Mikkola, 
2002). Environmental factors may modify tooth development that is basically under strict 
genetic control (Grahnen, 1956; reviewed by Pindborg, 1982; reviewed by Thesleff, 2000; 
Alaluusua et al., 2004). In many organs, clinical consequences of short-lasting environmental 
disturbances may not appear later, but teeth have an extraordinary feature: They do not 
remodel. Therefore, developmental defects of teeth are permanent, which makes them good 
target organs in study of the impact of past events on development. 
 Cancer in children is an uncommon disease, and the likelihood of being diagnosed with 
cancer before adulthood is about 1:300 for males and 1:333 for females (Ries et al., 1999). 
The numbers of long-term survivors have increased; nearly 80% of children with cancer can 
be cured, since today extensive supportive care allows for very intensive anticancer treatment 
protocols. At the same time, the late effects of childhood cancer and its treatment are 
becoming more common and better known (Dreyer et al., 2002). Both radiotherapy (RT) and 
anticancer chemotherapy (CT) have unwanted side effects, and if injury occurs in tissues with 
a low repair potential or with no remodeling potential at alllike mineralized areas of teeth
permanent damage is possible. 
 The effects of RT on teeth have been noticed long ago in animals (reviewed by 
Kimeldorf et al., 1963), and in children (Bruce and Stafne, 1950). Childhood anticancer 
therapy consisting of RT alone or combined with CT, but also CT alone, has disturbed tooth 
development (Jaffe et al., 1984). Since then, several studies have confirmed these findings 
(Section 5.2.). With the developing treatment regimens, new studies are necessary to verify 
their adverse sequelae. Transplantation of hematologic stem cells (SCT) has become an 
established mode of treatment also in children, but only a few studies report on the tooth 
development of the SCT recipients (Dahllöf et al., 1988; Näsman et al., 1994, 1997a; Uderzo 
et al., 1997).  
 The purpose of the present work was to study tooth agenesis, microdontia, and root-
crown (R/C) ratios of permanent teeth in SCT transplant recipients. Other aims were to 
develop a more objective methodology and to find a means to express the total sum of 
selected developmental dental disturbances with one figure. 
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REVIEW OF THE LITERATURE 
1. Tooth development 
1.1. Formation of the tooth crown 
Human dentition comprises two sets of teeth: 20 deciduous (primary) and 32 permanent 
(secondary) teeth. Four types of teeth, tooth families, form in the permanent dentition: eight 
incisors, four canines, eight premolars, and twelve molars. At the fusion of facial processes, 
epithelium of the first branchial arch and frontonasal process forms a continuous, primary 
epithelial band at the site of the future dental arches. Soon after this, it gives rise to the U-
shaped dental lamina. Teeth develop from this oral epithelium (ectoderm), and from the 
underlying mesenchyme, populated by the ectomesenchymal cells having their origin in the 
cranial neural crest. Along the dental lamina, at the sites of individual teeth, condensation of 
the mesenchymal cells occurs around the dental placode, which directs the budding of the 
epithelium to the underlying mesenchyme. In tooth development this is known as the bud 
stage (Figure 1) (Ten Cate, 1998; reviewed by Pispa and Thesleff, 2003).  
 At the transition from bud to cap stage, the inductive potential of the mesenchyme 
brings about a new gathering of nonproliferative cells at the tip of the epithelial bud, forming 
the so-called primary enamel knot (Jernvall et al., 1994; reviewed by Jernvall and Thesleff, 
2000). The enamel knot is a signaling center, believed to be involved in the regulation of 
tooth shape (reviewed by Thesleff and Nieminen, 1996; reviewed by Thesleff et al., 2001; 
reviewed by Pispa and Thesleff, 2003). This cap stage tooth germ consists of an enamel organ 
(also called dental organ) dental papilla and dental follicle (Figure 1). Later on, the cells of 
the enamel organ are to form the enamel of the tooth. The enamel organ consists of the inner 
and outer enamel epithelia (and stellate reticulum within the enamel organ), which meet at the 
rim of the enamel organ, forming the area known as a cervical loop. The condensed 
mesenchyme adjacent to the dental organ, the dental papilla, is the origin of dentin and dental 
pulp. The dense mesenchymal tissue surrounding the dental organ and the dental papilla, 
called the dental follicle, gives rise to the supporting tissues of the tooth (periodontium) (Ten 
Cate, 1998).  
 In the bell stage tooth germ, epithelial secondary enamel knots appear in the molars, at 
the sites of the future cusps. They express numerous signals guiding the crown shape. The 
enamel knots probably also guide the differentiation of the dental papilla cells, next to the 
inner enamel epithelium, into odontoblasts, starting from the cusp tips (Ten Cate, 1998; 
reviewed by Thesleff et al., 2001). Following the deposition of the organic dentin matrix by 
odontoblasts, ameloblast differentiation and enamel matrix secretion takes place at the 
interface of the epithelial and mesenchymal tissues. Mineralization of the dentine and enamel 
matrices follows almost immediately. The beginning of hard tissue formation fixes the final 
shape of the tooth crown (Ten Cate, 1998; Thesleff, 2003) (Figure 1).  
 Initiation of the permanent dentition is timed at the early bell stage. A new bud folds 
from the dental lamina towards the mesenchyme, lingual from the primary tooth bud. 
Permanent molars that have no primary predecessors develop from the distal extension of the 
dental lamina in the same way as do the deciduous teeth (Ten Cate, 1998). 
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Figure 1. Schematic illustration of the main stages of tooth development. Oral epithelium (ecto
forms a thickened epithelial band, dental lamina. Budding of this epithelium towards the under
cranial neural crest-derived ectomesenchyme starts at the sites of future primary teeth. Morphoge
proceeds through the bud and cap stages to the bell stage where differentiation of odonto
(mesenchymal) and ameloblasts (epithelial) takes place. Secretion of the dentin and enamel ma
begins, followed by mineralization that fixes crown form and size. Hertwigs epithelial root s
directs root development and induces cementoblast differentiation. Cementum (not shown) cove
roots of the teeth.  
 
1.2. Formation of the tooth root  
After the crown formation has been completed, a double-layered structure, Hert
epithelial root sheath (HERS), is formed as the cells of the inner and outer enamel epit
start to proliferate apically at the cervical loop area. It directs root morphogenesis, inclu
the size, shape and number of roots, and separates the cells of the pulpal ectomesench
(dental papilla) and the follicular ectomesenchyme (dental follicle) (reviewed by Ten 
1996; reviewed by Cho and Garant, 2000; Yamashiro et al., 2003). The inner layer of H
seems to induce the differentiation of odontoblasts from the mesenchymal cells and
formation of the first root dentin layer that is later covered with cementum (Thomas
Kollar, 1989; reviewed by Hammarström et al., 1996; reviewed by Cho and Garant, 2
After the first radicular mantle dentin is deposited, HERS disintegrates, leaving epith
rests of Malassez in the area of the future periodontal ligament (dental follicle). Se
proposals exist as to cementoblast origin. The traditional belief was that follo
disintegration of HERS, the mesenchymal cells of the dental follicle come into contact
the root surface and differentiate into cementoblasts. Today, the role of HERS and the o
of the cementoblasts seem more complicated. For instance, HERS may possibly secrete o
root surface polypeptides, related to enamel proteins, which may be required in the form
of the acellular cementum covering the cervical two-thirds of the root surface (reviewe
Hammarström et al., 1996; reviewed by Ten Cate, 1996; reviewed by Cho and Garant, 2
Furthermore, some evidence indicates that those cementoblasts forming acellular ceme
may derive from HERS, and those forming cellular cementum and reparative cementum
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derive from the neural crest-derived cells (Lezot et al., 2000; Zeichner-David et al., 2003). In 
general, the formation mechanisms of cellular cementum in the apical third of the root are 
unclear (reviewed by Hammarström et al., 1996). 
 
1.3. Regulation of tooth development 
Epithelial-mesenchymal interactions are mediated by numerous simultaneous and repeatedly 
utilized signal substances or growth factors, and these signaling networks are regulated by 
genes that determine the location, type, size, and shape of a tooth. Signals may be inductive or 
inhibitory. Messages can be mediated through receptor molecules at the cell membrane: 
Ligands of the signaling cells bind to specific receptors, activating the intracellular cascade 
leading to the regulation of the target genes via transcription factors. Due to the sequential 
nature of molecular signaling, an activated gene has the ability to activate the next target gene 
(reviewed by Thesleff and Nieminen, 1996; reviewed by Thesleff, 2000; reviewed by Thesleff 
and Mikkola, 2002). 
 Signals and growth factors fall into several families, four of which have been the most 
intensively studied: the transforming growth factor β (TGFβ) including bone morphogenetic 
proteins (BMPs), the fibroblast growth factors (FGFs), the Sonic hedgehog (Shh), and the 
Wnt families. More recently, two members of the tumor necrosis factor (TNF) family have 
been linked to tooth development, along with some other growth factors (reviewed by 
Thesleff and Mikkola, 2002). Early signals in oral ectoderm, belonging to the BMP and FGF 
families, shift the odontogenic potential from the epithelium to the mesenchyme, where it 
thereafter remains. It is noteworthy that these signals are shared not only between organs but 
also between species; i.e., they have been conserved for a long time in evolution, and results 
of tooth development studies conducted on animals are considered highly relevant also in 
humans (reviewed by Thesleff, 2000). Sequential and reciprocal signaling events during tooth 
morphogenesis are schematically presented in Figure 2. A detailed list of the molecules 
known to act during the stages of tooth development is presented by the Tooth and 
Craniofacial Development Group of the Developmental Biology Program, Institute of 
Biotechnology, University of Helsinki, Finland (Gene expression in tooth, http://bite-
it.helsinki.fi).  
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Figure 2. Schematic presentation of sequential and reciprocal signaling events during tooth 
morphogenesis. Growth factors and signals (upper case in boxes) and their target genes (italics in 
small boxes) expressed in epithelial (yellow) and mesenchymal (blue) tissues mediate cellular 
communication between or within epithelium and mesenchyme (arrows) in a developing tooth germ. 
In epithelium, signals are expressed in signaling centers (dental placode and primary and secondary 
enamel knots; in red). Knockout of several genes in mice (below diagrams) results in the arrest of 
tooth morphogenesis at the initiation or bud stages. (By courtesy of Irma Thesleff and Thomas Åberg.)  
 
1.4. Chronology of development of permanent teeth 
Initiation of permanent dentition occurs between the 20th week of fetal life (permanent central 
incisors and first molars) and the first year of life (permanent second molars). Initiation of the 
third molars occurs in the fifth year (reviewed by Ten Cate, 1996). The timing of onset and 
the sequence of mineralization in permanent teeth have been controversial subjects. Early 
reports were reviewed and sternly criticized by Logan and Kronfeld (1933), who wrote: Still 
more surprising, to our minds, is the fact that the old table of Legros and Magitot,1 according 
to which all permanent teeth from central incisor to first molar begin to calcify at the same 
time, was copied over and over again, and apparently no one found it worth while to see 
whether the statements contained in the table were correct before commending it to dental 
students and to the profession. Their own histologic study of tooth development was based 
on 25 human jaws ranging in age from birth to 15 years (Logan and Kronfeldt, 1933). The 
schedule they constructed was slightly modified by Schour and Massler, and it constitutes the 
basis for todays concept (Figure 3) (Schour and Massler, 1940).  
 In histologic studies, calcification of the permanent first molars has been reported to 
start around 32 weeks of fetal life (Ten Cate, 1998), at birth (Schour and Massler, 1940), or 
one month after birth (Logan and Kronfeldt, 1933). In radiographs, the earliest calcification 
could be seen only at the age of 6 months (Hess et al., 1932). Assessed from 1162 panoramic 
                                                 
1 According to Logan and Kronfeld, the table of Legros and Magitot stated that all permanent teeth appear one 
month after birth. The table was introduced in 1893 as Chronologie des follicles dentaires chez lhomme, 
Congrès de Lyon. 
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radiographs (PRGs) of Finnish children, crowns of the permanent teeth were completed 
between 3 and 7 years (third molar crowns at 13-14 years) (Haavikko, 1970). From this stage 
forward, it still took a minimum of 5 to 6 years and a maximum of 8 to 9 years before the 
roots had reached their full length and apices had closed. At the age of 15 to 16 years, the 
permanent dentition was fully developed, except for the third molars that matured only at 
about 20 years. Dispersion between individuals was wide, especially for the third molars. 
Tooth development in girls was, on average, 0.6 years ahead of the boys. A slight difference 
of 0.2 years occurred between the maxillary and mandibular teeth, the latter being earlier 
(Haavikko, 1970).  
 
 
Figure 3. Chronology of mineralization of permanent teeth (Koch and Thesleff, 2001). (Reprinted 
with permission from the Rights Department of Blackwell Publishing.)  
 
 
2. Disturbances in tooth development  
2.1. Etiology 
Disturbances in tooth development may involve the number, size, and shape of teeth but also 
aberrations in the matrix formation and mineralization of enamel or dentin or both. The 
etiology of disturbed tooth development can be genetic or acquired (environmental).  
 
2.1.1. Genetic factors—from mice and men  
Developmental disturbances of the teeth may be one clinical feature in several syndromes, 
such as Downs (Gorlin et al., 2001), Rieger (Semina et al., 1996), Kabuki (Matsune et al., 
2001), and Wolf-Hirschhorn syndromes (Nieminen et al., 2003), and recessive incisor 
hypodontia (Pirinen et al., 2001), to mention a few. The OMIM database (Online Mendelian 
Inheritance in Man, OMIM; TM) lists about 60 syndromes associated with hypodontia. 
Genetically determined dental defects also involve such conditions as amelogenesis 
imperfecta, dentinogenesis imperfecta, and dentin dysplasias not to be discussed further here. 
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 Mutations in many different genes are able to halt the development of all or some teeth 
(or other organs) or just disturb it (Figure 2). The same gene defects that are recognized in 
mice are often responsible also for aberrations in humans. The first gene shown to be essential 
in tooth development was Msx1: In homozygotic mice, no incisors were detectable, and the 
development of the first and second molars was arrested at the bud stage (Satokata and Maas, 
1994). Soon, mutations of the human MSX1 gene were found to cause oligodontia (absence of 
> 6 teeth) (Vastardis et al., 1996; van den Boogaard et al., 2000; Jumlongras et al., 2001). 
Teeth of the pax9 homozygous null mice failed to develop beyond the bud stage (Peters et al., 
1998), and families with PAX9 mutations presented with molars missing along with some 
other teeth (Stockton et al., 2000; Nieminen et al., 2001; Lammi et al., 2003). Moreover, 
corresponding gene defects of mice (Tabby, downless, and crinkled) and men (EDA, EDAR, 
and EDARADD, respectively) are known in several ectodermal dysplasias that primarily 
involve ectodermal organs such as teeth, hair, nails, and salivary and sweat glands. Their 
disturbances result in both missing teeth and alterations in tooth size and shape (reviewed by 
Mikkola and Thesleff, 2003; reviewed by Pispa and Thesleff, 2003; Pispa et al., 2004; Tucker 
et al., 2004).  
 
2.1.2. Environmental factors (“acquired disturbances”) 
Developmental dental disturbances may result from trauma, nutritional deficiencies, some 
diseases, drugs, environmental pollutants, and other factors. The etiology of many dental 
aberrations remains idiopathic, however. Treatment of cancer in childhood, both irradiation 
and anticancer chemotherapy, may compromise future tooth development. This topic is 
covered in Section 5.2.  
 Local tooth injuries, directed either to primary or permanent teeth, may disturb tooth 
development or destroy the tooth. Accidental removal of a permanent tooth germ may occur 
during primary tooth extraction. Following traumas to primary teeth (especially intrusion and 
exarticulation in patients < 5 years at the time of injury), alterations from minor enamel 
defects to severe distortion, may be seen in about 50 to 95% of their permanent successors 
(Andreasen and Ravn, 1971; Ravn, 1975). Injury of a permanent tooth may arrest its 
development or result in tooth loss due to inflammatory resorption. However, although up to 
30% of 12-year-old children have suffered dental injuries, severe developmental 
consequences are rare (Andreasen and Ravn, 1971; Andreasen et al., 1999).  
 Many systemic causes may affect tooth development. For instance, in patients who have 
suffered from rickets in early childhood, the cusp tips of permanent first molars and incisal 
edges of incisors are typically misshapen. Other diseases affecting calcium-phosphate 
metabolism, such as kidney and liver dysfunction, may have dental consequences that are 
mostly characterized by hypoplastic and/or hypomineralized enamel and/or discoloration of 
teeth (reviewed by Pindborg, 1982; Funakoshi et al., 1992; Nunn et al., 2000; Wondimu et al., 
2001). Congenital heart disease, severe malnutrition, gastrointestinal disorders including 
celiac disease, otitis media, high fever, pneumonia, infections of the upper respiratory tract, 
and asthma, among others, are possible etiological factors for hypomineralization 
disturbances of enamel (reviewed by Pindborg, 1982; Aine, 1986; Jälevik et al., 2001; 
Beentjes et al., 2002). No increased prevalence of hypodontia or microdontia has been 
reported in these conditions.  
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 Dioxins, environmental pollutants such as polychlorinated dibenzo-p-dioxines 
(PCDDs), polychlorinated dibenzofurans (PCDFs), and polychlorinated biphenyls (PCBs) 
have shown developmental toxicity, especially in those organs whose formation is dependent 
on epithelial-mesenchymal interactions. The most toxic man-made chemical, 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) is known to have several adverse effects on 
organogenesis, including that of teeth. Following environmental accidents in Taiwan and 
Japan, children born to mothers exposed to PCDFs/PCBs showed (among other defects) an 
increased number of natal teeth and poor tooth mineralization (Yamashita and Hayashi, 1985; 
Rogan et al., 1988). After the Seveso accident in Italy, developmental defects in teeth 
increased and the prevalence of missing permanent teeth was higher in children with heavy 
TCDD exposure than in those with low exposure (Alaluusua et al., 2004). Even at the 
prevailing levels of PCDFs/PCBs, hypomineralization (demarcated enamel defects) in the 
permanent first molars have increased in children exposed to dioxins via mothers milk, 
especially following prolonged breast-feeding (Alaluusua et al., 1996; Alaluusua et al., 1999). 
 Dioxin toxicity to teeth throughout their development has been well elucidated in 
rodents and in studies on cultured embryonic mouse teeth. In addition to the dose of dioxin, 
the stage of tooth development determines the clinical outcome. Following exposure of 
pregnant dams to TCDD, early exposure between the initiation and early bud stages of the 
pups third molars leads to frequent agenesis of these teeth (Miettinen et al., 2002). Higher 
doses may halt third molar development somewhat laterat the late bud stage (Lukinmaa et 
al., 2001). It has been concluded that the target tissue of TCDD is the presumptive dental 
epithelium that governs tooth development during the early stages. Thereafter, dental 
mesenchyme directs tooth development, and the first and second molars, developed beyond 
the bud stage at the time of the TCDD exposure, were present. However, their mesiodistal 
size was reduced; the earlier was the exposure, the greater the reduction (Miettinen et al., 
2002). The reduction in pups tooth size was also dose-dependent (Kattainen et al., 2001). 
 When lactating dams were exposed to high doses of TCDD one day after delivery, some 
of the pups third molars were missing and development was retarded in the ones present; root 
formation was also arrested in more advanced first and second molars, and apices were 
prematurely closed (Lukinmaa et al., 2001). In vitro studies showed that a very high TCCD 
concentration also affected the bell-stage first molars, where cusp morphology was disturbed. 
In the cap stage second molars, morphogenesis was totally inhibited or severely disturbed 
(Partanen et al., 1998). Furthermore, TCDD arrested tooth development in vitro when 
exposure began at the initiation stage, whereas later exposure reduced tooth size and disturbed 
cusp morphology. The mode of TCDD action was to induce early apoptosis in the cells of the 
dental epithelium, which would normally undergo apoptosis later (Partanen et al., 2004). In a 
recent study, pregnant rhesus monkeys received TCDD starting on day 20 of gestation and 
continued until day 90 after delivery. Of the offspring exposed to the highest dose of TCDD 
in utero and via milk most (10 of 17) presented with precocious eruption of primary teeth, or 
with missing or misshapen permanent teeth (Yasuda et al., 2005). Some dental adverse effects 
following TCDD exposure closely resemble the dental aberrations that are clinically and 
radiographically seen after childhood anticancer therapy. 
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2.2. Agenesis of permanent teeth 
2.2.1. Terminology and diagnosis 
The term tooth agenesis refers to the endpoint, a missing tooth, not taking into account the 
timing of the developmental disturbance or the underlying reason, which can be genetic or 
environmental. The commonly used term “congenitally missing teeth” has been called a 
misnomer, since permanent teeth are not present in the mouth at birth. This term also usually 
refers to genetic tooth agenesis and rules out environmental insults that may result in tooth 
agenesis after birth, following a normal start of tooth development. Hypodontia, perhaps the 
most widely used term, is used when 1 to 6 teeth (third molars excluded) are missing. 
Occasionally hypodontia is classified as mild (1 or 2 missing teeth), moderate (3 to 5 missing 
teeth), or severe (6 or more missing teeth) (Brook et al., 2002). Oligodontia mostly refers to 
situations with more than 6 teeth missing (third molars excluded), although the definition 6 
or more missing teeth also exists (Schalk-van der Weide et al., 1992). Anodontia means the 
complete absence of teeth. This literature review prefers the term originally used in the 
papers. Hypodontia and oligodontia have often been classified as isolated (nonsyndromic) or 
syndromic. The former shows no other aberrant developmental features, but in the latter, tooth 
agenesis is only one finding associated with syndromes. Syndromic hypodontia or oligodontia 
are not further discussed here.  
 The schedule of tooth development and variation between individuals must be 
considered before tooth agenesis is assessed. Although calcification usually begins at the age 
of 2 to 3 years in premolars and permanent second molars (Logan and Kronfeldt, 1933; 
Schour and Massler, 1940), mineralization of the second premolars in particular may show 
late onset. Agenesis should thus not be diagnosed before the age of 6 years in the permanent 
dentition, if third molars are excluded. Calcification of the third molars begins at a median age 
of 8 to 10 years but their very late appearance (14 to 18 years) is possible every now and then 
(Haavikko, 1970; Pirinen and Thesleff, 1995). 
 
2.2.2. Etiology and prevalence of isolated tooth agenesis 
Although environmental factors during tooth development may result in tooth agenesis, in the 
majority of cases the etiology of isolated permanent tooth agenesis is genetic. The best-known 
environmental factors are probably anticancer CT and irradiation, discussed in Section 5.2.1. 
Isolated tooth agenesis has also occurred in a group of people heavily exposed to dioxins due 
to an environmental accident (Alaluusua et al., 2004) (Section 2.1.2.).  
 A genetic basis for tooth agenesis has emerged from family studies and, more recently, 
from identification of genes involved. In the majority of cases, the mode of inheritance seems 
to be autosomal dominant (AD), with incomplete penetrance and variable expressivity. A 
significantly higher frequency of hypodontia appeared in the parents (41%) and siblings 
(26%) of the hypodontic patients than in the general population (6%) (Grahnen, 1956), and 
the AD inheritance pattern was observed in families regarding the frequency of missing (or 
peg-shaped) upper lateral incisors (Alvesalo and Portin, 1969). Detection of the two mutated 
genes MSX1 and PAX9 has offered direct evidence of AD tooth agenesis (Vastardis et al., 
1996; Stockton et al., 2000; Nieminen et al., 2001). Furthermore, autosomal recessive 
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(Ahmad et al., 1998), X-linked (Huskins, 1930), and polygenic inheritance models (Suarez 
and Spence, 1974; Chosack et al., 1975), as well as multifactorial models linking genetic and 
environmental factors (Brook, 1984; Brook et al., 2002), have been suggested.  
 Hypodontia prevalence ranges from the 0.3% reported for children in Jerusalem 
(Rosenzweig and Garbarski, 1965), to the 36.5% for a North American religious and genetic 
isolate, the Dariusleut Hutterites of Western Canada (Mahaney et al., 1990). In a recent meta-
analysis of prevalence of tooth agenesis in Caucasian populations in Europe, North America, 
and Australia, rates differed by continent and gender. With third molars excluded, the highest 
prevalence of 6.3% (7.6% for females, 5.5% for males) was found in Australia, followed by 
5.5% (6.3%, 4.6%) in Europe, and 3.9% (4.6%, 3.2%) in North America. The risk ratio for 
tooth agenesis in females, derived from all the studies included in the meta-analysis, was 1.37 
of that of males (Polder et al., 2004). In Finland, hypodontia prevalence, excluding third 
molars, was 8% (9.5% in females, 6.5% in males). Third molar agenesis in the same Finnish 
sample was 21% (Haavikko, 1971), in accordance with the 20 to 30% reported elsewhere 
(Grahnen, 1956; Lavelle et al., 1970; Lynham, 1990).  
 
2.2.3. Characteristics of isolated tooth agenesis 
According to a meta-analysis of 24 studies involving about 112 000 individuals, the most 
commonly missing tooth (excluding the third molar) was the mandibular second premolar, 
representing 41% of the missing teeth (Polder et al., 2004), almost the same (42%) as in the 
Finnish study (Haavikko, 1971). In that meta-analysis, maxillary lateral incisors and maxillary 
second premolars occupied the second and third places, but in a Finnish sample the sequence 
was reversed. Overall agenesis did not differ significantly between maxilla and mandible. 
More details are presented in Table 1. 
 Among those with hypodontia, agenesis of one tooth was the most frequent 
phenomenon both in the meta-analysis (48%) (Polder et al., 2004) and in the Finnish sample 
(55%) (Haavikko, 1971), with two teeth missing in 35% and 33% of the affected patients, 
respectively. Oligodontia, in the meta-analysis defined as agenesis of six or more teeth, 
appeared in 2.6% of the affected patients, but overall prevalence was only 0.14%. Unilateral 
tooth agenesis slightly exceeded bilateral occurrence (Polder et al., 2004). The maximum 
number of missing teeth was 6 in the Finnish study, involving 2.4% of the affected patients 
(overall prevalence 0.19%). Contrary to the meta-analysis findings, bilateral tooth agenesis 
was more frequent (55%) than were unilaterally missing teeth (36%). The rest of the patients 
had combined bi- and unilateral tooth agenesis, for instance, bilateral in the maxilla and 
unilateral in the mandible (Haavikko, 1971). 
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Table 1. Distribution of tooth agenesis according to the meta-analysis of 24 studies (Polder et al., 2004) and a 
Finnish sample (Haavikko, 1971). 
Maxilla Mandible 
Percentage of missing teeth Percentage of missing teeth 
Tooth 
Polder et al. Haavikko Polder et al. Haavikko 
I1 0.2 0 3.5 2.7 
I2 22.9 18.7 2.5 1.4 
C 1.3 0 0.3 0.7 
P1 2.8 3.5 1.4 0 
P2 21.2 29.2 41.0 42.4 
M1 0.7 0 0.3 0 
M2 0.6 0.7 1.2 0.7 
Total 49.7 52.1 50.3 47.9 
 
I1: central incisor; I2: lateral incisor; C: canine; P1: first premolar; P2: 
second premolar; M1: first molar; M2: second molar 
 
2.3. Reduced size and microdontia of permanent teeth 
2.3.1. Terminology and diagnosis 
The term microdontia describes reduced size of teeth, but no unequivocal definition for 
microdontia exists. At least one of the reasons is that in healthy populations tooth size varies 
between ethnic groups and sexes (Lavelle, 1972), and normal tooth size is difficult to 
determine. In practice, microdontia seems to refer mostly to a tooth of a size small enough to 
be obvious without measurements; diagnoses have been based on subjective clinical decisions 
(Dahllöf et al., 1988; Näsman et al., 1994, 1997a; Tsai and King, 1998). Reduced tooth size 
(mostly meaning reduced crown size) is a term frequently used when size reduction is not so 
obvious, and results are based on crown measurements from dental casts. Tooth size can be 
considered small if more than 2 SD below the average for a corresponding population (Koch 
and Thesleff, 2001). A 3.5 SD limit has also been used to separate small teeth from normal 
ones (Ooshima et al., 1996). One view is that a size discrepancy greater than 1 mm from the 
norm can easily be detected by the naked eye; consequently, this limit has also proven useful 
(Tsai and King, 1998).  
 
2.3.2. Etiology of the reduced permanent tooth size and microdontia 
Tooth sizelike agenesisis under genetic control that may be modified by environmental 
factors. Although microdontia associated with syndromes is not further discussed here, the 
fact that it reflects the genetic background involved in most of the cases is worth mentioning. 
Estimates of heritability for tooth crown size in non-syndromic patients have ranged around 
60% (Alvesalo and Tigerstedt, 1974; Townsend and Brown, 1978), and even higher (up to 
82%) in twins (Townsend et al., 2003). Heritability estimates of more than 80% for several 
crown measurements were reported in another twin study (Dempsey and Townsend, 2001). 
Reduced tooth size or microdontia is often considered a dental anomaly associated with 
hypodontia and, as such, suggested to be the differing expressions of one autosomal dominant 
gene causing agenesis (Grahnen, 1956; Alvesalo and Portin, 1969), with penetrance of 72% 
(Alvesalo and Portin, 1969). Interestingly, although agenesis and peg-shaped upper lateral 
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incisors seem to be different expressions of the same gene, other factors may cause strongly 
mesiodistally reduced teeth (Alvesalo and Portin, 1969). In support of the genetic etiology, 
reduced mesio-distal tooth crown dimensions have occurred in hypodontia and oligodontia 
patients and their relatives (Lysell, 1953; Lavelle et al., 1970; Brook, 1984; Schalk-van der 
Weide and Bosman, 1996; Brook et al., 2002). Moreover, the more severe the hypodontia, the 
smaller the teeth formed (Garn and Lewis, 1970; Schalk-van der Weide and Bosman, 1996; 
Brook et al., 2002). Brook proposed a model of a multifactorial continuum of tooth size 
reduction and tooth agenesis: The size of a tooth diminishes until below a certain threshold it 
no longer forms, resulting in agenesis (Brook, 1984). However, this idea is much older: 
Grüneberg noticed the association between missing third molars and reduced size of 
remaining molars in mice, speculating that the smaller the available piece of dental lamina, 
the less likely it is to form a tooth (Grüneberg, 1951).  
 Environmental factors are involved in determination of tooth size. In addition to 
genetics, a twin study emphasized also the substantial influence of environment on tooth 
crown size of up to 29% (Dempsey and Townsend, 2001). Crown diameters may be affected 
during prenatal life: Low infant birth weight and maternal smoking during pregnancy reduced 
some crown dimensions of deciduous and permanent teeth (Garn et al., 1980; Heikkinen et 
al., 1992; Heikkinen et al., 1994). Reduction in tooth size due to irradiation and chemotherapy 
is a clinically evident late adverse effect of pediatric anticancer therapy (Section 5.2.2.). The 
role of environmental pollutants (e.g., dioxin) in determination of human tooth size is 
unknown, although dioxins have reduced tooth size in animals both in vivo and in vitro 
(Section 2.1.2.). 
 
2.3.3. Characteristics and prevalence of microdontia in permanent teeth 
Microdontic teeth may present either with rather usual morphology (merely smaller than 
normal) or with peg-shaped crowns, tapering towards the incisal edge (Tsai and King, 1998). 
The prevalence of generalized microdontia, as occasionally described in connection with 
syndromes, is rare, with exact figures unknown. Some studies report microdontia (or peg-
shaped teeth) occurring more frequently in females (Meskin and Gorlin, 1963; Chung et al., 
1972), while others find the prevalence equal for both genders (Ooshima et al., 1996). In a 
healthy population, the most frequently affected tooth is a maxillary lateral incisor. Peg-
shaped maxillary lateral incisors have occurred in 1.3 to 1.7% of subjects in Sweden but, 
reflecting a common genetic background of agenesis and microdontia, in 3.1% to 6.7% of 
parents and siblings of the hypodontia patients (Grahnen, 1956). In a Finnish study, 1.3% of 
the study population had at least one peg-shaped and 2.3% had at least one strongly 
mesiodistally reduced (no exact criterion delineated) upper lateral incisor (Alvesalo and 
Portin, 1969). The microdontia prevalence for maxillary lateral incisors has been 3.3% in 
southern China (peg-shaped or mesiodistal reduction more than 1 mm) (Tsai and King, 1998). 
Prevalence of peg-shaped laterals among ethnic groups in Hawaii (according to ancestor) was 
1.6% in Japanese, 1.9% in Chinese, 3.1% in Filipino, and as high as 7.5% in Puerto Rican 
adolescents (Chung et al., 1972). A percentage of 1.9% was reported for native Japanese 
subjects in Japan (mesiodistally crowns deviated more than 3.5 SD from the sex-specific 
mean) (Ooshima et al., 1996). 
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2.4. Length of permanent teeth and their roots 
2.4.1. Terminology and studies 
Length of teeth, including crown and root lengths, has been studied for at least 100 years. 
Generally, data are sparse or lacking for methods (anatomic measurements and radiographic 
studies; various reference points), study materials, or both, making exact comparisons 
impossible. Common trends, however, are clear: For instance, in the maxilla, diminishing 
tooth length runs in the order: canines, central incisors, lateral incisors, second premolars, first 
molars, first premolars, second and third molars (Verhoeven et al., 1979). Root lengths are not 
usually reported separately. Instead, a so-called relative root length, also called a root-crown 
(R/C) ratio (Lind, 1972; Jakobsson and Lind, 1973), a ratio of crown length to root length 
(Brook and Holt, 1978), or a crown-root index (Carlsen, 1987) have served for study of 
relative root length in healthy populations. Because none of the studies reported the R/C ratios 
for all teeth, information on (relative) root length in different populations is very limited.  
 The mean length of each tooth type (measured from extracted teeth) was greater in the 
Netherlands for men than for women (Verhoeven et al., 1979). Sexual dimorphism of the 
order of 6% was reported in root length (longer roots in males) in one radiographic study 
(Garn et al., 1978), but no gender difference occurred in the two studies reporting R/C ratios 
of maxillary central incisors (Lind, 1972; Jakobsson and Lind, 1973)  
 
2.4.2. Etiology, prevalence, and characteristics of shortened root length  
Resorption may cause dental root shortening following originally normal development, or 
roots may be developmentally short, never reaching their expected length. Numerous 
environmental factors are able to cause the disturbed dental root development that may affect 
the size or shape of the roots or both, because roots, like other anatomic features, follow a 
normal variation. Short roots may also have a genetic background. 
 
Deficient development 
Systemic anticancer chemotherapy or radiotherapy that occurs when teeth are developing is 
able to disturb root development (Section 5.2.3.).  
 Occasionally, shortened roots or diminished relative root lengths have occurred in 
connection with systemic diseases. Some case reports include a patient history of Stevens-
Johnson syndrome (a severe form of erythema multiforme) with generalized abnormal root 
development or with varying degrees of arrested root development in the permanent dentition 
(de Man, 1979; Ranalli et al., 1984; Brook, 1994). Histologic abnormalities in Stevens-
Johnson syndrome involve the dermis and epidermis, and may be assumed to involve the 
epithelial cells of HERS, resulting in arrested root development (de Man, 1979). Patients with 
hypoparathyroidism show aberrant root development (and eruption of teeth) (Sunde and Hals, 
1961; Jensen et al., 1981). In some cases, the etiology remains idiopathic (Lerman and Gold, 
1977). 
 Short root anomaly (SR anomaly, SRA) designates a dental anomaly characterized by 
developmentally short and blunted roots, most often involving maxillary central incisors in 
healthy persons (Lind, 1972). In 15% of these patients, premolars and canines were also 
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affected. Etiology is still unknown, although the familial nature of SRA, indicating a genetic 
factor, was promptly noticed (Lind, 1972), and has been confirmed (Edwards and Roberts, 
1990; Apajalahti et al., 1999). Using the criterion root of the same size or smaller than the 
crown, a high 10% prevalence of SRA was reported in Japan (Ando et al., 1967). In 
Caucasians, the prevalence of SRA has been lower, from 1.3 to 2.7%, with girls more 
frequently affected (Jakobsson and Lind, 1973; Brook and Holt, 1978; Apajalahti et al., 
2002). 
 
Resorption 
The ability of dental trauma and orthodontic treatment to induce root resorption of different 
grades is well known (Brezniak and Wasserstein, 1993; Blake et al., 1995; Janson et al., 2000; 
Andreasen and Jacobsen, 2001). Risk for inflammatory or replacement resorption following 
extrusive or lateral luxation is about 5% or less, but as high as 50 to 70% after intrusive 
luxation or avulsion (Andreasen and Jacobsen, 2001). Short roots due to this kind of 
resorption are rare, however, as serious tooth injuries constitute only about 5% of dental 
traumas (Borssén and Holm, 2000). Furthermore, following trauma, root resorption seldom 
starts at the apical area, and consequently does not initially affect the root length.  
 Orthodontic tooth movement always induces root resorption, but this normal 
resorption does not change root length. More severe circumferential external apical root 
resorption leads to root shortening. Etiological factors behind orthodontic root resorption 
(ORR) may be patient- or treatment-related. Although none of the patient-related factors 
studied (e.g., general health, hormonal balance, gender, age, nutrition, habits, type of 
malocclusion) win unanimous support as regards their effect on ORR, adults are often 
considered more susceptible to root resorption than are children (Brezniak and Wasserstein, 
1993, 2002). Teeth with deviant root morphology, such as pipette-shaped, pointed, or 
dilacerated roots, may be at increased risk for the root resorption that occurs primarily in the 
maxillary anterior teeth (Levander and Malmgren, 1988; Sameshima and Sinclair, 2001, 
2004). A genetic contribution to individual root resorption susceptibility emerged in a family 
study showing siblings to experience similar levels of ORR. Moderately high heritability 
(about 60-80%) was attributed to this phenomenon in maxillary central incisors and 
mandibular first molars (Harris et al., 1997). Furthermore, it was recently demonstrated that 
those homozygous for the IL-1β allele 1 have a 5.6- fold (95% CI 1.9-21.2) increased risk for 
ORR greater than 2 mm compared with those not homozygous for this allele (Al-Qawasmi et 
al., 2003). Of all treatment-related factors affecting ORR, a recent meta-analysis showed that 
only total distance of apical displacement and total active treatment time were highly 
correlated with mean amount of apical root resorption (reviewed by Segal et al., 2004). 
 In ORR, average root resorption has usually been less than 2 to 2.5 mm (Linge and 
Linge, 1983, 1991; Mirabella and Artun, 1995; Harris et al., 1997; Mavragani et al., 2000; 
Sameshima and Sinclair, 2001) or, in percentages, has varied between 4.6 and 14.0% (Blake 
et al., 1995; Mavragani et al., 2000). Resorption exceeding 2.5 mm has occurred in one or 
more maxillary incisors in 16.5% of the patients aged 11.5 to 25 years (Linge and Linge, 
1991). Severe resorption, exceeding 4 mm or reaching one-third of the original root length, 
has been seen in 1.0 to 2.6% of teeth in general (Linge and Linge, 1983; Levander and 
Malmgren, 1988; McNab et al., 1999; Janson et al., 2000). 
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3. Cancer in children 
3.1. Incidence of childhood cancer 
Cancer in children is very rare worldwide. In industrialized countries, including Finland, only 
about 0.5% to 1% of all cancers occur in children under 15 years (Finnish Cancer Registry, 
2004; reviewed by Stiller, 2004). Types of pediatric cancer differ markedly from those of 
adults. Most childhood malignancies are of mesodermal origin (about 90%), with the 
ectoderm-derived cancers most frequent (> 85%) in adults only occasionally occurring in 
children (Pihkala, 2004). Three predominant groups of childhood cancers make up the 
majority of the diagnosed cases: leukemia, tumors of the central nervous system (CNS), and 
lymphomas (Figure 4).  
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Figure 4. Distribution of childhood malignancies in children less than 15 years of age in Finland 
(Pihkala, 2004).  
 
 Internationally, variations in pediatric cancer incidence and distribution of cancer types 
occur. Total incidence ranges from 70 to 160 per million children (International Agency for 
Research on Cancer, IARC, 2003; reviewed by Stiller, 2004). In Finland, about 150 to 160 
new cancers are diagnosed annually in children, with nearly 60% of these in males. The peak 
incidence rate occurs under 5 years of age, and the overall incidence rate in 0 to 14-year-olds 
is about 15/100 000 children (Finnish Cancer Registry, 2004).  
 
3.2. Etiology of childhood cancer 
For most cases of childhood cancer, the cause remains unknown, although some associated 
endogenous (mainly genetic) and exogenous (physical, chemical and biological agents) 
factors are known or suspected to be involved in their etiology. As regards this thesis, dealing 
with developmental dental defects after anticancer therapy and stem cell transplantation 
(SCT), cancer etiology is relevant only if the same factor might cause both cancer and 
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disturbances in tooth development. Since evidence for this is deficient, it can be passed over 
briefly with a few theoretically common etiological factors. 
 Ionizing radiation after the Chernobyl accident in 1986 raised the incidence of thyroid 
cancer, which was almost six-fold in children with the highest estimated doses of 1 Gy versus 
< 0.3 Gy doses (Astakhova et al., 1998). A small increase in incidence of childhood leukemia 
was also observed in Europe (reviewed by Moysich et al., 2002), but not in Finland (Auvinen 
et al., 1994). Environmental pollutants may play a role in the etiology of some childhood 
malignancies, although causal relationships are not very definitive. After the dioxin accident 
in Seveso (Italy) in 1976, relative risks for thyroid cancer and myeloid leukemia were 4.6 and 
2.7 (Pesatori et al., 1993). Ionizing radiation and exposure to dioxins may both disturb tooth 
development (Sections 5.2. and 2.1.2.).  
 The role of genetics as a common etiologic factor for cancer and disturbed tooth 
development was recently shown for the first time in humans when a mutation in the Wnt-
signaling regulator AXIN2 appeared to predispose humans to oligodontia and to colorectal 
cancer (Lammi et al., 2004). As signaling pathways are shared with different organs, it is 
possible that comparable etiologic factors exist.  
 
3.3. Principles of anticancer therapy 
Improvements in anticancer therapy have lead to an increased overall 5-year survival rate for 
childhood cancer from less than 30% in the 1960s up to 75 to 80% today (Smith and 
Gloeckler Ries, 2002). Surgery and radiotherapy (RT) were able to cure some children in the 
early days, but the introduction of combination CT in the late 1960s led to the dramatic 
increase in long-term remissions. Cancers of children consist of a diverse group of 
diagnosesand within a single diagnosis, several subtypes. The intensity of anticancer 
therapy is modified according to characteristics of the disease. Today, treatment has become 
very intensive if the disease is aggressive, but less intensive protocols are used for cancer 
types considered less aggressive. The aim of therapy stratification is to minimize treatment-
related late effects. All modes of anticancer therapysurgery, RT, and CTare still used in 
different combinations. 
 
3.3.1. Surgery  
The oldest form of curative therapy for local solid tumors is surgery, which nowadays is 
usually combined with other treatment modalities. Surgery plays a crucial role, for instance, 
in therapy for most solid tumors, such as Wilms tumor, neuroblastoma, some brain tumors, 
soft tissue sarcomas, and bone tumors (Shamberger et al., 2002; reviewed by Weinstein et al., 
2003; reviewed by Kalapurakal et al., 2004). 
 Biopsy is needed for diagnosis and staging, and in some cases, a solid tumor may be 
totally removed in this primary surgery. Alleviation of symptoms (palliative surgery) and 
resection of metastases may also be indications for surgery. Often, after biopsy, however, CT 
(and sometimes RT) primarily serves to reduce tumor size, which may allow total resection of 
an originally non-resectable tumor later, and diminish risk of injury to vital structures 
(Shamberger et al., 2002). 
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3.3.2. Radiation therapy  
Radiation therapy aims at achieving local and regional control of a malignancy with 
acceptable damage to adjacent normal tissues. This is a demanding task, especially in 
pediatric patients, since radiation is targeted to growing tissues more susceptible to damage 
than are adult tissues. Sometimes RT may serve to provide symptomatic relief to patients with 
incurable disease. Tumor type, volume, location, and patients age determine use and dose of 
RT, which continuously plays an important role, in combination with other treatment 
modalities, in several pediatric malignancies (Wilms tumor, neuroblastoma, Hodgkins 
disease, sarcomas, brain tumors). Three-dimensional localization of the tumor by computed 
tomography and magnetic resonance imaging has improved the possibility to protect normal 
tissues and target the radiation dose more precisely (conformal radiation). Total dose of 
radiation, size of the dose per treatment session (fraction), and dose rate can be varied to 
achieve the optimal balance between tumor control and complications threatening the 
surrounding normal tissues (Kouri et al., 1999; Tarbell and Kooy, 2002). Total body 
irradiation (TBI) is a special form of RT, frequently used prior to SCT (see also Section 3.4.).  
 Ionizing radiation is able to modify cellular DNA or break one or both of the cells 
DNA strands. The inherent radiosensitivity of both tumor cells and normal cells varies. In 
general, quickly proliferating cells (basal cells of oral mucosa, hematopoietic stem cells, many 
tumor cells) are damaged easier than are differentiated, non-dividing cells (neurons, mature 
hematopoietic cells). Cells possess repair mechanisms that, in most cases, can restore the 
original structure of the DNA molecule in a few hours (sublethal cell damage). More 
extensive damage may be lethal: That cells are unable to recover is noticed at one of the 
checkpoints of the cell cycle, and these damaged cells are directed to programmed cell death 
(apoptosis), or they die during the cell division (Figure 5). Besides shielding, toxic effects on 
normal tissues can be reduced by use of fractionated doses (total radiation dose divided into 
smaller fragments given at intervals). This is beneficial, since normal tissues have a greater 
capacity to repair sublethal radiation-induced injuries than do most malignant cells. Damage 
is worse in tumor cells with a high proliferation rate, as these cells reach new sensitive phases 
in their cell cycle before the next radiation dose. Increasing oxygen concentration in the tumor 
between the doses also enhances the cell-killing effect of the radiation (Servomaa and 
Rytömaa, 1997; Kouri et al., 1999; Tarbell and Kooy, 2002). 
 
3.3.3. Chemotherapy  
Chemotherapy is the backbone therapy in many pediatric malignancies that earlier were 
inevitably fatal. After inducing short-term remissions with a single-agent CT, the cure of 
some patients with leukemias and Hodgkin's disease with combination CT in the 1960s 
proved that drugs could cure some percentage of human cancers. The cytotoxic effects of 
anticancer CT are directed both at the malignant and normal cells, which necessitates a trade-
off between maximal anticancer efficacy and tolerable side effects. The maximally tolerated 
dose rate of anticancer drugs has increased over time when, for instance, with administration 
of hematopoietic growth factors and stem cell transplants, drug toxicity has been alleviated 
(Balis et al., 2002; Margolin et al., 2002).  
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 The cell cycle of dividing cells has four phases (Figure 5). Most anticancer drugs exert 
their cytotoxic influence on a specific phase (phase-specific), while others are active during 
several phases (non-phase-specific). Some chemotherapeutic agents prevent cell proliferation 
by interfering with DNA or RNA synthesis or by breaking their strands; others exert their 
influence via enzymes or cell membrane structures, resulting in disrupted cell division and/or 
cell death (Table 2). In general, an apoptotic or cytotoxic effect on tumor cells increases with 
increasing in vivo concentration of the drug, resulting, however, in acute or long-term 
toxicities in normal host cells. The best-known acute toxicities caused by anticancer drugs are 
probably alopecia and nausea, but myelosuppression and orointestinal mucositis are even 
more distressing (for toxicities, see Table 2). Combination CT, containing several cytostatic 
drugs that alone are also effective against the tumor being treated, has several advantages. 
More malignant cells can be eliminated at the susceptible phases by combining drugs with 
additive or synergistic mechanisms of action. Moreover, when the anticancer drugs have 
different toxicity profiles, damage to healthy tissues is diminished, and risk for drug 
resistance decreased (Elonen and Järviluoma, 1998; Balis et al., 2002). Maximal dose 
intensity (maximum tolerated dose given at the shortest possible intervals) correlates in most 
cases with better disease outcome (Balis et al., 2002). 
 
MiG1 S G2 
Check G0 
ApoptosisBig mistake 
Small mistake
Repair 
Cytotoxic
agent 
Check 
 
Figure 5. Phases of the cell cycle. G1: Cells produce RNA and proteins and prepare for DNA 
synthesis. S (Synthesis): DNA replicates. G2: Cells prepare for mitosis. Mi (Mitosis): Cells divide. G0 
(resting phase): Cells temporarily cease to divide but are able to move again to phase G1. After 
cytotoxic exposure, the checkpoints are critical: Directions are given there for moving forward in the 
cell cycle after repair procedures, or committing to apoptosis (programmed cell death) (Elonen and 
Järviluoma, 1998; Balis et al., 2002). 
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Table 2. Classification of anticancer drugs frequently used in pediatric hematology and oncology, mechanisms of 
action, toxicity profile, and main indications (Elonen and Järviluoma, 1998; Balis et al., 2002; Hande, 2004).  
Drug Main mechanisms of action Toxicity Common anti-tumor spectrum  
Alkylating agents  
Busulfan  DNA breaks and crosslinking M; HD: pulm, hep, muc, N, V, NT CML, HDC/SCT 
Cyclophosphamide 
(Cy) Cross-links DNA strands M, A, N, V, cyst; HD: card 
Lymph, ALL, NBL, Wilms, 
sar, HDC/SCT 
Ifosfamide (IFOS) Cross-links DNA strands M, A, N, V, cyst, ren, NT; HD: card Sar, germ cell 
Melphalan (L-PAM) DNA breaks and crosslinking M, N, V; HD: muc, diarr Sar, NBL, HDC/SCT 
Thiotepa DNA breaks and crosslinking M, ST HDC/SCT 
Non-classical alkylating agents 
Dacarbazine (DTIC) DNA methylation M (mild), N, V, hep NBL, sar, Hodgkin 
Antimetabolites 
Cytarabine (ara-C) 
(pyrimidine analog) 
Binds to DNA, RNA; inhibits 
DNA polymerase 
M, N, V, muc, GI, ocular, hep; HD: 
NT 
ALL, AML, lymph, 
HDC/SCT 
Hydroxyurea Enzyme inhibition (ribonucleotide reductase) M, muc, skin CML 
Mercaptopurine (6-MP) 
(purine analog) 
Binds to DNA, RNA; blocks 
purine synthesis M, hep ALL, CML 
Methotrexate (MTX) 
(folic acid antagonist) 
Blocks purine and thymidine 
synthesis by interfearing with 
folate metabolism  
M (mild), muc, hep; HD: NT, ren ALL, lymph, OS 
Plant alkaloids 
Etoposide (VP-16) 
(podophyllotoxin) 
Binds to topoisomerase II; 
causes DNA breaks 
M, A, N, V, muc, HSR, NT (mild), 
ANLL 
ALL, AML, lymph, NBL, 
sar, brain, HDC/SCT 
Teniposide (VM-26) 
(podophyllotoxin) 
Binds to topoisomerase II; 
causes DNA breaks 
M, A, N, V, muc, HT, HSR, NT 
(mild), ANLL ALL, AML, (HDC/SCT) 
Vinblastine 
(vinca alcaloid) 
Binds to microtubulin, 
prevents mitosis M, A, muc, NT (mild) Histiocytosis, Hodgkin 
Vincristine (VCR) 
(antimicrotubule agent) 
Binds to microtubulin, 
prevents mitosis NT, A, HT  ALL, lymph, most solid  
Antitumor antibiotics 
Daunorubicin 
(anthracycline) 
Topoisomerase inhibition, 
DNA damage (intercalation) 
M, muc, N, V, diarr, A, card (acute, 
chronic) ALL, AML, lymph 
Doxorubicin 
(anthracycline) 
Topoisomerase inhibition, 
DNA damage (intercalation) 
M, muc, N, V, diarr, A, card (acute, 
chronic) 
ALL, AML, lymph, most 
solid  
Idarubicin 
(anthracycline) 
Topoisomerase inhibition, 
DNA damage (intercalation) 
M, muc, N, V, diarr, A, card (acute, 
chronic) ALL, AML, lymph 
Bleomycin Free radicals result in DNA breaks Pulm, skin, muc, HSR Lymph, germ cell 
Dactinomycin 
(Actinomycin-D) 
Topoisomerase inhibition, 
DNA damage (intercalation) M, N, V, A, muc Wilms, sar 
Platinum analogs 
Carboplatin DNA cross-links with platinum M, N, V, hep (mild) Brain, germ cell, NBL, sar 
Cisplatin DNA cross-links with platinum M (mild), A, N, V, ren, oto, NT Brain, germ cell, NBL, OS 
Enzyme 
Asparaginase Asparagine depletion; lymphoblasts disturbed 
HSR, coagulopathy, N, V, NT, hep, 
pancreas ALL, lymph 
 
Abbreviations (toxicity): A, alopecia; ANLL, acute non-lymphoblastic leukemia; card, cardiac; cyst, cystitis; diarr, diarrhea; 
GI, gastrointestinal; HD, high dose; HDC high-dose chemotherapy; hep, hepatic; HSR, hypersensitivity reaction; HT, 
hypotension; M, myelosuppression; muc, mucosa; N, nausea; NT, neurotoxic; oto, ototoxicity; pulm, pulmonary; ren, renal; 
ST, stomatitis; V, vomiting  
Abbreviations (anti-tumor spectrum): ALL, acute lymphoblastic leukemia; AML, acute myeloblastic leukemia; CML chronic 
myeloid leukemia; HDC/SCT, high-dose chemotherapy prior to stem cell transplantation; lymph, lymphoma; NBL, 
neuroblastoma; OS, osteosarcoma; sar, sarcoma 
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3.4. Hematopoietic stem cell transplantation 
Hematopoietic stem cells (HSCs), derived from totipotent embryonal stem cells, are immature 
cells that are already determined to a certain tissue lineage but are still pluripotent (= 
multipotent), i.e., able to give rise to all cells of the myeloid and lymphoid lineages (reviewed 
by Sell, 2004). They can reconstitute hematopoiesis in patients suffering from diseases 
primary affecting hematopoietic or lymphatic systems (stem cell transplantation, SCT), or 
rescue patients whose treatment necessitates very intensive and consequently toxic therapy 
that secondarily destroys hematopoiesis (stem cell rescue, SCR) (Guinan et al., 2002). Bone 
marrow has been a traditional source of HSCs (therefore the term bone marrow 
transplantation, BMT), but nowadays HSCs are more frequently harvested from peripheral or 
umbilical cord blood. The terms are SCT, SCR, and also peripheral blood stem cell 
transplantation (PBSCT) and (umbilical) cord blood transplantation (CBSCT). Identification 
of HSCs is based on the cell-surface protein, CD34 antigen, expressed primarily on 
hematopoietic progenitor cells representing about 1 to 5% of marrow cells and 0.1 to 0.2% of 
peripheral blood cells (reviewed by Little and Storb, 2002; Nash, 2004). From the first 
unsuccessful efforts at human BMT in 1957 (reviewed by Little and Storb, 2002), 
hematopoietic stem cell transplantation (HSCT = SCT in this thesis) has become a successful 
treatment in several otherwise fatal hematologic, oncologic, and immunologic diseases in 
adults and in children.  
 The transplant is called autologous if the source of HSCs is the patient him-/herself, and 
allogeneic when HSCs have been harvested from another person. The availability of 
autologous HSCs may be compromised or ruled out in patients who have earlier been exposed 
to intensive anticancer therapy or when contamination of the transplant with malignant cells is 
probable. The preferred donors of allogeneic HSCs are human leucocyte antigen (HLA) -
matched siblings, but for patients who lack such a sibling or other closely HLA-matched 
family donor, a matched unrelated donor is sought from donor registries. The possibility of 
finding an unrelated donor for Caucasian patients is about 80%, although it is dependent on 
the definition of suitable HLA matching (Guinan et al., 2002; reviewed by Little and Storb, 
2002).  
 Prior to the SCT procedure, remission is induced with anticancer CT (excluding patients 
with immunological deficiencies). Preparative regimens for SCT include myeloablative high-
dose chemotherapy (HDC; examples in Table 4, page 56), often combined with total body 
irradiation (TBI), both to eradicate possible residual disease, to create marrow space, and
when allogeneic stem cells are usedto suppress the patients immune system to avoid 
rejection (Guinan et al., 2002; reviewed by Little and Storb, 2002). This treatment causes 
irreversible bone marrow toxicity that without infusion of the new hematopoietic progenitor 
cells would be lethal. After SCT, successful engraftment usually occurs in 10 to 28 days. The 
post-transplant period may be complicated by bacterial, viral, and fungal infections; intensive 
supportive care is necessary (Guinan et al., 2002). 
 Autologous SCT (SCR) is used in treatment of several originally metastasized or 
recurrent solid tumors with poor prognosis such as neuroblastoma (Saarinen et al., 1996; 
Matthay et al., 1999), Wilms tumor (Campbell et al., 2004), and Hodgkins disease 
(Lieskovsky et al., 2004). Event-free survival rates from 40 to 60% have been reported after 
follow-ups of 3 to 5 years. Allogeneic transplants are commonly used in the treatment of 
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patients with high-risk ALL and AML in the first complete remission (CR), or in the second 
CR for the relapsed patients. The best treatment results have been achieved with allogeneic 
SCT also in chronic myeloid leukemia (CML). Moreover, congenital hematopoietic (e.g., 
thalassemia) or immunologic defects (e.g., severe combined immunodeficiency) and acquired 
disorders of marrow function (e.g., severe aplastic anemia), may require allogeneic SCT 
(Guinan et al., 2002; Nash, 2004).  
 
3.4.1. Graft-versus-host disease 
Patients receiving an allogeneic SCT are at risk for graft-versus-host disease (GVHD), which 
occurs when genetically disparate, immunocompetent donor lymphocytes are transferred into 
a recipient who is immunocompromised and incapable of rejecting the donor graft. Despite 
prophylactic immunosuppressive therapy for GVHD, the donor T-cells may recognize the 
recipients diverse histocompatibility antigens and attack recipient cells, resulting in signs and 
symptoms of acute GVHD, involving primarily the skin, gastrointestinal tract, and liver 
(Guinan et al., 2002). It has, however, been noticed that leukemia patients who develop 
GVHD have a lower risk for recurrent disease after transplantation. This advantage, the 
graft-versus-leukemia-effect, is often successfully utilized in treatment of the patients with a 
high risk for recurrent leukemia. 
 Symptoms of chronic GVHD may occur about 3 months after transplantation, but may 
develop much later, even a year after allogeneic SCT. Incidence of chronic GVHD runs from 
25 to 80%. The rate is usually lower in children than in adults, lower after cord blood 
transplantation, and lower after having a transplant from a matched sibling donor (reviewed 
by Farag, 2004; reviewed by Higman and Vogelsang, 2004). Chronic GVHD most commonly 
involves the skin (65-80%), mouth (48-72%), liver (40-73%), and eyes (18-47%). Other 
possible involvement sites are the gastrointestinal tract (16-26%), lungs (10-15%), and joints 
(2-12%). Malnutrition is common, and even hair loss, destruction of sweat glands, and 
vertical ridges on the nails are possible (reviewed by Higman and Vogelsang, 2004). Salivary 
gland involvement is characterized by reduced saliva quantity and its altered quality 
(reviewed by Nagler and Nagler, 2004). Both the disease and its treatment with 
immunosuppressive medications (such as methotrexate, corticosteroids and cyclosporin A) 
increase risk for life-threatening infections. Immunosuppressive therapy can be discontinued 
in most cases after 9 to 18 months, but must be prolonged in patients with clinically extensive 
chronic GVHD (reviewed by Farag, 2004; reviewed by Higman and Vogelsang, 2004).  
 
3.5. Key characteristics of selected childhood malignancies 
3.5.1. Leukemia 
Leukemia is the most common childhood cancer, and in Finland accounted for about 32% of 
all cancers occurring before age 15 during the period 1968 to 1998. Acute lymphoblastic 
leukemia (ALL) comprises about three-fourths of the leukemia diagnoses, and acute myeloid 
leukemia (AML) accounts for the majority of the remaining cases (International Agency for 
Research on Cancer, IARC, 2003). In general, the peak incidence in ALL (not in AML) 
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occurs at approximately age 2 to 3 (4) years and is higher in males (Smith et al., 1999; 
Margolin et al., 2002).  
 ALL is thought to arise in the bone marrow via a malignant transformation of a single 
lymphoid progenitor cell that proliferates and replaces the normal hematopoietic cells. 
Production of the normal marrow elements is disturbed, resulting in anemia, 
thrombocytopenia, and neutropenia of varying degrees. In addition to the bone marrow, 
leukemic blasts may already be present and proliferating in liver, spleen, thymus, lymph 
nodes, testes, and the central nervous system (CNS) at the time of diagnosis. ALL is a 
biologically heterogenous disorder. Increased knowledge of the importance of clinical and 
biological prognostic factors (initial white blood cell count, age, sex, cell morphology, 
response to induction therapy, immunochemistry, cytogenetic markers) has fine-tuned the 
treatment strategies. Treatment of high-risk patients has become extremely intensive, but the 
less intensive treatment of low-risk patients aims at a cure with minimal treatment-related 
adverse effects (Margolin et al., 2002; Pui et al., 2004; Saarinen-Pihkala et al., 2004; 
Whitlock and Gaynon, 2004). The average duration of therapy for children with ALL is 2 to 
2.5 years, and 5-year survival rates are 75 to 80% (Smith et al., 1999; Gustafsson et al., 2000; 
reviewed by Pui et al., 2001). 
 Treatment of ALL consists of remission induction, consolidation, (intensification), and 
maintenance therapy. Combination CT and (preventive) CNS therapy with craniospinal 
irradiation (CRI) have been the cornerstones of treatment. However, with the development of 
other treatment methods, CRI has been limited to avoid numerous late adverse effects 
(Saarinen-Pihkala et al., 2004). Allogeneic SCT, the most aggressive mode of therapy, is 
utilized for some very high-risk patients even in the first CR but, most frequently, in relapsed 
patients in the second CR (reviewed by Pui et al., 2001; Margolin et al., 2002). Finland, as all 
other Nordic countries, employs the protocols of the Nordic Society of Pediatric Hematology 
and Oncology (NOPHO). Patients are stratified to several risk groups: standard risk, 
intermediate risk, and high risk (the latter includes intensive, very intensive, and extra 
intensive therapy groups), and their treatment varies according to NOPHO-ALL 2000 
protocols. Therapeutic or prophylactic CRI of 18 to 24 Gy may be given as a part of intensive 
or very intensive therapy, but the need is considered separately in very young children (< 4-5 
years). The extra intensive therapy includes an allogeneic SCT in the first CR. In the Nordic 
countries (Denmark, Finland, Iceland, Norway, Sweden) during the 1990s, the survival rate 
for ALL patients at 5 years was 77.6% (Gustafsson et al., 2000). The 9-year event-free 
survival of high-risk ALL patients was lower, 61%, including subgroups of very high-risk 
patients with low survival rates (e.g., 25% for patients with precursor-B cell ALL with a high 
initial white blood cell count of ≥ 200 x 109/liter) (Saarinen-Pihkala et al., 2004). 
 AML includes a heterogenous group of hematologic malignancies arising as a 
transformation of myeloid lineage progenitor cells. The incidence of AML is stable in 
childhood, with males and females equally affected (Golub and Arceci, 2002). About 10 
children per year are diagnosed in Finland (Pihkala, 2004). Exposure to radiation and 
chemotherapeutic (alkylating) agents are risk factors for AML. For instance, after the atomic 
bombs in Japan, a 20-fold increased incidence of AML (and ALL) occurred (Smith et al., 
1999; Golub and Arceci, 2002). AML presents with several subtypes, and currently the 
standard and high-risk criteria are based on cytogenetic and moleculargenetic characteristics 
and response to therapy. In Finland, AML patients have been treated according to NOPHO 
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protocols since the 1980s, and in the latest version (NOPHO-AML03), the treatment begins 
with two chemotherapy courses (induction), followed by stratification of the patients to 
standard and high-risk. In standard risk patients, consolidation therapy continues with several 
courses of conventional chemotherapy (CCT) following each other at 3- to 4-week intervals. 
The treatment period is shorter than in ALL, usually 7 to 10 months. Allogeneic SCT is 
recommended for the high-risk patients, preferentially after the first course of consolidation 
CT. Overall 7-year survival rate in the NOPHO-AML93 study was 64% (Lie et al., 2003), 
which internationally represents one of the best results reported (Pui et al., 2004). In the 
absence of a suitable donor, treatment with autologous stem cell support has also been used in 
children with recurrent disease. This salvage therapy seemed to be useful, especially in 
patients with a long (> 12 months) first CR (Godder et al., 2004).  
 
3.5.2. Lymphomas 
Lymphomas, originating from various cells of the lymphocyte linage, are the third most 
frequent types of cancers in children (Figure 4). The two predominant lymphomas are non-
Hodgkin lymphoma (NHL), and Hodgkins disease (HD), both further divided into 
subgroups. Together, lymphomas constitute about 10 to 15% of childhood malignancies. In 
young children, NHL is more frequent than HD, with the reverse in adolescents. HD is 
uncommon in children younger than 10, but its incidence increases during the early teen and 
adolescent years. In Finland, about 10 new NHL cases are diagnosed in children annually, and 
the number of HD diagnoses is even lower, about 4 per year (Percy et al., 1999; Pihkala, 
1999).  
 Some risk factors for lymphomas exist. Patients with congenital or acquired 
immunodeficiency syndromes and patients with immunosuppressive medication after organ 
or stem cell transplantation are at increased risk for NHL (post transplant lymphoproliferative 
disease). The Epstein-Barr virus has been associated with HD, and clustering of HD cases in 
families and the higher risk in monozygotic than dizygotic twins for HD suggest a genetic 
predisposition or a common environmental factor (Percy et al., 1999; Hudson and Donaldson, 
2002; Magrath, 2002).  
 Treatment varies according to type of lymphoma and extent of disease at diagnosis. 
Patients with a local NHL have an excellent prognosis after a short course of multiagent 
chemotherapy. NHL in children is often disseminated (lymphoblastic lymphoma) from the 
outset, and more intensive therapy is necessary, especially for patients with bone marrow or 
CNS involvement. The borderline between ALL and NHL involving the bone marrow is 
unstable. Thus, the treatment of disseminated NHL follows, or is identical to, the regimens 
designed for the treatment of ALL, extending up to allogeneic SCT after myeloablative 
therapy. RT is not considered to provide any extra benefit for cure and is used for children 
only in special cases. Prognosis for disseminated NHL resembles that for ALL: 60 to 80% of 
patients can be cured. With allogeneic or autologous SCT, survival rates of 30 to 60% have 
been reported after recurrent disease (Percy et al., 1999; Pihkala, 1999).  
 RT-related adverse effects have promoted interest in the combined-modality therapy for 
HD. Radiation dose and volume have been reduced in growing children, and the intensity and 
duration of multiagent CT has been tailored according to anatomic disease stage and presence 
or absence of symptoms at diagnosis. Many pediatric treatment protocols use six cycles of 
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combination CT and irradiation (15-25 Gy) of the involved field (Percy et al., 1999; Hudson 
and Donaldson, 2002). Approximately 90 to 95% of children with non-disseminated HD 
recover, as well as 70 to 90% of patients with disseminated disease. In recurrent HD, 
autologous (sometimes allogeneic) SCT can cure 20 to 30% of patients with a short and 50 to 
80% of patients with a long (> 12 months) primary remission (Percy et al., 1999; Lieskovsky 
et al., 2004).  
 
3.5.3. Neuroblastoma 
Neuroblastoma (NBL), a tumor of the sympathetic nervous system, is derived from primordial 
neural crest cells that later populate sympathetic ganglia and adrenal medulla; the neoplasm 
thus originates from a sympathetic ganglion along the spine or in the adrenal gland. NBL 
etiology is unknown. It comprises 8 to 10% of childhood malignancies and is the most 
common cancer diagnosed in the first year of life. About 80% of the patients are less than 4 
years at diagnosis (Goodman et al., 1999; Brodeur and Maris, 2002). NBL spreads early to the 
lymph nodes, bone marrow, bone, and liver, with approximately 70% of patients having 
metastases at diagnosis in this biologically heterogenous neoplasm with its highly variable 
behavior. In very young children (< 1 year), spontaneous regression may occur, but in older 
children with metastatic NBL the outcome is poor, even after intensive therapy (Brodeur and 
Maris, 2002; reviewed by Weinstein et al., 2003). In Finland, about 10 new cases are 
diagnosed annually; incidence is rather uniform, at least in industrialized countries 
(International Agency for Research on Cancer, IARC, 2003).  
 Patients can be divided into risk groups, for instance, according to age, stage of the 
disease, histology, and genetic features of the tumor. Amplification of the proto-oncogene 
MYCN (also known as N-myc) is especially associated with aggressive and metastatic disease 
Treatment protocols comprising surgery, RT, and anticancer CT have been introduced for 
low-risk, intermediate-risk, and high-risk patients (risk-related therapy). In addition to 
surgery, light CT is used for some low-risk patients. In infants with 4S disease (localized 
primary tumor with dissemination limited to liver, skin, or bone marrow), spontaneous 
regression may occur, but minimal CT or local RT is sometimes used; high survival rates, 
usually reaching 80 to 90%, have been reported (Brodeur and Maris, 2002; reviewed by 
Weinstein et al., 2003). Intermediate-risk patients are usually treated with moderately 
aggressive CT and surgery, with RT used in selected cases. Survival rates vary greatly, 
between 10% and 94%, which probably is an indication of heterogeneous treatment groups 
(reviewed by Weinstein et al., 2003). Survival of high-risk patients with multiagent CT 
regimens has been only about 15% (Brodeur and Maris, 2002). For this group, maximal 
therapy is needed, meaning HDC, often TBI, and autologous SCR, sometimes two or even 
three times, in addition to surgery, CCT, and RT. Furthermore, administration of 13-cis-
retinoic acid (known to reduce proliferation and induce differentiation in neuroblastoma cell 
lines) after CT or SCR seems to improve prognosis (Matthay et al., 1999; reviewed by 
Weinstein et al., 2003). After autologous SCR, the maximum long-term survival rates of 53% 
for high-risk NBL have been achieved in Finland (Saarinen et al., 1996).  
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3.5.4. Wilms’ tumor 
Wilms tumor (WT, nephroblastoma), the most common renal cancer in children, derives 
from undifferentiated embryonal mesodermal tissue and represents about 6% of the cancer 
diagnoses in children aged under 15 years. In the first 2 years of life, WT incidence is highest. 
After 7 years of age, embryonic cells, which differentiate and essentially disappear with age, 
are very seldom a source of cancer. (Bernstein et al., 1999; Grundy et al., 2002; reviewed by 
Sell, 2004). Increased risk for WT appears in some congenital anomalies such as Beckwith-
Widemann and Sotos syndromes, and also in Denys-Drash and WAGR (Wilms tumor, 
aniridia, genitourinary malformation, mental retardation) syndromes, associated with the 
mutated WT suppressor gene WT1. Ethnic incidence variations and familial occurrence in a 
small subset of patients (about 1.5%) are considered indicative of the genetic component in 
the etiology. No conclusive evidence exists for a role played by environmental exposure 
(Bernstein et al., 1999; Grundy et al., 2002; reviewed by Stiller, 2004).  
 In most patients, WT is a unilateral neoplasm. The most common, and in about 80% the 
only site of metastases are the lungs, followed by liver and lymph nodes. The extent of the 
tumor at diagnosis is the basis for the five-grade staging: moving from stage I to stage IV 
means moving from a local tumor, limited to a kidney, to a tumor with distant metastases. In 
stage V, the tumor is bilateral. Stage and histology (favorable/unfavorable) are used in the risk 
assessment that guides the therapy planning, but molecular genetic features may further fine-
tune the treatment protocols in the future (Grundy et al., 2002; reviewed by Kalapurakal et al., 
2004).  
 Surgical resection (mostly nephrectomy), either as an initial therapy or after an initial 
CT remains important (reviewed by Kalapurakal et al., 2004). Percutaneous needle biopsy 
may be taken first to clarify the histology, followed by preoperative CT, the intensity of 
which is modulated by tumor stage and histology (Saarinen et al., 1991). Prognosis is poor 
after local recurrence and, to avoid this, postoperative RT to the tumor bed is often used. 
Whole-lung irradiation has been recommended for children with pulmonary metastases, but 
new CT-based treatments are sought to eliminate the adverse effects of RT. The trend is 
toward shorter and more gentle therapy for children with low-risk tumors and toward more 
intensive therapy for those with high-risk disease (Grundy et al., 2002; de Kraker et al., 2004; 
reviewed by Kalapurakal et al., 2004). In patients with relapsed WT (long-term survival < 
30% after conventional therapy), disease-free survival 3 or 4 years after HDC and autologous 
SCR has been 30 to 50%, (Pein et al., 1998; Campbell et al., 2004). Overall 5-year survival in 
children with WT is 85 to 90% (International Agency for Research on Cancer, IARC, 2003).  
 
3.5.5. Rhabdomyosarcoma  
Soft tissue sarcomas (STS) include a diverse group of neoplasms that originate from 
embryonal mesenchyme and make up 4 to 8% of pediatric cancers. The most common is 
rhabdomyosarcoma (RMS), which arises from cells of skeletal muscle lineage and represents 
about half of all childhood STS. RMS can occur anywhere in the body, with the head and 
neck area most frequently affected (40%), followed by the genitourinary tract (25%). 
Metastases are primarily found in lungs, bone marrow, lymph nodes, and bones. In children 
less than 15 years, the annual incidence of RMS ranges from 4 to 7 cases per million, with the 
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highest incidence in small children (< 4 years) (Gurney et al., 1999; Wexler et al., 2002; 
International Agency for Research on Cancer, IARC, 2003; reviewed by Stevens, 2005). 
Although most RMS cases are sporadic, adult relatives of children with RMS have shown a 
high frequency of adrenocortical and breast carcinomas. An association has also been noticed 
with neurofibromatosis and some other familial syndromes (Wexler et al., 2002; reviewed by 
McDowell, 2003). 
 RMS is classified into histologic subtypes (the two most common being embryonal and 
alveolar) carrying specific molecular genetic abnormalities, and to stages according to 
primary site, size, and invasiveness of the tumor, involvement of lymph nodes, and presence 
or absence of metastases. Stage, site, and pathological subtype are the most important factors 
affecting treatment outcome (Wexler et al., 2002; reviewed by Stevens, 2005). 
 Although the treatment philosophy for RMS varies among centers, multimodal therapy 
consisting of surgery, RT, and CT is usual. Primary surgical removal of the tumor is 
performed whenever possible, but all patients need CT to eradicate residual disease. Often, 
after reduction of the size of the tumor with multiagent CT, secondary excision is necessary, 
to assess treatment results and to remove any residual tumor. RT is frequently delivered to 
diminish the chance of local recurrence or to control metastases. Late effects of RT have 
made it necessary to reassess the use of RT, but no agreement has been achieved thus far. 
Overall survival of RMS patients ranges from 60 to 75% (Gurney et al., 1999; Stiller et al., 
2001; reviewed by Stevens, 2005), with great differences between diagnostic groups. The 
metastatic disease is still a major treatment challenge, since 3-year event-free survival rates 
are only about 20 to 30% (Williams et al., 2004). According to one meta-analysis, patients 
treated with HDC and SCT did not do better: Event-free survival at 3 to 6 years was 24 to 
29% (Weigel et al., 2001).  
 
 
4. Late effects of pediatric anticancer therapy 
For young adults in 2010, the estimated number of childhood cancer survivors is 1:250 
persons (in 2002 this was about 1:900) (Dreyer et al., 2002). Late adverse effects of both RT 
and CT are becoming more familiar, and their clinical implications are increasing. Dental 
aberrations belong among these late effects (Section 5.2.), but are only one small part of the 
entity. Many late adverse effects must be considered as regards clinical dental treatment, but 
most effects have no known associations with tooth development. Late effects of anticancer 
therapy are thus not covered in detail. 
 
4.1. The mouth and related tissues 
High-dose RT (usually 50-70 Gy) for oral cancer or primary tumors of nearby areas is a risk 
for trauma-related or spontaneous osteoradionecrosis (ORN) of the jaws. Because in 
childhood these tumors are rare, ORN is seldom of concern in a pediatric population. It is of 
note that radiation effects on bone do not diminish but rather increase over the course of time, 
as tissues become more fibrotic and hypovascular (reviewed by Vissink et al., 2003a).  
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 RT directed to the salivary glands reduces salivary flow rate, pH, and buffering 
capacity, and saliva turns viscous. Qualitative and quantitative changes compromise several 
protective functions of saliva, impair oral functions such as speech and swallowing, and 
predispose teeth to rapidly progressing radiation caries (reviewed by Vissink et al., 2003b). 
Following CT and HDC of pediatric SCT patients, the mean salivary secretion rate was 
lowest about 3 to 6 months after SCT, but recovered in one year to the level before SCT, 
which already was lower than normal. After 4 years, the mean salivary secretion rate 
exceeded the baseline value by 49% and did not differ from healthy controls. TBI of 10 Gy 
prior to SCT caused a long-term reduction in the mean salivary secretion rate, which remained 
18% below the baseline level in the 4-year follow-up (Dahllöf et al., 1997). RT-related 
salivary gland damage was confirmed later in a scintigraphic study (Bågesund et al., 2000). 
Dahllöf et al. (1997) found no reduction in salivary flow rate in patients with or without 
chronic GVHD. In contrast to that, salivary gland involvement in GVHD reduced the salivary 
flow rate as much as 55 to 90%, and elevated concentrations of sodium, immunoglobulin G, 
and albumin, and reduced immunoglobulin A (IgA). These changes may be due to T-cell 
infiltration of glandular parenchyma, resulting in salivary parenchymal atrophy (reviewed by 
Nagler and Nagler, 2004).  
 Despite salivary dysfunction, the caries experience of the SCT patients, of CT (+RT) 
patients, and of controls did not differ (Näsman et al., 1994; Dahllöf et al., 1997; reviewed by 
Leiper, 2002b). Findings on the effects of conventional anticancer therapy on dental and oral 
health are contradictory (reviewed by Leiper, 2002b). For instance, the caries experience of 
pediatric cancer patients was in some studies in the same range as in healthy controls 
(Maguire et al., 1987; Nunn et al., 1991; Oguz et al., 2004), in other studies cancer patients 
had more decayed and filled teeth than did healthy children (Purdell-Lewis et al., 1988; Pajari 
et al., 1988c, 1995; Dens et al., 1995). 
 
4.2. Other late effects 
Growth disturbances after CT are often temporary, but RT of cranial, spinal, and abdominal 
areas or of epiphyseal growth plates, and TBI as one part of preparative regimens for SCT, are 
risks for permanent and progressive growth disturbances (Hovi et al., 1991; Moell et al., 
1994; Hovi et al., 1999). RT may primarily affect bone growth or act secondarily, causing 
hypothalamic-pituitary axis damage. Malnutrition prior to SCT, growth hormone deficiency 
after TBI and HDC, and glucocorticoids as a part of anticancer therapy or in the treatment of 
GVHD all decrease growth (Taskinen and Saarinen-Pihkala, 1998; Hovi et al., 1999; 
reviewed by Brennan and Shalet, 2002; Dreyer et al., 2002). RT to the neck region or to the 
cranium and also TBI prior to SCT may result in thyroid dysfunction, again by direct damage 
to the thyroid gland or disruption of the hypothalamic-pituitary-thyroid axis (reviewed by 
Brennan and Shalet, 2002; reviewed by Brougham et al., 2002). Gonadal function may be 
damaged after anticancer CT (especially after HDC with alkylating agents), and especially 
after RT. The ovaries are less vulnerable to irradiation and CT than are testes, although 
pubertal development and fertility are both severely endangered in both genders (reviewed by 
Brennan and Shalet, 2002; reviewed by Brougham et al., 2002). Decreased bone mineral 
density after childhood ALL has been described, as well as disturbed lipid and glucose 
metabolism after allogeneic SCT (Arikoski et al., 1998; Taskinen et al., 2000). 
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 Mediastinal RT and administration of anthracyclines (daunorubicin, doxorubicin) and 
alkylating agents (Cy) expose patients to (often subclinical) cardiac late effects, such as 
impaired exercise tolerance, arrhythmias, and cardiomyopathy (Pihkala et al., 1995; reviewed 
by Pai and Nahata, 2000; reviewed by Leiper, 2002a). Pulmonary dysfunction (restrictive or 
obstructive disease or diffusion problems) has been associated with RT, some 
chemotherapeutic agents (e.g. bleomycin, Cy, Mel), and chronic GVHD. Pulmonary late 
effects are more frequent after very intensive CT and SCT beyond the second CR, as 
compared with SCT in the first CR (Dreyer et al., 2002; reviewed by Leiper, 2002a). Renal 
toxicity with an abnormal glomerular filtration rate and persistent tubular dysfunction has 
occurred after RT, and also after administration of some anticancer agents, especially cisplatin 
(reviewed by Leiper, 2002a; Pietilä et al., 2005). Additional deterioration may be induced 
after allogeneic SCT, for instance, by immunosuppressant cyclosporin A. Concomitant use of 
other nephrotoxic agents, such as amphotericin B, may further exacerbate renal dysfunction 
(Dreyer et al., 2002; reviewed by Leiper, 2002a). Neurophysiologic and neurologic 
abnormalities have appeared due to anticancer CT alone (methotrexate, vincristine), but 
addition of RT (CRI in leukemia, RT for brain tumors, TBI prior to SCT) may cause further 
impairment of cognitive or nerve function (Ilveskoski et al., 1996; Lehtinen et al., 2002; 
reviewed by Leiper, 2002a). In children treated for cancer, the risk for a second malignant 
neoplasm (SMN) is approximately 3 to 12% within 20 years of their first diagnosis. In a 
Nordic cohort, relative risk for SMN was 4.3, being highest after a latency of ≥ 10 years in 
those patients < 5 years at the treatment of the first malignant neoplasm. Latency was shortest 
(mean 5.4 years) for leukemias and longest (17-18 years) for tumors of breast and digestive 
tract. CT potentiated the carcinogenic effect of RT (Garwicz et al., 2000). Alkylating agents 
and topoisomerase II inhibitors (Table 2, page 30) have been associated with therapy-related 
AML, while thyroid cancer, breast cancer, and soft tissue sarcomas are often secondary to RT 
(Dreyer et al., 2002; reviewed by Leiper, 2002b). After pediatric allogeneic SCT, 40 to 50% 
of the second malignancies have been post-transplant lymphoproliferative disorders, with the 
highest risk occurring during the first year after therapy. Solid tumors usually appear several 
years after SCT, being 34 times more common than expected in the general population. The 
youngest children (< 5 years at therapy) are at the greatest risk, especially after TBI or CRI or 
both (reviewed by Leiper, 2002b). 
 
 
5. Effects of anticancer therapy on tooth development 
Effects of radiotherapy or anticancer chemotherapy on tooth-forming cells and tooth 
morphogenesis have been mainly studied in rodent incisors, which differ from human teeth: 
They grow continuously, and cell differentation, matrix secretion, and calcification are in 
process also in full-grown animals. Consequently, in spite of the animals age, studies reveal 
the effects of therapy on tooth-forming cells in various phases of differentation, and on their 
precursors, as well as on secretion and calcification processes. Even if the results may be 
comparable at cellular level with developing (roots of) human teeth, the morphological 
outcome is not, since human teeth have only a limited growth capacity. Rodent molars and 
teeth of cats, dogs, and monkeys reach their maturity with the closure of the apices like 
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human teeth, so their morphological outcome can be better compared with humans. In these 
cases, the animals ageactually the stage of tooth developmentis of vital importance. 
Often, effects of anticancer therapy offer a spectrum from mild alterations to tooth agenesis, 
varying with timing of therapy in relation to tooth developmental stage, which varies among 
teeth and is species-characteristic. 
 Animal studies can give clues to the aberrations of human tooth development, but direct 
comparison must be carefully considered. For instance, the equivalent doses of radiation or 
chemotherapeutic agents for animal species and humans are unknown. Furthermore, in animal 
studies, alterations in tooth development can be studied after radiotherapy alone or after 
exposure of animals to a single chemotherapeutic agent. This is not the situation with 
children, who are treated with combination chemotherapy, often accompanied by 
radiotherapy. Infections and their treatment, as well as nutritional deficiencies common during 
anticancer therapy, may also contribute to aberrant tooth development in children (reviewed 
by Pindborg, 1982).  
 
5.1. Animal studies and in vitro experiments 
5.1.1. Radiotherapy 
Tribondeau and Récamier were the first to recognize radiation effects on tooth development, 
back in 1905, by studying kittens (Bruce and Stafne, 1950). Since that time, numerous 
experiments have been made on rats and mice but also on hamsters, rabbits, dogs, and 
monkeys. Although the radiation sensitivity of tooth-related cells may differ between animal 
species and between animals and man, radiation-induced microscopic or macroscopic dental 
findings are markedly similar in them all (reviewed by Kimeldorf et al., 1963). 
 The first sign of injury, within hours after exposure, is nuclear fragmentation in 
precursors of odontoblasts and ameloblasts (reviewed by Kimeldorf et al., 1963). Other 
writers indicate the first adverse effect of radiation as being edema of the pulpal proliferative 
zone, often followed by cystic cavities as seen in the incisors of rats (Medak et al., 1952; 
Adkins, 1967) or Syrian hamsters (Medak et al., 1954). After a heavy irradiation, severe 
hemorrhage and thrombosis of the pulp vessels has been reported in dogs (Kalnins, 1954). 
Depending on dose, degenerative changes in or necrosis of differentiating (non-secretory) 
odontoblasts occur and typical dentin niches, described also following anticancer CT (Section 
5.1.2.), develop as the sign of a temporary disturbance. Thin dentin and predentin zones, 
degenerated and depolarized odontoblasts, and osteodentin in the pulp characterize the 
classical dentin niche. Formation of the osteodentin, regarded as a sign of odontoblast 
damage, begins in the pulp adjacent to the niche in rat incisors (Medak et al., 1952; Collet and 
Thonard, 1965; Koppang, 1967; Koppang and Stokke, 1969; Lindvall et al., 1972), in rat 
molars (Collet and Thonard, 1965), and in monkeys (Gowgiel, 1961). Following the 
degenerative cellular changes and transient disturbances in dentinogenesis, a regenerative 
process is often seen after doses of 1500 to 4000 r in continuously growing rat incisors. This 
is indicated by development of new incisors separated from the pre-irradiation teeth, small 
in size but showing rather normal structure, although often a mottled surface (Medak et al., 
1952; English et al., 1954; Hansen and English, 1957). However, in incisors of Syrian 
hamsters, proliferating odontoblasts are destroyed, with no recovery, after doses of 4200 or 
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4800 r. Differentiated old odontoblasts could still produce dentin (Medak et al., 1954) and 
were suggested to be among the most radio-resistant cells of the body (Kalnins, 1954).  
 Differentiated ameloblasts in mouse molars (Burstone, 1950) and rat incisors (Medak et 
al., 1952; English et al., 1954) were also remarkably radio-resistant. In the majority of the 
studies, in which amelogenesis was reported, ameloblasts were considered more radioresistant 
than were odontoblasts of a similar stage. Contradictory results have been reported: a low 
dose of 375 r (Dale, 1953) and somewhat higher 500 to 900 r doses (Lindvall et al., 1972) 
regularly caused changes in the enamel but not always in the dentin of rat incisors. However, 
there is agreement that at least high radiation doses (> 1500 r) can disturb odontogenic 
epithelium and differentiation of ameloblasts, or the cells may become necrotic, resulting in 
hypoplastic changes in the enamel. Amelogenesis can regenerate, at least in rat incisors after 
radiation-induced inhibition or cessation (Medak et al., 1952; Dale, 1953; English et al., 1954; 
Hansen and English, 1957). In Syrian hamster incisors, the odontogenic epithelium behaved 
differently: local proliferation formed knoblike structures that enlarged to keratin-filled cysts. 
Thus, the odontogenic epithelium did not resume its original function in the recovery process, 
indicating possible differences between species (Medak et al., 1954). 
 The typical acute and long-term dental changes after irradiation are dose-dependent. 
Mild radiation damage results only in temporary changes that may not be noticeable 
macroscopically. More severe insults may cause permanent changes in formation of the dental 
hard tissues, manifesting themselves during a long follow-up as altered tooth size and shape 
(short, tapered, or blunted roots, microdontia), ankylosis or, in extreme cases, as tooth 
agenesis. These changes resemble each other in the developing teeth of several species, for 
instance in macacus rhesus monkeys (Gowgiel, 1961), cats (Donohue and Perreault, 1964), 
mice (molars) (Burstone, 1950), and Syrian hamsters (molars) (Bruce, 1950). After irradiation 
of 2000 r (~ 20 Gy, given in two equal doses 7 days apart) to cats, cessation of root formation 
occurred in the developing teeth. The blunted apical ends of the roots were partially or 
completely sealed with oseodentine, and dystrophic calcification of pulps was visible. Some 
teeth remained embedded in the jaws (Donohue and Perreault, 1964). Higher irradiation doses 
(4500 r, 5500 r, and 7500 r; fractions given during 5.5 to 12.5 weeks) to monkeys with their 
permanent teeth in various stages of development inhibited further crown and root 
development and destroyed the germs of the third molars that were not yet visible in the pre-
irradiation radiographs. Calcification of the crowns was unaffected. Osteodentin closed the 
apices, and pulp tissue was fibrotic. Most teetheven those without rootserupted, but some 
became ankylosed (Gowgiel, 1961). In mouse molars, a single irradiation dose of 1500 r, 
3000 r, or 5000 r resulted in aberrations of tooth development in a dose- and time-dependent 
manner. Irradiation of young animals (< 1 week) resulted in deficient root development in the 
first and second molars, and the third molars, less developed at the time of irradiation, 
emerged in some cases only as irregular masses of dentinoid material. Ankylosis of the 
molars was evident also in mice, especially after high irradiation doses (Burstone, 1950). 
Stage of tooth development was crucial also in the dental outcome of Syrian hamsters after 
various irradiation doses of approximately 1300 to 2500 r to the molar region; tooth agenesis 
and dwarfing of tooth crowns or roots or both occurred (Bruce, 1950b).  
 The minimum radiation dose that causes acute or long-term alterations in tooth-related 
cells and tissues varies by animal species and irradiation design. Moreover, methods of the 
examination (e.g., macroscopic, microscopic, decalcified, or ground sections) affect the 
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possibility of recording any changes. In rat incisors, some nuclear changes have been reported 
at 6 hours following a radiation of 25 r, but only doses of 400 r or greater resulted in 
degenerative changes (reviewed by Kimeldorf et al., 1963). Dentinogenesis has been 
disturbed in 60% of rat incisors after 600 r, but after 300 r the treated rats did not differ from 
controls (Collet and Thonard, 1965). In other studies, however, dentin niches occurred in rat 
incisors even after doses of only 200 or 300 r (Koppang, 1967; Koppang and Stokke, 1969).  
 The mechanism(s) of action, by which the harmful effect of radiation turns into 
disturbances in dentinogenesis, has inspired speculation. Direct effects of radiation on the 
tooth-forming cells, especially on preodontoblasts and differentiating odontoblasts, has 
probably been the most accepted mode for this action, but indirect mechanisms have also been 
suggested. For instance, radiation-induced destruction of blood vessels, resulting in 
hemorrhages and edema in the pulp and thrombosis of the other vessels, causing further 
deprivation of the blood supply may result in secondary changes in odontoblasts (Medak et 
al., 1952; Kalnins, 1954), or may prevent differentation of odontoblasts (Burstone, 1950). 
Some authors also remind us of the possibility that the original insult may be against the 
odontogenic epithelium needed in initiation of the odontoblast differentiation (Burstone, 
1950; Hansen and English, 1957).  
 
5.1.2. Anticancer chemotherapy 
Alkylating agents 
Several studies on rat incisors and molars have demonstrated dose-dependent adverse dental 
effects of cyclophosphamide (Cy), an important member of the group of alkylating agents 
(Table 2, page 30). Intraperitoneal Cy doses from 25 to 150 mg/kg body weight in rats caused 
disturbances in their maxillary and mandibular incisors. The two highest doses (150 and 125 
mg/kg) caused interruption of odontogenesis in all mandibular incisors and lingual aspects of 
maxillary incisors, and osteodentin closed up the pulp cavity. Labial aspects of maxillary 
incisors were more resistant, although all teeth were affected by interrupted odontogenesis or 
constriction (reduction in width). The lingual aspects of mandibular incisors were the sites 
most sensitive to Cy toxicity, and after the dose of 50 mg/kg, all teeth were severely injured 
(70% interrupted odontogenesis, 30% constrictions). The most resistant labial aspects of 
maxillary incisors showed constrictions in 10% and less severe dentin niches (reduced 
thickness of the dentin wall, osteodentin) in 90% of teeth. Even the smallest dose caused 
dentin niches in more than half the teeth. Furthermore, cystic cavities with congested vessels 
and hemorrhage occurred dose-dependently in apical areas (Koppang, 1973a). Offspring of 
rats who had received a single dose of Cy (40 or 50 mg/kg) during pregnancy presented with 
similar but more frequent changes in their incisors than did the adults (constrictions, niches, 
and edema). In addition, external tooth resorptions and scalloping of the dentinoenamel 
junction, seldom seen in adult rats, were present (Koppang, 1978). (For comparison, see 
Table 4, page 56, for HDC doses in children). 
 After Cy administration of 40, 80, and 120 mg/kg in single peritoneal doses, acellularity 
of basal pulp and cessation of root growth occurred in rat incisors. The time period to re-
establish root growth increased with increasing dose (Adatia, 1975). Reduction in the growth 
rate of rat incisors occurred after a Cy dose of 40 mg/kg, but this was followed by an 
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increased growth rate, so that no remarkable difference was eventually noticeable. The depth 
of the dentine niches corresponded with the niches that were seen after 950 rad of whole-body 
irradiation to rats, although Cy-induced niches were longer (Lindvall et al., 1972; Koppang, 
1981). 
 The most sensitive tooth-forming cells in rat incisors were preodontoblasts that had not 
yet started protein production, and the resulting dentine niches developed during 24 hours 
after a Cy injection of 25 mg/kg. After 40 mg/kg of Cy, precursors of preodontoblasts were 
also injured, resulting in larger niches (Koppang, 1973b). Mature odontoblasts, ameloblast, or 
enamel formation were unaffected (Koppang, 1973a, 1973b). Other studies confirmed the 
presence of unaffected differentiated odontoblasts and the high sensitivity of preodontoblast 
precursors to Cy but, in contrast to the finding of uninjured enamel formation by Koppang 
(1973a, 1973b), a dose-dependent mild toxicity was noticed also in the odontogenic 
epithelium (Adatia, 1975; Orams, 1983).  
 Delayed drug-related mortality (70-180 days after Cy administration) in rats occurred 
following a single high-dose Cy injection (75 mg/kg) (Vahlsing et al., 1975, 1977). The 
authors considered the deaths to be due to dental abnormalities preventing the rats from 
eating. Some rats had short or missing maxillary incisors, others presented with overgrown 
often abnormally oriented incisors. Following the Cy exposure, interruption of odontogenesis 
resulted in formation of pre- and post-experimental incisors separated from each other. The 
pre-experimental incisors erupted until lost, and when the post-experimental incisors erupted 
they were often morphologically aberrant and overgrown, preventing normal eating. These 
clinical findings were later confirmed (Reade and Roberts, 1978).  
 Two successive peritoneal Cy injections (both 30 mg/kg body weight) were given to 
rats at the ages of 10 and 13 days. At 10 days, the crowns of the first molars have developed 
and root formation is just beginning. In the second molars, approximately two-thirds of the 
crowns have formed, and the third molars have reached the bell stage, where dentin and 
enamel formation has begun in the occlusal part. Cy injections resulted in wide cell-free areas 
in the cervical region of the pulp of the third molars, close to the epithelium, followed by 
osteodentin formation. In the first and second molars the number of cells was reduced in the 
apical region, but no large cell-free areas appeared. Osteodentin formation closed the apical 
foramina and resulted in shortened root length. Even bacteria penetrated the osteodentin, 
causing pulpal and periodontal infection, considered a sign of poor-quality dentin (Näsman 
and Hammarström, 1996). In scanning electron microscopy these findings were confirmed. 
Crown morphology and size of the first and second molars were not affected since they were 
already fixed when Cy was injected, but the less developed bell-stage third molars were small 
with diverging cusp morphology and a porous structure. Root lengths of the first and third 
maxillary molars in the treated animals varied from 41 to 70% of control values. Again, the 
less-developed third molars suffered more than the first molars. Roots were also thin and 
tapered when compared to controls roots. The authors remind us that these changes are very 
similar to those found in children after pediatric anticancer therapy (Näsman et al., 1997b).  
 Many other anticancer agents of this group are used in pediatric cancer treatment, but no 
studies are available as regards tooth development. 
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Antimetabolites 
Several cytotoxic agents of this group are widely used in pediatric hematology and oncology 
(Table 2, page 30) but have been very little studied as regards tooth development. Hamster 
molar tooth germs were exposed in organ cultures to methotrexate (MTX) concentrations 
running from as high as 103 M to 107 M. Only the highest concentration tested (103 M) 
induced a small, insignificant decrease in cell mass, but with no histologic changes evident. 
The authors suggest that MTX causes no harm to the developing teeth of children (Wöltgens 
et al., 1998). The pyrimidine analogue antimetabolite 5-fluorouracil (5-FU), given in a single 
injection to 8-week-old mice (140 mg/kg estimated 10% lethal dose), caused moderate cell 
death of the epithelial sheath in maxillary incisors. Consequently, local dentin defects arose, 
but normal odontogenesis was established later, leaving a transient dentin injury (Satoh et al., 
2001).  
 
Plant alkaloids 
Two antimicrotubular agents, vinblastine (VBL) and vincristine (VCR) (vinca alkaloids, 
Table 2, page 30), inhibit mitosis by binding to tubulin but also by interfering with other 
cellular functions, e.g., transport of proteins. Microtubules play an important role in enamel 
maturation when ameloblasts transport organic components from the enamel matrix. They 
also function in maintaining cell shapes. Thus, effects of antimicrotubular agents on 
ameloblast morphology and function occurred following VBL or VCR exposures. A single 
intravenous VBL injection (4 mg/kg) to rats caused a decrease in the number of microtubules 
of maturing ameloblasts in their incisors at one hour, and at 2 hours the microtubules almost 
disappeared. Reduction in ruffle-ended ameloblasts occurred, or the ruffles became shorter, 
with dislocation of nuclei, mitochondria, and endoplasmic reticulum (Akita et al., 1983). 
Changes in cell morphology and polarity, as well as disappearance of microtubules in both 
secretory and maturation stage ameloblasts after VBL administration, were later confirmed 
(Yamamoto et al., 1997). A decrease in immunopositive staining for α-tubulin, a structural 
component of microtubules, appeared from 1 to 6 hours after vinblastine injection. In 48 
hours, most changes had recovered (Yamamoto et al., 1997). Furthermore, VBL decreased 
Ca2+, Mg2+-adenosine triphosphatase activity in both ruffle-ended ameloblasts and membrane-
associated calcium (Eisenmann et al., 1992). This was thought to demonstrate VBL 
interference with the normal calcium influx into the enamel (McKee and Warshawsky, 1986). 
Irregular enamel formation occurred in mice incisors, continued at least 15 days after VBL 
injection, but recovered by day 60 (Satoh et al., 2001). 
 VBL had acute and protracted injurious effects in rat incisors also on preodontoblasts 
and odontoblasts. Both showed minor changes (displaced nuclei, grains in cytoplasm) 6 hours 
after the injection (2 mg/kg) but in 24 hours young odontoblasts, located incisal to the site of 
enamel secretion, were greatly changed in shape or destroyed, and old odontoblasts showed 
changes in morphology. In 3 days, the number of preodontoblasts was reduced and 
odontoblasts still presented with anomalous shapes. After 7 days, preodontoblasts and young 
odontoblasts had recovered and dentin niches and osteodentin appeared in the area of old 
odontoblasts (Mikkelsen, 1978). Moreover, VCR, injected at different doses, produced 
mitotic disturbances in preodontoblasts and their mesenchymal precursors, and these 
increased with increasing doses. High VCR doses also affected the differentiated 
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odontoblasts, causing morphologic derangement and having lethal effect even on some non-
dividing cells. VCR interferes with the dentin matrix production by inhibiting the synthesis of 
collagen precursors or by reducing odontoblasts ability to secrete them or both, leading to 
irregular predentin production (Stene, 1978; Stene and Koppang, 1980). With a longer follow-
up, dentin niches due to reduced dentin production appeared, and their size increased with 
increasing doses (Stene, 1979).  
 Compared to vinca alkaloids, epipodophyllotoxins (etoposide, teniposide) have a 
different mechanism of action. To my knowledge, these have never been studied in vivo or in 
vitro as regards tooth development (Table 2).  
 
Antitumor antibiotics 
Doxorubicin (= adriamycin), commonly used in pediatric anticancer therapy, belongs to the 
anthracycline group (Table 2, page 30). Its effects on odontogenesis have been widely studied 
in rat experiments. One day following a single doxorubicin injection of 5 mg/kg body weight, 
destruction of preodontoblasts and some adjacent progenitor pulp mesenchymal cells 
occurred in incisors. The older the odontoblasts became, the more resistant they were to the 
toxic effects of the drug, and old, fully differentiated odontoblasts were unaffected (Dahl, 
1984; Karim, 1985a). At the follow-up from 3 to 7 days, mesenchymal cell aggregations were 
first visible near the areas of destroyed cells, and at these sites osteodentin formation began in 
the pulp (Karim, 1985b). Most of the changesreduced dentin production, altered 
odontoblast morphology, irregular dentin deposition, and formation of osteodentin in the 
pulpwere visible after doses of 5 mg/kg, with changes being more prominent with 
increasing (10 and 20 mg/kg) doxorubicin doses (Dahl, 1984; Karim and Eddy, 1984; Dahl 
and Stromme Koppang, 1985). No recovery of early preodontoblasts, the most sensitive to 
doxorubicin, occurred after any of the doses during the observation periods. When the total 
dose of doxorubicin was divided into several smaller doses, its odontogenic cytotoxicity 
increased, and regeneration was greatly delayed when compared with single-dose 
administration (Dahl, 1985).  
 The same kind of acute changes have appeared in incisors after an adriamycin dose of 
5.3 mg/kg to 8-day-old mice (Satoh et al., 2001). In follow-up, irregular dentinogenesis 
(osteodentin), cell debris, edema, disorganized odontoblasts, and inflammation of the alveolar 
bone surrounding the tooth apex were still apparent on days 10 to 18. These alterations did 
not recover during the observation period of 60 days. Ameloblasts and enamel formation 
remained unaffected (Satoh et al., 2001). Exposure of golden hamster 3-day-old (bell-stage) 
maxillary second molars to adriamycin (1 mg/liter) during the first 2 hours of cell culture 
resulted in the development of teeth smaller than normal. Growth in the cervical loop area 
was inhibited, with mild necrosis within the apical pulp. With an adriamycin concentration of 
5 mg/liter, necrosis was more extensive, and preodontoblasts and their precursors were 
destroyed and, furthermore, with 10 mg/liter, even some young odontoblasts and ameloblasts 
died. When molars were treated with adriamycin (5 mg/liter) and then cultured for 1 day, 
necrosis appeared in the pulp, and in the young cusps, necrosis destroyed all preodontoblasts 
and their precursors (Karim et al., 1989). 
 Dactinomycin (actinomycin-D) injection (0.375 µg/kg) has caused considerable 
necrosis of preodontoblasts and peripheral pulpal cells in developing rat incisors. Later, 
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osteodentin formed in the pulp, and decreased dentine production manifested itself as a 
sharply defined dentine niche. Dentine was normal both incisally and apically of the niche. 
No evidence appeared of the interference of dactinomycin with the differentation of 
ameloblasts or the functions of the enamel organ (Adkins, 1972). In organ culture, several 
constant dactinomycin concentrations reduced dose-dependently the dry weight of the 
developing tooth germs of hamsters, but these disturbed the mineralization only at the highest 
concentration tested (5 x 105 M). This dose was cytotoxic to all odontogenic cells, including 
the secretory odontoblasts and ameloblasts. Cell proliferation rate was reduced even at low 
concentrations, with the most sensitive cells being preodontoblasts that (based on the nuclear 
morphology) appeared to undergo apoptotic cell death. Cell death was described as apoptotic 
at concentrations < 107 M, but as necrotic due to acute cytotoxicity at higher doses (> 106 
M) (Lyaruu et al., 1997).  
 The effects of daunorubicin on hamster tooth germs resembled those of dactinomycin. 
Exceptionally, the most sensitive cells were preameloblasts, followed by preodontoblasts, 
with the mode of cell death being apoptotic at low daunorubicin concentrations, but toxic at 
high concentrations (Lyaruu et al., 1999).  
 
Platinum analogs 
The only agent reported in relation to tooth development is cisplatin, studied in one 
experiment on mice. Only minimal cell death occurred in precursor cells of the epithelial 
sheath on day 3 after the cisplatin injection (7.5 mg/kg), with no changes during follow-up 
until day 60 (Satoh et al., 2001). 
 
5.2. Development of permanent teeth after anticancer therapy during childhood 
The effect of radiotherapy (RT) on developing human teeth has become evident from case 
reports, one of which described five patients whose oral or facial hemangiomas or 
lymphangiomas were treated with irradiation at an early age (Bruce and Stafne, 1950). The 
authors listed the effects of irradiation on teeth: It 1) can injure a tooth germ to the extent 
that a tooth will not form; 2) causes dwarfing of permanent teeth; 3) effects dwarfing of the 
roots of permanent teeth that are undergoing development during irradiation; 4) effects 
premature completion of calcification of permanent teeth and 5) may cause early eruption of 
permanent teeth. These findings, except the early eruption, and often with hypocalcification 
added, have been confirmed (Gorlin and Meskin, 1963; Donohue et al., 1965; Pietrokovski 
and Menczel, 1966; Lines et al., 1979; Folwaczny and Hickel, 2000).  
 RT is usually combined with anticancer CT. If the dental area is irradiated or receives 
scattered irradiation, it is difficult or impossible to distinguish between CT and RT effects. In 
most cases, however, irradiation fields do not include the teeth, which allows for studies in 
which CT effects can be examined separately. The information received from these studies 
varies by study population, treatment protocol, and study method. Dental consequences in the 
children most heavily treated with HDC, with or without TBI, and with SCT have not been 
widely studied, but when compared to children treated with CCT, the latter were less affected 
(Näsman et al., 1994, 1997a; Duggal, 2003). 
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 Teeth extracted from patients having been cured of childhood cancer have also been 
histologically studied. The distribution of prominent incremental lines in their dentine 
corresponded with the periods of intravenous VCR therapy. VCR probably disturbed the 
microtubular function of odontoblasts and resulted in the decreased amount of dentine matrix 
that became hypercalcified when the normal amount of calcium was deposited in this 
decreased matrix (Macleod et al., 1987; Maguire et al., 1987). No changes appeared in the 
enamel (Macleod et al., 1987). In contrast, incremental lines occurred also in the enamel in 
two teeth of a patient exposed to multiagent CT, HDC, and TBI (10 Gy, single fraction) prior 
to SCT. Furthermore, gross hypoplasia appeared in the cervical area developing at the time of 
TBI (Dahllöf et al., 1994).  
 The key results of selected clinical studies of developmental dental defects (especially 
tooth agenesis, microdontia, and root development) are summarized in Table 3. 
 
5.2.1. Tooth agenesis  
After CCT, the percentage of patients with tooth agenesis varied from 5 to 28% (mean 16% in 
the Table 3 studies). The lowest figure can be explained by the method used: The most 
commonly missing teeth, second premolars and third molars, were excluded, because these 
teeth quite frequently are lacking also in a healthy population (Sonis et al., 1990). The highest 
percentage included the third molars (Maguire et al., 1987), at least one of which is missing in 
20 to 30% of healthy people. The prevalence of tooth agenesis, excluding third molars, 
usually ranges from 4 to 8% (Section 2.2.2.). Thus, tooth agenesis seems to be slightly 
elevated after CT.  
 In the three studies on BMT recipients, which reported the prevalence of tooth agenesis, 
percentages were 56%, 58% (Näsman et al., 1994, 1997a), and 11% (Uderzo et al., 1997). It 
remains unclear whether the third molars were included in the Näsman studies, but obviously 
they were excluded from the latter. These studies failed to tell the age at which the diagnosis 
of tooth agenesis for various teeth was made. Thus, detailed information of tooth agenesis in 
SCT recipients is lacking (Table 3). 
 
5.2.2. Microdontia  
No subjective or objective criteria are given for the microdontia assessments in which, after 
CCT, microdontia prevalence varied from 10 to 38% (mean 20%) (Table 3). The importance 
of age at treatment as regards dental outcome was noticed in microdontia studies, with young 
patients being more vulnerable (Maguire et al., 1987; Sonis et al., 1990; Kaste et al., 1998).  
 Prevalence of microdontia in the three BMT groups was 25%, 68%, and 75% (Dahllöf 
et al., 1988; Näsman et al., 1994, 1997a) (Table 3).  
 
5.2.3. Root development of permanent teeth 
Since solid criteria or features expressing disturbed dental root development are lacking, 
several assessment methods, most of which have been based on subjective visual judgment, 
lead to disparate results. Treatment with CCT or CT and CRI disturbed root development in 
15 to 28% of patients. In the two studies (Rosenberg et al., 1987; Sonis et al., 1990) in which 
 Review of the literature 
 
48 
some kind of grading or measuring was done, figures ranged from 77 to 94%. Except for 
canines in the earlier 1988 study, root areas and ratios of root and crown areas were smaller in 
cancer patients than in controls (Pajari et al., 1988a; Duggal, 2003) (Table 3). 
 Root development is disturbed in almost all BMT patients (Dahllöf et al., 1988; Näsman 
et al., 1994, 1997a), and BMT patients are also more severely affected than are patients 
treated with CT (and sometimes with CRI). However, one study with 27 BMT patients gives a 
rather small prevalence, 33%, for root hypoplasia (Uderzo et al., 1997). 
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AIMS OF THE STUDY 
The purpose of the present study was to investigate the development of permanent teeth in a 
group of pediatric stem cell transplant (SCT) recipients. Another goal was to develop a simple 
and objective method to express numerically the quantity of dental disturbances. 
 
Specifically, the aims were to examine the effects of TBI and age at SCT on 
• tooth agenesis  
• microdontia  
• dental root development  
and  
• to develop an objective method to study root development in SCT patients, and to 
compare results to corresponding values in healthy people 
• to develop and test a method by which the sum of developmental disturbances of 
individual patients permanent teeth can be expressed with one index figure 
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SUBJECTS AND METHODS 
6. Study population  
6.1. Stem cell transplant recipients (I, III, IV)  
Eligible patients were all those of Finnish decent who had undergone SCT under the age of 10 
years at the Hospital for Children and Adolescents, University of Helsinki, between 1980 and 
1999. The minimum follow-up period after SCT was one year. Of the 85 eligible patients, 13 
did not wish to take part in the study (mean age at SCT 6.0, range 1.5 to 9.7 years), and 8 
patients were not reachable (mean age at SCT 3.7, range 1.1-7.9 years). Furthermore, 8 
patients originally willing to take part in the study were excluded due to their death (N = 2) or 
terminal care (N = 1), other severe health problems (N = 1), cooperation problems and/or to 
very young age (N = 4). Thus, 56 patients (mean age at SCT 4.3, range 1.0-9.4 years), 66% of 
the original eligible survivors, were included in the final study group. The Medical Ethics 
Committee of the Hospital for Children and Adolescents, University of Helsinki, approved the 
study protocol. Table 4 lists study patients with key characteristics. Further details on the 
mean ages (ranges), numbers of patients and teeth examined, and patient groupings appear in 
Tables 5 and 6. 
 
6.1.1. Treatment of patients before stem cell transplantation 
Conventional multiagent chemotherapy was started for those children diagnosed with cancer. 
Patients with ALL, AML, and NHL were treated according to Nordic protocols (Gustafsson et 
al., 2000; Lie et al., 2003), including prednisolone, vincristine, doxorubicin, methotrexate, L-
asparaginase, cyclophosphamide, cytosine arabinoside, and 6-mercaptopurine. Anticancer 
chemotherapy for the NBL patients consisted of vincristine, cyclophosphamide, dacarbazine, 
cisplatin, and doxorubicin, in individual cases modified with ifosfamide and etoposide 
(Saarinen et al., 1996). Wilms tumor patients received vincristine, actinomycin D, 
cyclophosphamide, and doxorubicin, which were also used for the one RMS patient, with 
ifosfamide and etoposide added. The two patients with CML were treated with hydroxyurea, 
while the patients with myelodysplastic syndrome (MDS) and severe aplastic anemia (SAA) 
received no conventional chemotherapy before the SCT procedure. The patient with yolk sac 
tumor was treated with chemotherapy courses consisting of bleomycin, etoposide, and 
cisplatin.  
 Radiotherapy, targeted to the tumor bed or local metastases, was administered to 17 
patients. Six patients received RT to the skull area: CRI (12 to 24 Gy) to three leukemia 
patients and local irradiation to three NBL patients for metastases situated in the left frontal 
bone (20 Gy), right orbital area (20 Gy), and left temporal bone (6 Gy). The effect of minor 
scattered irradiation on developing teeth was considered insignificant, especially when 5 of 
the 6 patients later also received TBI. In the remaining 11 patients, the RT targets were far 
from the developing teeth.  
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6.1.2. Conditioning for stem cell transplantation 
In all patients, the preparative regimen for SCT included HDC. Chemotherapeutic agents with 
dosages are listed in Table 4. In addition, 39 of 56 patients received TBI of 10 to 14 Gy, 
overlapping with developing teeth. TBI of 10 Gy was delivered to one patient in a single 
fraction; all the others had TBI in 2 Gy fractions during 3 days. Two patients with TBI 
excluding the head, and one patient with total nodal irradiation (see Table 8, pages 69-70) 
were considered non-TBI patients as regards tooth development.  
 
6.2. Healthy adolescents and young adults (I, II) 
The healthy subjects in Studies I and II participated in a longitudinal investigation initiated at 
the Department of Pedodontics and Orthodontics in 1967 with the permission of the National 
Board of Health. The main aim of that study was to gather information on tooth development 
and craniofacial growth in Finnish children (Nyström, 1982). During the years 1967 to 1969 
maternity nurses at five Mother and Child Welfare Centers in Helsinki informed women 
carrying their first children about the study. These mothers volunteered to bring 382 children 
to their first dental examination at 6 months, and the number of children increased to 435 
when mothers later brought 53 siblings of the first-born babies. These children, born between 
1967 and 1973, were all of Finnish descent. They were examined clinically also at 9, 12, and 
18 months, then semiannually until 1980, and annually thereafter. At the age of 16 years, 187 
adolescents were still participating in the study (Nyström et al., 2001). Three to four PRGs per 
patient were taken during the course of the study. The study subjects were healthy, with no 
history of severe childhood diseases or treatments known to affect tooth development. Among 
these subjects, 18 PRGs were randomly picked to test a scale called the Defect Index (DeI), 
created for the group of SCT recipients (I). For the study of root-crown (R/C) ratios of 
permanent teeth in a normal population (II), study records and PRGs of all 187 subjects were 
examined. After excluding those with the history of orthodontic treatment (N = 36), the PRGs 
with reference points for tooth measurements not clearly visible in several teeth (N = 27), and 
PRGs technically unacceptable (N = 16), the study material comprised PRGs of 108 healthy 
Finnish adolescents. Age and grouping information is in Tables 5 and 6. 
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Table 4. Key characteristics of the stem cell transplantation (SCT) patients, who participated in the studies. 
Follow-up from SCT to most recent panoramic radiograph. 
Patient  Gender Diagnosis Age at SCT, yrs Follow-up, yrs TBI HDC Study 
1. F(emale) NBL 1.0 13.6 No Mel I; III; IV 
2. M(ale) ALL 1.1 13.2 Yes Ara-C III; IV 
3. F NBL 1.2 2.0 No Mel (I) 
4. M NBL 1.4 9.0 Yes VMP I; III; IV 
5. F NBL 1.4 6.0 No Mel I; III; IV 
6. F NBL 1.5 14.3 No Mel I; III; IV 
7. M NBL 1.9 3.8 No ECT I; III 
8. F NBL 2.0 9.1 Yes VMP I; III; IV 
9. F NBL 2.0 9.3 Yes VMP I; III; IV 
10. F NBL 2.2 10.1 Yes VMP I; III; IV 
11. M AML 2.2 7.0 Yes Cy III; IV 
12. F MDS  2.2 5.9 Yes Cy III; IV 
13. M NBL 2.3 9.6 Yes VMP I; III; IV 
14. F NBL 2.4 2.2 Yes VMP III; IV 
15. M AML 2.5 8.8 Yes Ara-C III; IV 
16. F Yolk sac tumor  2.5 3.1 No ECT III; 
17. M NBL 2.7 14.7 No Mel I; III; IV 
18. M AML 3.1 4.4 Yes Ara-C III; 
19. M NBL 3.1 13.7 Yes VMP I; III; IV 
20. F NBL 3.1 5.7 Yes VMP I; III; IV 
21. M NBL 3.2 10.7 Yes VMP I; III; IV 
22. F NBL 3.2 7.5 No VMP I; III; IV 
23. F ALL 3.5 6.0 Yes Mel III; IV 
24. M ALL 3.6 4.3 Yes Ara-C III; IV 
25. M SAA 3.9 12.3 Yes Cy III; IV 
26. F NBL 3.9 10.4 Yes VMP I; III; IV 
27. M NBL 4.1 13.1 Yes VMP I; III; IV 
28. F AML 4.2 14.1 Yes Cy III; IV 
29. M Wilms tumor 4.2 4.7 No Mel III; IV 
30. F RMS 4.7 7.2 No ECT III; IV 
31. F Wilms tumor 5.0 6.2 No Mel III; IV 
32. F ALL 5.0 9.0 Yes Ara-C III; IV 
33. F Wilms tumor 5.1 4.1 No Mel III; IV 
34. F ALL 5.2 3.8 Yes Ara-C III; IV 
35. F AML 5.2 20.6 Yes Cy III; IV 
36. F AML 5.2 7.9 Yes Cy III; IV 
37. M CML 5.2 7.3 Yes Cy III; IV 
38. M ALL 5.4 3.4 Yes Ara-C III; IV 
39. M ALL 5.4 4.5 Yes Ara-C III; IV 
40. M ALL 5.4 5.5 Yes Ara-C III; IV 
41. F CML 5.5 1.8 Yes Ara-C III; IV 
42. F ALL 5.6 8.5 Yes Cy III; IV 
43. M NHL 5.7 2.1 Yes Cy III; IV 
44. M NBL 5.8 7.7 No Mel I; III; IV 
45. M ALL 5.8 4.0 Yes Mel III; IV 
46. M ALL 5.9 2.7 Yes Mel III; IV 
47. M Wilms tumor 6.1 8.0 No Mel III; IV 
48. M SAA 6.2 7.2 No Cy III; IV 
49. M ALL 6.3 1.5 Yes Cy III; IV 
50. M Wilms tumor 6.4 8.3 No Mel III; IV 
51. F NHL 6.4 5.0 Yes Ara-C III; IV 
52. F AML 6.8 3.0 Yes Mel III; IV 
53. M NBL 7.9 1.0 No VMP III; IV 
54. F AML 8.7 4.3 Yes Ara-C III; IV 
55. F AML 9.0 10.7 Yes Cy III; IV 
56. M MDS  9.4 3.1 Yes Cy III; IV 
 
Abbreviations: TBI: total body irradiation; HDC: high-dose chemotherapy; NBL: neuroblastoma; ALL: acute lymphoblastic 
leukemia; AML: acute myeloid leukemia; CML: chronic myeloid leukemia; MDS: myelodysplastic syndrome; NHL: non-
Hodgkin lymphoma; SAA: severe aplastic anemia; RMS: rhabdomyosarcoma; Ara-C: cytosine arabinoside 3 g/m2 x 12; Cy: 
cyclophosphamide 120 to 200 mg/kg; Mel: melphalan 140-180 mg/m2; VMP: etoposide 300 mg/m2, melphalan 140 + 70 
mg/m2, cisplatin 90 mg/m2; ECT: etoposide 250 mg/m2 x 3, carboplatin 500 mg/m2 x 3, thiotepa 300 mg/m2 x 3 
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Table 5. Mean ages of patients at stem cell transplantation (SCT) with follow-up periods after SCT, and mean 
ages of study subjects at panoramic radiography (PRG).  
 Study I  Study II Study III Study IV 
Mean age (years) of SCT patients at 
             SCT (range) 
             PRG (range) 
 
2.6 (1.0-5.8) 
10.5 (3.2-17.3) 
  
4.3 (1.0-9.4) 
11.7 (4.7-25.7) 
 
4.4 (1.0-9.4) 
11.7 (4.7-25.7) 
Mean follow-up (years) after SCT (range 7.9 (1.9-14.6)  7.4 (1.0-20.6) 7.2 (1.0-20.6) 
Mean age (years) of healthy subjects at  
             PRG (range) 
 
18.7 (14.5-24.3) 
 
18.3 (12.6-25.4)   
 
 
7. Methods 
7.1. Radiographic and clinical examinations  
Radiographic and clinical examinations of the 53 SCT recipients were performed at the 
Institute of Dentistry, University of Helsinki. The PRGs of these patients were taken by two 
experienced radiographers using either the Orthopantomograph® OP 100 (GE Healthcare, 
Tuusula, Finland) or the PM 2002 CC (Planmeca Co., Helsinki, Finland), with respective 
magnification factors of 1.3 and 1.2. Lateral cephalograms were also taken. The PRGs (and 
other dental information available) for three patients came from their local health centers. The 
author of this thesis performed all other clinical examinations.  
 Clinical examination of the SCT patients included recording of caries (also initial), 
hypomineralization lesions, fillings, extractions, eruption of teeth, occlusion, periodontal 
tissues (not probing depth), and oral mucosa. Alginate impressions for plaster casts were 
taken whenever possible, i.e., when children agreed to undergo the procedure. Patients or their 
guardians were asked about the childs dental care (professional and home care), symptoms 
occurring in teeth and other oral tissues (pain, dryness), as well as their opinion of the childs 
ability to chew all kinds of food. They were asked if they knew any relatives with missing 
teeth or other dental disturbances. Since the results of the clinical examination are not 
analyzed in this thesis, they are not described in detail. 
 The study protocol was repeated in 2 to 3 years for the SCT patients with developing 
dentitions. If dentition was fully developed at the time of the first examination (except for 
third molars), no further visits were planned. Many patients (or guardians) or the childrens 
local dentists contacted the author and hoped for extra visits when some specific dental 
problems occurred. Several patients were thus clinically examined 3 to 5 times during the 
course of the study, but other parts of the study protocol were carried out only when necessary 
for treatment or treatment planning. If extra PRGs were taken, they were utilized in the 
study. 
 PRGs of the healthy subjects were also taken at the Institute of Dentistry, University of 
Helsinki (Nyström et al., 2001), with either an Orthopantomograph 5 (Palomex Co, Tuusula, 
Finland) or Cranex DC (Sorodex Co, Helsinki, Finland), each with a magnification factor of 
1.3. The same two radiographers took the PRGs of healthy subjects and SCT patients. The 
author, seeking, in particular, information on childhood diseases, dental trauma, tooth 
extractions, and orthodontic treatment, reviewed all files concerning clinical examinations of 
the healthy subjects.  
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7.2. Assessment of permanent tooth agenesis from panoramic radiographs (I, III) 
Since the developmental schedules of different teeth vary, specific age limits were set for the 
recording of tooth agenesis (Section 1.4., Figure 3). Permanent incisors, canines, and first 
molars were always considered eligible for the tooth agenesis assessment. First premolars 
were not judged as lacking before the age of 5 years. The age limit for the second premolars 
and permanent second molars was 6 years. In Study I, third molars (wisdom teeth) were 
considered missing only at the age of 13 or later. Some characteristics of the poor-risk NBL 
patients, examined for tooth agenesis in Study I, are presented in Tables 5 and 6. 
 Age limits for assessment of tooth agenesis in Study III, and in the thesis Results were 
the same as in Study I (see above) except for the third molars, for which the limit was reset to 
12 years. The effects of HDC, TBI, and age at SCT on tooth agenesis were studied in two 
separate assessments, excluding or including the third molars, with study groups formed 
accordingly (Table 6; more details in Tables 4 and 5). Many of the NBL patients included in 
both Studies I and III had longer follow-up times in Study III, which was carried out only 
when most patients had already attended their second examination.  
 
7.3. Assessment of microdontia from panoramic radiographs (I, III) 
Microdontia was assessed by subjective visual judgment. Only the remarkably small teeth, in 
which crown size (mesio-distal dimension seen on PRGs) was estimated to be half or less 
than normal, were considered microdontic. For characteristics of study groups see Tables 5 
and 6. 
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Table 6. Study topics and grouping of study subjects in Studies I-IV and in Results of the thesis, with numbers of 
patients examined in each (sub)group. Numbers of root-crown (R/C) ratios investigated also given.  
Study no.; 
study topic 
N, patients,  
perspective(s) of the study  Patient grouping (N) 
No. of R/C 
ratios studied 
Study I 
Tooth agenesis 
18 NBL patients (3 excluded), 
18 healthy test subjects, 
third molars included 
TBI group (10) 
Non-TBI group (5) 
Healthy test group (18) 
 
Microdontia 
18 NBL patients (1 excluded), 
18 healthy test subjects, 
third molars included 
TBI group (10) 
Non-TBI group (7) 
Healthy test group (18) 
 
R/C ratio 
18 NBL patients (3 excluded), 
18 healthy test subjects, 
third molars included 
TBI group (10) 
Non-TBI group (5) 
Healthy test group (18) 
238 
126 
464 
Defect Index 
(DeI) 
18 NBL patients (1 excluded), 
18 healthy test subjects, 
third molars included 
TBI group (10) 
Non-TBI group (7) 
Healthy test group (18) 
 
Study II 
R/C ratio 108 healthy subjects, third molars excluded 
Males (53) 
Females (55) 
1382 
1397 
Study III 
Tooth agenesis  
#1) 52 SCT recipients, third 
molars excluded 
#2) 29 (updated N = 32 in the 
thesis) SCT recipients ≥ 12 yrs, 
third molars included 
TBI group (#1 = 38; #2 = 18) 
Non-TBI group (#1 = 14; #2 = 11) 
Group Y: ≤ 3.0 yrs at SCT (#1 = 13; #2 = 6) 
Group M: 3.1-5.0 yrs at SCT (#1 = 15; #2 = 9) 
Group O: ≥ 5.1 yrs at SCT (#1 = 24; #2 = 14) 
 
Microdontia 
55 SCT recipients, 
third molars excluded 
  
TBI group (39)/non-TBI group (16) 
Group Y: ≤ 3.0 yrs at SCT (16) 
Group M: 3.1-5.0 yrs at SCT (15) 
Group O: ≥ 5.1 yrs at SCT (24) 
 
Study IV 
Total (52) 
TBI group (38) 
Non-TBI group (14) 
945 
674 
271 
Group Y: ≤ 3.0 yrs at SCT (14) 
            TBI/non-TBI (10/4) 
226 
    154/72 
Group M: 3.1-5.0 yrs at SCT (14) 
            TBI/non-TBI (10/4) 
262 
     185/77 
52 SCT recipients, 
third molars and microdontic teeth 
excluded 
Group O: ≥ 5.1 yrs at SCT (24) 
            TBI/non-TBI (18/6) 
457 
     355/122 
TBI group (29)    
Non-TBI group (10) 
605 
237 
Group Y: ≤ 3.0 yrs at SCT (11) 
            TBI/non-TBI (8/3) 
215 
     145/70 
Group M: 3.1-5.0 yrs at SCT (12) 
            TBI/non-TBI (9/3) 
242 
     175/67 
SDS of the R/C 
ratio 
39 SCT recipients with advanced 
tooth development (= more than 
50% of the teeth fully developed),
third molars and microdontic teeth 
excluded 
Group O: ≥ 5.1 yrs at SCT (16) 
            TBI/non-TBI (12/4) 
385 
     285/100 
Thesis 
55 SCT recipients; 
third molars excluded 
Total (55) 
TBI group (39)/non-TBI group (16)  
TBI group (27)/non-TBI group (9)  
Group Y: ≤ 3.0 yrs at SCT (11) 
            TBI/non-TBI (8/3)  
Group M: 3.1-5.0 yrs at SCT (10) 
            TBI/non-TBI (8/2)  
Individual 
Defect Index 
(IDeI) 
36 SCT recipients with advanced 
tooth development (= at minimum 
20 teeth of 28 included in the 
index), 
third molars excluded Group O: ≥ 5.1 yrs at SCT (15) 
            TBI/non-TBI (11/4)  
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7.4. Assessment of root-crown ratios from panoramic radiographs (I, II, IV) 
A previously described method, originally used to study the root-crown (R/C) ratios (also 
called relative root length) of upper maxillary incisors (Lind, 1972), was adapted for the 
assessment of R/C ratios in all permanent teeth. The heights of the crowns and the lengths of 
the roots were measured according to the same measurement principles in Studies I, II, and IV 
(Figure 6). The R/C ratios of individual teeth were calculated by dividing root length by 
crown height. A tooth was excluded from R/C ratio assessment if the apex was not closed, 
reference points used in the measurements were not reliably visible, roots were unusually 
curved, there existed a history of dental trauma, or attrition or abrasion of the crown was 
detectable.  
 
Figure 6. Method for measuring crown height and root length. In teeth with two buccal roots, the 
longer one was measured. Palatal roots were omitted. 
m: visually determined midpoint of a straight line connecting the points of intersection between the 
contours of the root and crown;  
Crown height (Crh): perpendicular line from point m to the incisal/occlusal reference line (i). In 
canines and most premolars, line i was set by placing one of the parallel lines of the measuring grid 
visually perpendicular to the long axis of the tooth and tangential to an incisal tip or to a buccal cusp. 
In incisors and molars, line i was set by placing the line of the grid so as to follow the incisal edge or 
to connect the buccal cusps, respectively. 
Root length (Rl): distance from point m perpendicular to the apical tangent a, which was parallel to 
the incisal/occlusal reference line i. 
 
 A transparent plastic measuring grid (PM 2002 CC, RadioDent Co, Helsinki, Finland), 
with parallel lines at intervals of one and two millimeters (Figure 7), was used in the 
measurements, which were rounded to the nearest half or whole millimeter. Instead of the 
absolute linear measurements (millimeters) of root lengths and crown heights, only ratios 
were used in the studies to eliminate the effect of the varying magnification factors between 
different machines and regions of the same radiograph (Welander et al., 1989; Thanyakarn et 
al., 1992a).  
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Figure 7. Plastic measuring grid. 
 
7.4.1. Categories of root-crown ratios in Study I 
The categories of R/C ratios in Study I were based on the normal R/C value of 1.6 for 
maxillary central incisors (Lind, 1972) and on the authors clinical judgment as to the extent 
of injury. The first category, D0, included undisturbed teeth with R/C ratios > 1.6; in D1-
category (mild disturbance) the R/C ratios were 1.2 to 1.6, in D2 (severe disturbance) 0.9 to 
1.1, and in D3 (very severe disturbance) < 0.9. The same limits were used for all permanent 
teeth. Category number expressed the number of defect points (1, 2, or 3), reflecting 
disturbances especially in root development.  
 
7.4.2. Determination and reproducibility of root-crown ratios in Study II 
After completion of Study I, it seemed probable that normal R/C ratios vary among teeth. 
To clarify the normal R/C ratios for individual teeth, these were measured in a group of 
healthy adolescents, separately in males and females (II) (Table 6). Furthermore, the 
measurement method was described in detail (Figure 6), and its reproducibility was tested 
both for intra-examiner (A1 and A2) and for inter-examiner (A1 and B) measurements. The 
error of the method (em) was calculated by the formula 
2
m
de
2n
= ∑ , 
where d is the difference between double assessments (A1-A2 or A1-B), and n is the number 
of double determinations. Error variances (em2) were calculated for all teeth and compared to 
the biological variance of the corresponding tooth which came from the standard deviations 
(SD) of the repeated measurements by the formula  
2 2 2
A1 A2 BSD SD SDbiological variance
3
+ +
= . 
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7.4.3. Treatment of root-crown ratios in Study IV 
R/C ratios of fully developed permanent teeth were calculated in the group of SCT recipients, 
andbased on gender-specific R/C ratios in a healthy population (II)standard deviation 
scores (SDSs) were calculated for all R/C ratios of the SCT patients. SDS, also called a z-
score, indicates how much and in what direction the patients value deviates from the mean 
value of the normal population, expressed in units of the populations standard deviation. 
SDSs were calculated according to the formula 
pat meanRC RCSDS
SD
−
= , 
where RCpat is the R/C ratio of a patients tooth, and RCmean and SD are the tooth- and gender-
specific mean R/C ratio and standard deviation of the corresponding tooth in a healthy 
population. The effects of TBI and age at SCT on SDSs were studied in several subgroups 
(Table 6). 
 
7.5. Defect indices (I, Results of the thesis) 
Defect Index (DeI) combines tooth agenesis (D5; gives 5 defect points), microdontia (D4; 4 
defect points), and abnormalities in the R/C ratio (D1, D2, D3; 1, 2, and 3 defect points, 
respectively; see Section 7.4.1.) in a single figure expressing severity of damage in a 
dentition. The following formula was used in the calculation: 
( ) ( ) ( ) ( ) ( )D1 D2 D3 D4 D5DeI N ×1 N ×2 N ×3 N ×4 N ×5= + + + + , 
where N is the number of teeth in the respective disturbance category D1, D2, D3, D4, or D5 
(consequently, the higher the final figure, the more severe the dental damage). The theoretical 
maximum of the DeI was 160 in Study I with third molars included. 
 Individual Defect Index (IDeI), a more precise second version of the DeI, based on the 
gender-specific R/C ratios in a healthy population (Section 7.4.3.), was developed later. After 
the calculation of SDSs of the R/C ratios, new limits were set for the determination of defect 
points according to SD score. Defect points for the IDeI were as follows: 
• Tooth agenesis; defect points: 5 
• Microdontia; defect points: 4 
• SDS of R/C ratio inside ±2; defect points: 0 
• SDS of R/C ratio between 2.1 and 3.0 or 2.1 and 3.0; defect points: 1 
• SDS of R/C ratio between 3.1 and 4.0 or 3.1 and 4.0; defect points: 2 
• SDS of R/C ratio between 4.1 and 6.0 or 4.1 and 6.0; defect points: 3 
• SDS of R/C ratio between 6.1 or less or 6.1 or more; defect points: 4 
The sum of the defect points described the entire damage to the dentition. The theoretical 
maximum (all teeth missing, including third molars) of the IDeI is 160. The main findings 
concerning the use of IDeI are presented in Results of the thesis. Patient-groupings are in 
Table 6. 
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7.6. Statistical analyses (I-IV) 
The Statistical Package for the Social Sciences (SPSS for Windows), versions 9.0, 10.0, and 
11.0 (SPSS, Inc., Chicago, Illinois, USA) were used in statistical analyses. A statistical 
method was selected as appropriate depending on study design, type of test variable 
(continuous, categoric), and distribution of this variable (normal, non-normal). A non-
parametric Mann-Whitney test was used on several occasions, since the study groups were 
small and did not follow a normal distribution. For example, the number of developmental 
defects and DeI (continuous variables) between TBI and non-TBI groups (I) and the number 
of missing and/or microdontic teeth between the TBI/non-TBI and age groups (III) were 
compared with the Mann-Whitney U-test. It was utilized also in comparing differences in 
SDSs and other continuous variables between study groups (IV). The statistical significance 
of the categoric variables between groups (e.g., presence or absence of tooth agenesis and 
microdontia; number of teeth with R/C ratios outside ±2 or ±3 SDS limits) was studied with 
the Pearsons chi-square (χ2) test or the Fisher exact test (III, IV). The Pearson correlation 
coefficient and linear regression analysis were used to study associations of TBI and age at 
SCT with number of missing and microdontic teeth (III). Pearson correlation coefficients 
were also calculated for repeated intra- and inter-examiner R/C ratio assessments, and their 
paired differences were tested with the paired t-test (II). The independent sample t-test was 
applied when the R/C ratios were compared between males and females (II). P-values less 
than 0.05 were considered significant. 
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RESULTS AND DISCUSSION 
8. Agenesis of permanent teeth  
Tooth agenesis was assessed in 52 SCT patients (Study III), including also the NBL patients 
of Study I. During follow-up, new PRGs were obtained and the most recent ones were used 
when study results were analyzed. In this Results section, the information is again in part 
updated from the newest PRGs, and with small differences appearing in absolute numbers of 
teeth when compared to results in the original publications. New information is also 
presented. 
 
8.1. Tooth agenesis in stem cell transplant recipients (I, III, and updated) 
8.1.1. Prevalence of tooth agenesis in permanent teeth 
Third molars excluded 
In the SCT patient group (N = 52; III), the prevalence of tooth agenesis was 31% (16 of 52 
patients). TBI had no effect on the agenesis prevalence that was 32% and 29% in the TBI and 
non-TBI groups, respectively (Table 7). In the group of 17 NBL patients, prevalence of tooth 
agenesis was 76%, with a significant difference between TBI and non-TBI patients (p = 
0.015) (Table 7). 
 The effect of age on prevalence of tooth agenesis was investigated by dividing the 
patients into three age groups: Y (Youngest; ≤ 3.0 years), M (Middle; 3.1-5.0 years), and O 
(Oldest; ≥ 5.1 years), according to age at SCT. Teeth were lacking in 10 of 13 (77%) patients 
in Group Y, with no difference between TBI- and non-TBI groups. It is of note that 3 of 4 
patients lacked teeth following anticancer CT alone (Table 7). The possibility that anticancer 
chemotherapy (CCT and HDC) caused tooth agenesis was especially high, if children were 
less than 2 years old at the beginning of treatment (Table 8). Group M was less affected, with 
a 40% prevalence of tooth agenesis. In Group O, no teeth were missing (Table 7).  
 
Third molars included  
The final results for tooth agenesis can be seen only after the third molars are included in the 
assessment. In a subgroup of the SCT recipients who were ≥ 12 years at PRG (agenesis of the 
third molars not confirmed before age 12), or who were younger but with the third molars 
present, an agenesis assessment including all teeth was performed (in Study III, N = 29; 
updated N = 32). The prevalence of tooth agenesis was high, 66%, with a tendency toward 
higher prevalence among TBI patients (75%) than among non-TBI patients (50%). The 
difference was not significant, however (Table 7). At least one of the third molars was 
missing in 17 of 32 (53%) patients.  
 Most of the patients (77%) treated for NBL presented with tooth agenesis (Table 7). 
Teeth were missing from all (100%) TBI patients but from only 3 of 7 (43%) non-TBI 
patients (p = 0.07) (Table 7). The mean age of the NBL patients was low, 2.4 years at 
diagnosis and 3.0 years at SCT (medians 2.2 and 2.7 years), which mostly explains this high 
prevalence of tooth agenesis. 
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 Prevalence of tooth agenesis examined for age groups Y, M, and O was 88%, 78%, and 
47%. All patients in the youngest TBI group and more than half the children in the oldest TBI 
group were affected (Table 7). The earlier observations that both young age at SCT (or 
diagnosis) and preparative regimen including TBI elevated the risk for tooth agenesis were 
confirmed.  
 
8.1.2. Number of missing teeth 
Third molars excluded  
In the SCT patients (N = 52), the mean number of missing teeth was slightly higher in the 
ones with TBI than in the non-TBI patients (1.7 vs. 0.8), but this difference was non-
significant (Table 7). The patients treated for NBL were more severely affected than were 
SCT recipients on average. The mean number of missing teeth in the NBL patients was 3.7 
(range 0-11), and rose to 5.4 in the TBI group, which significantly differed from the non-TBI 
patients (Table 7).  
 Patient age at SCT had a negative correlation with number of missing teeth (r = 0.580− ; 
p < 0.001). Mean number of missing teeth was highest (3.9) in Group Y, whereas no teeth 
were missing in Group O. Both younger groups (Y and M) differed from Group O. The mean 
number of missing teeth did not differ significantly between the TBI and non-TBI groups, 
although a clear tendency toward higher numbers was evident among TBI patients (e.g., 4.7 
vs. 2.0 in Group Y) (Table 7; Figure 8).  
 In the Finnish population, the mean number of missing teeth in patients with hypodontia 
has been 1.7 (Haavikko, 1971). Anticancer therapy made the number of missing teeth higher 
than that number found in genetic hypodontia; in the 16 SCT patients with tooth agenesis, 
mean numbers of missing teeth were 4.8 (SD 2.4) in the whole group, and 5.5 (SD 2.4) and 
2.8 (SD 1.0) in the TBI (N = 12) and non-TBI (N = 4) groups, respectively (p = 0.020). The 
difference between the NBL patients in the TBI and non-TBI groups further affirmed the fact 
that risk for tooth agenesis was associated not only with age, but was also increased due to 
TBI. However, all the patients with tooth agenesis had been less than 5 years old at SCT 
(Table 8; Figure 8).  
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Figure 8. Numbers of missing teeth (third molars excluded) in individual patients (N = 52), according 
to age at stem cell transplantation (SCT). Patients were with or without total body irradiation (TBI and 
non-TBI patients). Note that all patients less than 2 years old at SCT were missing teeth. 
 
Third molars included  
In a subgroup of 32 SCT recipients, the detrimental effect of TBI was indicated by the higher 
mean number of missing teeth in the TBI than in the non-TBI patients (4.2 vs. 1.1; p = 0.026). 
The mean age of the non-TBI patients was slightly lower than that of the TBI patients, but 
median age tended to be higher in the non-TBI group. This demonstrates the higher number of 
older individuals, not so susceptible to tooth agenesis, among the non-TBI patients (Table 7). 
Thus, in addition to irradiation, this age distribution might have had some effect on results. 
 In the group of NBL patients (N = 13), the mean number of missing teeth was 5.3, with 
a significant difference between TBI (8.3) and non-TBI (1.3) patients (Table 7). The NBL 
patients, typically young at diagnosis, are at high risk for extensive agenesis of permanent 
teeth.  
 The mean number of missing teeth in Groups Y and M was equal (4.9) and differed 
significantly from that of Group O (Table 7). The highest mean number of missing teeth (7.8) 
was in the TBI children who were ≤ 3.0 years at SCT (Group Y) (Table 7). All missing teeth 
in Group O were third molars. Patient age at SCT showed a negative correlation with number 
of missing teeth (r = 0.585; p < 0.001). Age explained 58% and 32% of the variation in 
number of missing teeth in the TBI and non-TBI groups, respectively (Figure 9). Thus, when 
all teeth were included, age at SCT had a strong effect on number of missing teeth, especially 
in the TBI group. 
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Figure 9. Number of missing teeth in relation to total body irradiation (TBI) and age at stem cell 
transplantation (SCT). Only those 32 patients ≥ 12 years old at PRG were included. Third molars were 
included.  
 
 At the most recent examination, 25 of all 52 patients presented with tooth agenesis (all 
teeth included according to age rules; see Section 7.2.). Mean number of missing teeth in 
these 25 patients was 5.1 (SD 3.2), with means of 6.0 (SD 3.2) in TBI (N = 19) and 2.3 (SD 
1.0) in non-TBI patients (N = 6) (p = 0.011). 
 In Figure 10, PRGs show examples of tooth agenesis in SCT patients (cases 36, 13, 8, 
and 19). 
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Figure 10. Examples of panoramic radiographs. For Individual Defect Index (IDeI) see Section 12.  
  
Healthy person, 
IDeI = 0.  
Case 17 (Table 8). 
IDeI = 17. 
 
 
Case 36 (Table 8). 
IDeI = 54.
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Case 8 (Table 8). 
IDeI = 91.
Case 13 (Table 8). 
IDeI = 76.
Case 19 (Table 8). 
IDeI = 117.
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8.1.3. Characteristics of tooth agenesis in stem cell transplant recipients 
Tooth agenesis (third molars omitted) was similarly distributed between maxilla and mandible 
both in the SCT patients and the Finnish population sample (Table 9). In both samples, the 
most frequently missing tooth was a lower second premolar, followed by an upper second 
premolar. Eye-catching differences were evident in maxillary lateral incisors, whose 
frequency of missing teeth in population samples usually occupies second or third place 
(Table 1, page 22), but were seldom lacking in SCT patients when counted as percentages of 
missing teeth. On the contrary, the percentage of missing second molars was considerably 
high in SCT patients but very low in the population (Table 9). These differences can be taken 
as indications of the differing etiology of tooth agenesis: environmental factors have modified 
the pattern of genetic hypodontia that was not excluded in the SCT group. 
 In the group of 25 SCT patients with tooth agenesis (all teeth included according to age 
rules; see Section 7.2.), 8 patients, all with TBI, had agenesis of some third molars (all four 
were missing in 6 patients) combined with agenesis of some other teeth, mainly second 
premolars (Table 8). Four patients had agenesis of some teeth, but their third molars were 
present. These patients had been very young, 1.6 years or less, at SCT or at diagnosis, and 
they all were non-TBI patients. Nine patients had agenesis of one or more third molars, but all 
the other teeth were present. Of these patients, 8 had been 5 years or more at SCT. In the 
remaining 4 patients, who were too young for assessment of third molars, 6 to 11 teeth were 
missing. They all had been young (2.0-3.1 years) at SCT and had received TBI (Table 8). 
Three of these individuals were more than 11 years at the latest PRG, and there is the strong 
possibility that the third molars will be also lacking. 
 
Table 9. Distribution of tooth agenesis in the 52 SCT recipients and in a Finnish population sample of 1041 
subjects (Haavikko, 1971).   
Maxilla Mandible 
Percentage of missing teeth Percentage of missing teeth 
Tooth 
Hölttä;  
SCT patients 
Haavikko;  
Finnish 
population 
Hölttä;  
SCT patients 
Haavikko;  
Finnish 
population 
I1 0 0 0 2.7 
I2 3.9 18.7 0 1.4 
C 0 0 0 0.7 
P1 7.8 3.5 2.6 0 
P2 28.6 29.2 32.4 42.4 
M1 0 0 0 0 
M2 11.7 0.7 13.0 0.7 
Total 52.0 52.1 48.0 47.9 
 
I1: central incisor; I2: lateral incisor; C: canine; P1: first premolar; P2: second 
premolar; M1: first molar; M2: second molar 
 
 One or more of the third molars was missing in 21% of the subjects (10% of third 
molars) in the Finnish population sample of Haavikko (1971). In the SCT patients, the 
corresponding figure was much higher, 53% (39% of third molars). Due to the large variation 
in development schedule, the age limit for the third molar agenesis was set at 12 years. 
However, the median age for follicle formation was about 9 years in the healthy population 
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(Haavikko, 1970), and in our SCT recipients, the first signs of third molar development were 
usually evident at 8 to 10 years. These facts suggest that the prevalence of third molar 
agenesis will be even higher when all patients become old enough for the analysis. At the 
moment, the prevalence would be 69% if all patients ≥ 11 years at PRG were included. 
 
8.2. Discussion of tooth agenesis 
8.2.1. Effect of age at anticancer therapy 
Those insults that occur before tooth mineralization has advanced beyond its initial phases 
may destroy the tooth germ, but it is unlikely that attacks taking place later will result in 
agenesis. The earliest mineralization occurs around birth in the first molars, followed by the 
central incisors, lower lateral incisors, and canines at 3 to 4 (or 6) months (Logan and 
Kronfeldt, 1933; Schour and Massler, 1940). Anticancer therapy is very seldom delivered 
before that age, and no agenesis of these teeth was seen in the study patients, even though the 
earliest diagnoses were made at 0.2 and 0.4 years. In general, agenesis of these early teeth is 
very rare (Table 9) (Haavikko, 1971; Polder et al., 2004), and it is usually of genetic origin or 
is associated with syndromes (Arte, 2001). Calcification of the upper lateral incisors begins 
later, at 10 to 12 (or 15) months (Logan and Kronfeldt, 1933; Schour and Massler, 1940), and 
very early anticancer therapy might be responsible for the agenesis of these teeth. It may be 
impossible in certain circumstances to determine whether agenesis of the upper lateral incisor 
is of genetic or environmental origin (Table 8, Case 2). In one of the two patients with 
missing upper lateral incisors, etiology cannot be related to the anticancer therapy that started 
at the time that about three-quarters of the crown development should have been completed 
(Table 8, Case 27; Figure 3, page 17). 
 According to histologic findings, calcification of the first premolars begins at 1.5 to 2 
years, and second premolars and second molars follow at 2 to 2.5 and 2.5 (or 2) to 3 years, 
respectively (Logan and Kronfeldt, 1933; Schour and Massler, 1940). Theoretically, based on 
this schedule, environmental insults that occur during the first 2 to 3 years of life may cause 
agenesis of these teeth. This seems to be fairly valid also in practice. Of the patients old 
enough at PRG for assessment of all their teeth, tooth agenesis was present in all patients who 
were ≤ 2 years at SCT, and in 15 of 16 (94%) whose anticancer CT started before age 3. 
However, in patients who were older than 3.5 at SCT, absence of teeth other than third molars 
was very rare (Table 8).  
 It is more difficult to explain why some patients less than 3 years at SCT and/or at the 
start of treatment, had no agenesis of premolars or second molars. For instance, cases 10, 11, 
and 12 (Table 8), each with a different disease, were diagnosed and transplanted at similar 
ages and received TBI, but only one had tooth agenesis. Moreover, number of missing teeth 
showed wide variation, especially in the TBI group. Several speculations can be presented. 
The MDS patient did not receive CCT before HDC, which probably diminished the total 
toxicity of her treatment. The tooth-forming cells were saved from the intermittent CT courses 
that might have killed the odontogenic cells, if previous regimens had already caused them 
some functional or structural injuries. This explanation does not apply to the AML patient 
who was treated also with CCT. Cyclophosphamide (Cy) was the chemotherapeutic agent 
used for HDC in both of the patients without tooth agenesis (Cases 11 and 12 in Table 4). 
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Perhaps the Cy concentrations around tooth buds did not cross the limit at which irreversible 
injuries could occur, and the tooth-forming cells escaped apoptotic or toxic death. It is 
possible that some other HDC regimens, for instance VMP, which consists of three drugs with 
different mechanisms of action, are more toxic to tooth germs than is Cy alone. No 
experimental studies yet confirm this, and in a small study series like ours it was impossible 
to separate the roles of different chemotherapeutic agents or HDC protocols in tooth agenesis. 
Cy alone dose-dependently disturbs the development of rat incisors and molars, but no tooth 
agenesis has been reported. This is to be expected, however, because the experimental 
animals have been too old, i.e., their tooth development had already passed the initial 
phases at which Cy could have theoretically destroyed tooth germs (Section 5.1.2., alkylating 
agents). 
 One more probable explanation can be offered for inter-individual differences in tooth 
agenesis: variations in the timing of tooth formation, as seen in PRGs, between individuals are 
common. Tooth development is a very complicated sequence, in which several signal 
moleculesvia many stepsactivate their target genes, that, in turn, control the next steps of 
tooth development (Section 1.3.; Figure 2). After reviewing those detailed mechanisms of 
tooth development, a schedule, measuring time in months, is of limited value. As regards the 
exact consequences of toxic environmental insults to teeth, timing may be a question of hours 
rather than days, weeks, or months. Thus, differences in tooth development between 
individual patients occur, even if they all have been treated with the same anticancer protocol 
at about the same age. 
 
8.2.2. Effect of total body irradiation 
The typical injurious effects of RT on human teeth (Section 5.2.) are confirmed in several 
animal experiments reporting dose-dependent and, to some extent, species-specific dental 
changes (Section 5.1.1.). RT first destroys the differentiating odontoblasts and their 
precursors, although the minimum harmful doses and exact molecular mechanisms of the 
resulting cell death remain unknown. Developing human teeth have shown some 
abnormalities even after a radiation dose of 4 Gy (Fromm et al., 1986). Timing of RT in 
relation to tooth development is important: tooth agenesis may be induced only if the 
irradiation is delivered before or at the initial phases of calcification, i.e., during the first 3 
years of life (Section 1.4.; Figure 3). Calcification of the third molars begins late, at the age of 
7 to 10 years (Schour and Massler, 1940), and RT may destroy the cells of the dental lamina 
prior to initiation of the third molars, or may destroy the developing tooth germs any time 
before calcification. 
 In the SCT patients (N = 52; third molars excluded) TBI did not cause an increase in the 
prevalence of tooth agenesis. Differences were small also when patients were grouped by age 
at SCT. Since the age groups differed from each other more than did the irradiation groups 
within each age group, it seemes that age at SCT is a more serious risk for tooth agenesis than 
is TBI. Only among NBL patients did TBI significantly increase the prevalence of tooth 
agenesis (Table 7, page 68). This result should be treated with caution, however, since in a 
small group, individual patients have much weight. For instance, in the non-TBI group, two 
patients (Cases 44 and 53 in Table 8, pages 69-70) were so old at diagnosis (4.8 and 7.4 
years) that treatment could not have caused them tooth agenesis (except of the third molars), 
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no matter whether they received TBI or not. Prevalence of tooth agenesis increased when 
third molars were included in the assessment (N = 32). The TBI groups tended to be more 
severely affected than were the non-TBI groups (Table 7). 
 The number of missing teeth in the TBI groups was significantly higher than in the non-
TBI groups, when all patients or Group Y were observed (third molars included). This 
difference was especially clear in patients treated for NBL. The same tendency was clear in 
all other assessments, although the number of patients in the subgroups was small, and 
significance was not reached in most comparisons (Table 7). TBI thus appeared to cause the 
number of missing teeth to rise, which may have important clinical implications as indicated 
by the maximum number of missing teeth, which was 4 in the non-TBI and 12 in the TBI 
group (Tables 7 and 8; Figures 8 and 9, pages 66 and 67).  
 
8.2.3. Agreement with previous clinical studies 
Most earlier studies include only children treated with CCT, in several cases connected with 
CRI in ALL (Table 3, pages 49-52). Prevalence of tooth agenesis ranged between 5% (Sonis 
et al., 1990) and 30% (Näsman et al., 1994) (see Table 3 for more information). However, 
these figures cannot be directly compared to the prevalence of 31% in the SCT group (Study 
III), due to varying patient groups and methods used. In the 1990 study, abnormalities in 
maxillary lateral incisors, agenesis of second premolars and development of the third molars 
were excluded since, according to the authors, disturbances occur in these teeth at a relatively 
high frequency. Teeth were missing only in patients who had been treated at the age of < 5 
years and had received CRI of 24 Gy (Sonis et al., 1990) (Table 3). If we had omitted these 
same teeth in the present SCT group, the agenesis prevalence would have been 21%, much 
higher than the 5% reported earlier. The age limit for tooth agenesis is well in accordance 
between these two studies. There is a slight contradiction as to the effect of irradiation on 
tooth agenesis, since in the previous study teeth were missing only in the irradiated patients 
(Sonis et al., 1990), but in the the current study (III) equally in irradiated and non-irradiated 
patients. The intensive HDC of the SCT patients may explain this difference. 
 Third molars were included in at least two studies, one by Maguire et al. (1987) and the 
other by Kaste et al. (1998), in which agenesis prevalences were 28% and 17%. These 
percentages were considerably smaller than the current figure, 66%. The 20% prevalence of 
third molar agenesis alone (Maguire et al., 1987) was about the same as the prevalence (21%) 
in a healthy Finnish population (Haavikko, 1971), but much lower than the 53% in the present 
SCT group. There are multiple possible reasons for these differences, although comparisons 
are difficult when many authors give neither the treatment protocols used, patients age at the 
beginning of anticancer therapy, nor criteria for assessment of tooth agenesis (Table 3). Mean 
age or age distribution of the patients or both may affect results. The current SCT patients 
were more intensively treated with CCT and HDC, and they may have been younger at 
treatment than the patients in the older studies treated with CCT and sometimes CRI; this 
would make the present SCT group more susceptible to tooth agenesis. In addition, TBI, also 
focused on tooth germs, was delivered to most of the SCT patients in the present study, but 
only minor scattered irradiation affected some tooth germs when CRI was given to the 
leukemia patients treated with CCT.  
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 In studies on SCT recipients, variations also occur in methodology, age of patients, and 
treatment protocols. In the groups of 19 and 16 BMT patients with TBI (7-10 Gy; single 
fraction at least to the patients in the 1994 study), agenesis prevalences were 58% and 56% 
(Näsman et al., 1994, 1997a). These figures probably include third molar agenesis, since 
many patients more than 5 years at SCT were lacking teeth (Näsman et al., 1994). The 
percentages were high when compared to the 31% (third molars excluded) in the present SCT 
patients. However, the earlier percentages probably should be compared to ours with the third 
molars included. In that case, the new (62% in Study III; updated figure 66%) and the older 
results would be in closer accordance. A higher prevalence in our study was expected, since 
the mean age of our patients at SCT was lower (4.3 years) than the mean ages at diagnosis in 
the patients (6.5 and 6.3 years) studied by Näsman et al. To my knowledge, the highest 
prevalence of tooth agenesis reported, 80% (third molars included), was in the 15 SCT 
patients treated for NBL (Study I). It can be speculated that treatment of NBL is more toxic to 
tooth germs than is treatment of other malignant diseases. This cannot, however, be confirmed 
in the current study, since the low mean age of these NBL patients at SCT (2.8 years; I) is a 
strong prognostic factor for tooth agenesis regardless of the treatment protocol.  
 One study of 27 hematological SCT patients, probably excluding the third molars, gave 
a low tooth agenesis prevalence of 11% (Uderzo et al., 1997). The median ages of those 
patients at diagnosis and at BMT were 6.6 and 9 years. Only 5 of the patients were less than 5 
years at SCT, which makes the low prevalence of tooth agenesis obvious, even if 25 of the 27 
patients received TBI of 12 Gy.  
 
8.3. Conclusions on tooth agenesis 
Based on the observations of the SCT recipients studied: 
1. Prevalence of tooth agenesis was high, 31% (third molars excluded), in SCT recipients 
when compared to that of the Finnish population (8%). With all teeth included, agenesis 
prevalence was 66%. 
2. Agenesis prevalence for third molars alone was 53% (21% in the population) and will be 
even higher when all patients are old enough for assessment.  
3. Maxillary lateral incisors represented 3.9%, and permanent second molars represented 
24.7% of all missing teeth. These teeth differed most from the genetic hypodontia, in 
which the reported proportions were 20.1% and 1.4%, respectively.  
4. Mean number of missing teeth in those individuals with tooth agenesis was higher than 
reported for genetic hypodontia. 
5. No missing teeth, except third molars, were observed in patients who were 4 years or 
older at the start of CT and 5 years or older at SCT. 
6. Tooth agenesis occurred after CT alone, especially in patients ≤ 2 years at SCT.  
7. Young age at SCT (or at the start of CT) was a stronger risk factor for the tooth agenesis 
than was TBI, although TBI caused additive impairment. 
8. TBI led to increased numbers of missing teeth (third molars included), which was high in 
the SCT recipients ≤ 5 years at SCT. 
9. The youngest TBI patients (≤ 3.2 years at SCT) displayed the most serious consequences 
of anticancer therapy as regards the prevalence of tooth agenesis and number of missing 
teeth. 
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9. Microdontia 
9.1. Microdontia of permanent teeth in stem cell transplant recipients (I, III, and 
updated) 
In the studies on prevalence of microdontia and number of microdontic teeth, only the 
assessments excluding third molars are presented. Third molars would not much change the 
results: Only three of them in one patient were microdontic (Case 56 in Table 8, pages 69-70). 
Results presented here have been slightly updated since the earlier reports (I, III).  
 
9.1.1. Prevalence of microdontia 
Third molars excluded 
Microdontia was present in 24 of 55 SCT recipients (44%). Non-TBI patients tended to be 
slightly more affected (50%) than were TBI patients (41%). Three-quarters of all the patients 
in Group Y, including all children in the non-TBI group, presented with microdontia. 
Irradiation did not bring out marked differences within the age groups. Patients in Group M 
were also severely affected, and both younger groups differed from Group O when all the 
patients or only the TBI patients were included (Table 10).  
 Microdontia was very common in patients treated for NBL, with approximately 80% of 
the patients involved (I, Table 10). Young age at treatment probably was the main reason for 
the high microdontia frequency that occurred almost equally in the TBI and non-TBI patients. 
 Figure 10 (pages 71-72) presents examples of microdontia in SCT patients (cases 17, 
13, and 19). 
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9.1.2. Number of microdontic teeth 
In the SCT patients (N = 55), the mean number of microdontic teeth was 1.5, with no 
difference between TBI and non-TBI patients. Patient age was negatively correlated with 
mean number of microdontic teeth (r = 0.388; p = 0.003). Age explained only 14% and 40% 
of the variation in TBI and non-TBI groups, respectively (15% in the whole study group). 
Patients who had been 5 years or older at SCT (Group O) had significantly fewer microdontic 
teeth than did those in the two younger groups, Y and M (Table 10; Figure 11). Counting only 
the 24 patients with microdontia, the mean number of microdontic teeth was 3.3. TBI patients 
were more affected, with a mean number of 3.9 (SD 3.4; range 1-12) teeth, a difference not 
significant when compared to the non-TBI patients with 2.3 (SD 0.5; range 2-3) microdontic 
teeth. Patients in Group M were most severely affected (4.7; SD 4.2; range 1-12), although 
Group Y was not significantly different (2.8; SD 1.1; range 1-4). It should be noted, however, 
that in Group M were two patients treated for a recurrent disease, whose microdontia was not 
in line with the rest of the groups. Without these patients, whose treatment began at an early 
age, the number of microdontic teeth in Goup M would be 2.6 (range 1-3) (Table 8, pages 69-
70; Figure 11). 
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Figure 11. Number of microdontic teeth in relation to total body irradiation (TBI) and age at stem cell 
transplantation (SCT) (N = 55), with third molars excluded. The two patients with 12 microdontic 
teeth had been treated with conventional chemotherapy starting at ages 1.6 and 1.4 years, and their 
recurrent disease was treated with high-dose chemotherapy, TBI, and SCT. 
 
9.1.3. Characteristics of microdontia in stem cell transplant recipients 
Mandibular first premolars were most frequently microdontic (27.5%), and together with 
maxillary first premolars they represented almost half of all microdontic teeth (Table 11). 
Maxillary lateral incisors are the most frequently microdontic (often peg-shaped) teeth in 
population studies (Grahnen, 1956; Alvesalo and Portin, 1969) (see also Section 2.3.3), but 
these came after premolars and second molars in SCT recipients, with only two (5%) patients 
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affected. One of these patients was already 4.8 years at the start of CT, and the treatment 
could not be the reason for his peg-shaped maxillary lateral incisors that must have had a 
genetic background. Microdontia of the second molars is a rare phenomenon in healthy 
populations but turned out to be quite frequent in SCT recipients. Thus, the microdontia 
pattern after anticancer therapy differed much from the pattern in genetic microdontia, 
confirming the effect of anticancer therapy in microdontia. The relative proportion of 
microdontic teeth and their distribution in maxilla and mandible are presented in Table 11. As 
regards the combined proportion of tooth agenesis and microdontia, maxillary teeth were 
slightly more frequently affected than were mandibular teeth. Maxillary second premolars had 
been most vulnerable to treatment, followed by mandibular second premolars (Table 11).  
 
Table 11. Relative proportions of teeth (in percentages) of the total number of microdontic, of missing, and of the 
combined microdontic and missing teeth in the group of 55 stem cell transplant recipients.  
Maxilla Mandible Tooth 
Microdontic 
teeth (%) 
Missing teeth 
(%) 
Microdontic + 
missing teeth (%) 
Microdontic 
teeth (%) 
Missing teeth 
(%) 
Microdontic + 
missing teeth (%) 
I1 0 0 0 0 0 0 
I2 5.0 3.9 4.5 0 0 0 
C 0 0 0 0 0 0 
P1 21.3 7.8 14.6 27.5 2.6 15.3 
P2 17.5 28.6 22.9 7.5 32.4 19.7 
M1 0 0 0 0 0 0 
M2 11.3 11.7 11.5 10.0 13.0 11.5 
Total 55.0 52.0 53.5 45.0 48.0 46.5 
 
I1: central incisor; I2: lateral incisor; C: canine; P1: first premolar; P2: second premolar; M1: first molar; M2: second molar 
 
 
9.2. Discussion of microdontia 
9.2.1. Tooth size and shape—theory and practice 
Determination of tooth size is under genetic control, and genetic influence is always present in 
the background, even if some environmental factors may modify this predestined process 
(Section 2.3.2.). The size and shape of a tooth crown depends on the morphogenesis of the 
epithelium during cap and bell stages. Epithelial signaling centers, primary and secondary 
enamel knots, are considered to be of fundamental importance in regulating tooth shape by 
integrating the several linked signaling pathways. The primary enamel knot appears at the tip 
of the tooth bud, at the site where epithelial folding initiates tooth crown development 
(transition from bud to the cap stage). Enamel knot cells themselves do not proliferate but are 
able to stimulate cell division in the enamel epithelium and the dental papilla (Jernvall et al., 
1994). They express more than ten signals whose functions are not well known (Vaahtokari et 
al., 1996a; reviewed by Thesleff and Mikkola, 2002; reviewed by Pispa and Thesleff, 2003). 
Sonic hedgehog is known to play a role in dental patterning: In its absence, the size and the 
shape of teeth in mice were severely affected (Dassule et al., 2000). Enamel knot signals 
affect both the epithelial and mesenchymal cells, maintaining the expression of earlier 
induced signals and transcription factors and inducing new ones (reviewed by Thesleff and 
Mikkola, 2002; Thesleff, 2003). The primary enamel knot is removed by apoptosis 
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(Vaahtokari et al., 1996b) and, soon after, follows the formation of the secondary enamel 
knots in teeth having several cusps, at the sites of future cusp tips. Numerous activating and 
inhibiting signals are required to determine the number and size of cusps and the distances 
between them. The first odontoblasts differentiate from the cells of dental papilla underlying 
the secondary enamel knots, and deposit the dentin matrix. The cusp pattern becomes fixed as 
soon as the dentin matrix mineralizes (reviewed by Thesleff et al., 2001). The epithelial 
folding and the growth of the cervical loops, along with the differentation of odontoblasts and 
ameloblasts, shape the tooth crown by the end of the late bell stage. 
 Toxic compounds may at high doses destroy part of the tooth-forming cells by direct 
toxicity or, at lower doses, may trigger the apoptotic pathway (Lyaruu et al., 1997, 1999). 
Consequently, the decreased number of viable cells, a labor shortage, results in the building 
of a tooth of reduced size. Based on the signaling theory, environmental insults (e.g., 
anticancer CT and RT) that can disturb the formation of the primary or secondary enamel 
knots, or their signaling, may result in microdontia. The exact mechanisms are unknown. As 
seen in clinical practice and in animal studies, both anticancer CT and RT are capable of 
altering cell behavior or destroying the cells, depending on circumstances. Even a single 
chemotherapeutic agent, cyclophosphamide (Section 5.1.2., alkylating agents), is able, in rats, 
to reduce crown size and disturb cusp morphology of the developing third molars (Näsman 
and Hammarström, 1996). Studies on the toxicity of dioxins to developing embryonic mouse 
teeth give interesting results (Section 2.1.2). In teeth developed beyond the bud stage at the 
time of exposure, mesiodistal size is reduced dose-dependently (Kattainen et al., 2001; 
Miettinen et al., 2002). Smaller tooth size and disturbed cusp morphology has also been 
noticed in embryonic mouse teeth, developed beyond the initiation stage after in vitro dioxin 
exposure (Partanen et al., 2004). These changes highly resemble those following anticancer 
therapy, and might direct further research toward the biochemical mechanisms whose 
disturbances are responsible for reduced tooth size.  
 
9.2.2. Microdontia in stem cell transplant recipients 
Microdontia prevalence (44%) was high among the SCT recipients and was distributed among 
several teeth (Table 11). Studies on microdontia prevalence in general deal with maxillary 
lateral incisors, since other teeth are seldom involved. In Finland, at least one maxillary lateral 
incisor with a strongly mesiodistally reduced crown size has been found in 2.3% of one study 
population (Alvesalo and Portin, 1969). Consequently, it seems obvious that anticancer 
therapy is a credible reason for the reduced tooth size seen in SCT patients, although genetic 
microdontia was not excluded in the present study population.  
 The prevalence of microdontia would probably have been even higher, had mesiodistal 
crown sizes in the SCT group been measured and compared with the values in a healthy 
population. In several patients, maxillary lateral incisor(s) were evidently small, but to 
avoid overestimation in a subjective assessment, they were not judged microdontic. Small 
(not peg-shaped) maxillary lateral incisors occurred in patients less than 2 years old at 
diagnosis (Table 8, pages 69-70). Schedules of tooth mineralization (Figure 3, page 17) 
(Logan and Kronfeldt, 1933; Schour and Massler, 1940) turned out to be good guides for 
predicting teeth that were at risk for microdontia: First premolars were at risk before the 
second premolars and second molars that develop later. In general, risk for microdontia was 
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high in patients less than 4 years at SCT (Table 8; Figure 8, page 66). The age-group division 
of the patients showed that the highest prevalence of microdontia was in Group Y, but the 
highest mean number of microdontic teeth was in Group M (Table 10). However, in small 
patient groups like the present one, even a single diverging individual causes marked changes 
in study variables, so results should be treated with caution. For instance, in Group M, the 
mean value of microdontic teeth would have been lower than in Group Y, had the two 
children with 12 teeth involved been excluded. These two patients had already been treated 
with CCT, starting from 1.4 and 1.6 years, at the time when their first premolars were 
vulnerable to CT. Later, when their second premolars and second molars were susceptible to 
treatment, they received HDC and TBI prior to SCT, due to recurrent disease. No teeth were 
missing from these patients and, consequently, they all were subject to microdontia.  
 The clinical significance of microdontia varies by number of affected teeth and tooth 
size. Within the so-called microdontic teeth tooth size ranges from very small, scarcely 
visible grains to teeth that are normally shaped but small. Even the smallest teeth with no 
value from the occlusal point of view mostly erupt and resorb the primary teeth, which would 
have been more useful. Some type of microdontia classification, taking size alterations into 
account, would be practical in determining the clinical significance of the damage in 
individual patients. 
 
9.2.3. Agreement with previous clinical studies 
One common problem with microdontia studies is the subjective nature of their assessments, 
which makes comparisons questionable. The majority of the studies reporting microdontia do 
not even provide written criteria of microdontia. In a group of 82 children treated for ALL and 
solid tumors, the prevalence of microdontia was 23% (Maguire et al., 1987) (Table 3, pages 
49-52). Age of patients during treatment was not given (at examination 3-22 years), but it 
seems probable that many were so old that there was only a small or no theoretical possibility 
for microdontia. The authors noticed that therapy during the first 3.5 years of life resulted in 
small teeth more likely than did later treatment, and maxillary teeth were affected more often 
than mandibular teeth. In the patients 3 years or younger at treatment, microdontia prevalence 
was 38%. This age finding and the more frequent damage in maxillary teeth were in good 
agreement with the current study (III), but the microdontia prevalence in our young patients 
was notably higher (75%). The intensive treatment of our SCT patients offers an explanation 
for this difference. The microdontia prevalence of 22% occurred in ALL patients, but only 
those patients with CRI were affected. In one subgroup of patients < 5 years at diagnosis and 
with CRI of 24 Gy, the prevalence was 75% (Sonis et al., 1990) (Table 3). In that study, 
surprisingly, CRI, in which teeth receive only a small, scattered irradiation dose, seemed to 
play an important role in the etiology of microdontia, whereas in the present study, TBI, 
directed also to tooth germs, had little effect. 
 Prevalence of microdontia in other studies ranged from about 10 to 38% (Nunn et al., 
1991; Näsman et al., 1994, 1997a; Kaste et al., 1997), with the highest prevalence in patients 
treated for NBL (Kaste et al., 1998) (Table 3). A higher prevalence, 79%, occurred in the 
current study for the NBL patients (Table 10). This was an expected result, since all the 
patients had been intensively treated for poor-risk NBL (Stage III-IV), but the previous study 
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by Kaste et al. (1998) also included stage I-II NBL patients who were not treated with equal 
intensity. Only two of their patients received BMT (Table 3).  
 The microdontia prevalence among SCT recipients has been reported in only a few 
studies (Table 3). The pioneer work with 16 patients found 4 patients with microdontia (25%) 
(Dahllöf et al., 1988). They all were young (5.4 years or less) at SCT and had received TBI in 
a single fraction over a period of 4 hours. Only one patient in this age group, one treated 
without TBI, did not have microdontia. Other patients were older at treatment, so microdontia 
caused by therapy was unlikely, except in the third molars. These results seem to be in line 
with those of the present study when age at SCT is taken into account. Two other studies gave 
a microdontia prevalence of 68% and 75% for BMT patients (Näsman et al., 1994, 1997a), 
both higher than the 44% found here. Mean age of patients does not explain this difference: In 
previous studies patients were older, and consequently, their teeth should have been less 
vulnerable. At least many (perhaps all) of those patients received TBI in a single fraction, 
which might have been more injurious to teeth than was our fractionated TBI. The most 
probable explanation is, however, that criteria in the assessment of microdontia differed.  
 
9.3. Conclusions on microdontia 
Patient groups in our study were quite small, and it was not always possible to draw absolute 
conclusions as to the effects of age, CT, or irradiation on microdontia, although some 
tendencies were apparent. 
1. Prevalence of microdontia was high, 44% (third molars excluded), in the SCT recipients 
when compared with that of a healthy population.  
2. Microdontic teeth were seldom present in patients who were 5 years or older at SCT. 
Thus, young age at SCT (< 5 years) was a risk for microdontia. 
3. Some 60 to 75% of the patients who were < 5 years at SCT later presented with 
microdontia.  
4. CT alone caused microdontia, and TBI did not result in a higher prevalence.  
5. TBI had no significant effect on number of microdontic teeth. 
6. In the SCT patients, microdontia was differently distributed within tooth types than that 
reported for genetic microdontia. The most frequently microdontic teeth were first 
premolars, which represented almost half of all microdontic teeth. Second premolars and 
second molars were also affected more often than were the maxillary lateral incisors that 
are mostly affected in genetic microdontia. 
7. Schedules of tooth mineralization were good guides in predicting the teeth at risk for 
microdontia during anticancer therapy.  
 
 
10. Combined tooth agenesis and microdontia 
10.1. Patients affected with tooth agenesis or microdontia or both 
Agenesis or microdontia or both affected 49% of the 55 SCT recipients when third molars 
were excluded from assessment. With third molars included (N = 32), 72% were affected. 
More than 90% of the patients in Group Y had tooth agenesis or microdontia or both, and 
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these two contributed almost equally to the prevalence. All patients ≤ 3 years at SCT were 
affected when third molars were included in assessment. In Group M, microdontia was more 
prevalent than tooth agenesis, and third molar agenesis increased injury prevalence to 78%. 
Without third molars, the Group O patients were less frequently affected than were the other 
groups. In this group, however, third molars raised injury prevalence from 13 to 53%, and 
the difference between groups M and O disappeared (Figure 12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Percentages of patients with tooth agenesis, microdontia, combined agenesis and 
microdontia (third molars excluded), and combined agenesis and microdontia of all teeth (third molars 
included) in age groups Y (≤ 3 years at SCT), M (3.1-5.0 years at SCT), and O (≥ 5.1 years at SCT). 
Omitting third molars, prevalence of tooth agenesis and microdontia in group O differed from groups 
Y and M (agenesis: Y vs. O: p < 0.001; M vs. O: p = 0.002 and microdontia: Y vs. O: p < 0.001; M vs. 
O: p = 0.003). Each group differed from the others when tooth agenesis and microdontia were 
combined (Y vs. M: p = 0.033; Y vs. O: p < 0.001; M vs. O: p = 0.003). With all teeth included, 
prevalence of combined agenesis and microdontia differed significantly only between groups Y and O 
(p = 0.026).  
 
10.2. Combined number of missing and microdontic teeth  
The mean number of missing or microdontic teeth or both, when third molars were excluded, 
decreased from the youngest to the oldest group. Group O differed from the others in all 
comparisons (Figure 13). With all teeth included, Group M had the highest mean number of 
missing or microdontic teeth or both (6.6, median 6.0). However, the clinical significance of 
the tooth injuries in Group Y may be more marked than in Group M, since the number of 
damaged teeth other than third molars was higher. Missing third molars diminish the length of 
the dental arch, which seldom causes severe harm, but injuries to the teeth, situated more 
anteriorly on the alveolar ridge, result in gaps that may compromise occlusion. In short, all 
children who are 5 years or less at the time of SCT are at risk for severe dental damage due to 
anticancer therapy.  
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Figure 13. Mean number of missing, microdontic, combined missing and microdontic teeth (third 
molars excluded), and combined mean number of all missing and microdontic teeth (third molars 
included) per patient in age groups Y (≤ 3 years at SCT), M (3.1-5.0 years at SCT), and O (≥ 5.1 years 
at SCT). Without third molars, the mean number of affected teeth in group O differed from the other 
groups in terms of agenesis (Y vs. O: p = 0.001; M vs. O: p = 0.038), microdontia (Y vs. O: p < 0.001; 
M vs. O: p = 0.005), and combined tooth agenesis and microdontia (Y vs. O: p < 0.001; M vs. O: p = 
0.004). With all teeth included, the combined mean number of damaged teeth was highest in Group M, 
although Group Y was almost equally affected. Group O differed from the others (Y vs. O: p = 0.001; 
M vs. O: p = 0.015).  
 
 
11. Root-crown ratios of permanent teeth (I, II, IV) 
11.1. Assessment method 
Developing a simple, objective, yet valid and reproducible method for assessing defects of 
dental root development was the reason for the studies of root-crown (R/C) ratio. The 
measurement method, adapted from an earlier one (Lind, 1972), was used in the three studies 
with R/C ratios assessed from PRGs. In panoramic radiography, different magnification 
factors apply to the horizontal and vertical dimensions outside the central plane of the layer, 
and between different regions of the same radiograph (McDavid et al., 1985; Welander et al., 
1989). The horizontal distortion is marked, but the the vertical magnification factor between 
the central plane of the layer and the planes displaced ±10 mm is less than ±5% (McDavid et 
al., 1985). Thus, the PRG method is considered acceptable for vertical measurements, which 
have been reproducible (Larheim et al., 1984; Carels et al., 1991; Thanyakarn et al., 1992a; 
Stramotas et al., 2000). We chose a method assessing R/C ratios instead of absolute linear 
measurements, because alterations in tooth angulation affect radiographic tooth length, but the 
change in the R/C ratio is negligible, because the root and the crown usually lie in almost the 
same vertical plane (Brook and Holt, 1978). In the present study, palatal roots were omitted 
due to their diverging inclination compared to that of the crown, which may result in 
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proportionately greater enlargement than that seen in buccal roots (Thanyakarn et al., 1992a). 
No further attention was paid to magnification factors, since use of the ratio eliminated their 
effect.  
 Assessment of R/C ratios is accurate and reproducible when the patients are correctly 
positioned (Stramotas et al., 2000). In the present study (II), reproducibility of the method was 
good in intra- (correlation 0.87, p < 0.001) and inter-examiner (correlation 0.83, p < 0.001) 
assessments. Furthermore, mean R/C ratios between the repeated measurements did not differ.  
 The error of the method is always present and consists of errors in the radiographic 
procedure and in the measurements by the observer(s). In Study II, the magnitude of the error 
of the method (em) in the intra- and inter-examiner R/C assessments varied among teeth from 
1.8% (intra and inter) for maxillary lateral incisors to 4.3% for mandibular first premolars 
(intra) and to 4.7% for mandibular second premolars (inter). Biological variances in R/C 
ratios always exceeded the error variances (em2) of the corresponding teeth. The mean em2 
percentage of biological variance was 13.2% in intra- and 18.9% in inter-examiner 
evaluations. The main source of the error has earlier been the difficulty in recognition of 
reference points (Larheim et al., 1984; Thanyakarn et al., 1992b). For the current studies, two 
very experienced radiographers had taken the PRGs, and patients were probably correctly 
positioned. Thus, the largest share of the em likely stems from observer performance, i.e., 
from difficulty in determining the intersection between the root and crown or, in some cases, 
in determining incisal or apical reference points. Changing of reference points would have 
had no advantage, since a similar difficulty in locating reference points was noted by 
investigators who used the cemento-enamel junction as the dividing line between crown and 
root (Mavragani et al., 2000; Sameshima and Asgarifar, 2001). 
 The PRG method has some limitations. Especially in the premolar region, a typical 
PRG-related problem is overlapping of teeth (Welander et al., 1989), which worsens the 
visibility of the reference points in the intersection of the crowns and the roots. The maxillary 
sinuses may also impair visibility. As a result, about 30% of the maxillary first premolars had 
to be excluded from the study. Another disadvantage, related to the method itself, is that only 
lengths (heights) of the roots and crowns are observed. This method leaves an anomaly 
unnoticed in teeth with thin but normal length roots. This disadvantage could be avoided 
with area measurements, which, however, make high demands on the PRGs: Horizontal 
measurements included in the area measurements are less reliable than vertical ones, except 
on the central plane of the layer (Rejebian, 1979; McDavid et al., 1985; Larheim and Svanaes, 
1986; Welander et al., 1989). This problem can in part be overcome with a ratio of root and 
crown areas, which reduces the effect of image distortion on the results. Ratios, no matter 
whether based on length or area measurements, do not reveal dental damage if crowns and 
roots are equally affected.  
 As long as no perfect method for R/C assessment is available, some limitations and 
methodologic errors must be accepted. On the grounds of our results, R/C ratios of permanent 
teeth can be assessed from panoramic radiographs with acceptable accuracy and 
reproducibility. The method can be utilized, in addition to study of the effects of childhood 
disease or its treatment on R/C ratio, also in describing the amount of root shortening in some 
syndromes, or in following the amount of root resorption in orthodontic patients.  
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11.2. Root-crown ratios of permanent teeth in healthy subjects (II) 
R/C data for the healthy Finnish population was planned to serve for comparison with various 
patient groups or individuals in study of root-crown aberrations. The R/C ratios of 
contralateral teeth were pooled in the results, since they did not differ significantly from each 
other. R/C ratios are given separately for maxillary and mandibular teeth both for males and 
females (Table 12). The highest mean R/C ratios were registered for the mandibular second 
premolars in both genders, closely followed by the mandibular first premolars. The lowest 
mean values were for central incisors. Ranking was the same for the corresponding maxillary 
teeth. R/C ratios were higher for the mandibular teeth than for the corresponding maxillary 
teeth. Some significant differences in R/C ratios appeared between males and females, but in 
most teeth these values were almost equal (Table 12). Our results suggest that, when studying 
developmental root deficiency, separate reference values for normal R/C ratios should be 
used for maxillary and mandibular teeth and even for males and females. 
 
Table 12. Mean root-crown (R/C) ratios with standard deviations (SD) and 95% confidence intervals (CI) for 
mature permanent teeth in males (M) (N = 53) and females (F) (N = 55). 
¤ 
Teeth N, M N, F 
Mean 
R/C, 
M 
Mean 
R/C, 
F 
SD, 
M 
SD, 
F 
95% CI,  
M 
95% CI, 
F 
Maxilla vs. 
mandible, 
M 
Maxilla vs. 
mandible,  
F 
M 
vs. 
F 
11, 21 105 106 1.86 1.78 0.17 0.16 1.82-1.89 1.75-1.81 ***  ** 
12, 22 102 105 2.04 1.97 0.21 0.18 2.01-2.09 1.93-2.00 NS  ** 
13, 23 103 102 2.10 2.10 0.22 0.21 2.06-2.15 2.06-2.14 ***  NS 
14, 24 78 68 2.16 2.15 0.22 0.22 2.11-2.21 2.10-2.20 ***  NS 
15, 25 88 92 2.19 2.21 0.22 0.25 2.14-2.24 2.15-2.26 ***  NS 
16, 26 101 92 1.87 1.80 0.15 0.15 1.84-1.90 1.76-1.83 ***  ** 
17, 27 105 100 1.99 1.94 0.17 0.18 1.96-2.02 1.90-1.97  NS  * 
            
31, 41 95 105 1.97 1.92 0.16 0.14 1.94-2.01 1.89-1.95  *** ** 
32, 42 102 107 2.05 2.02 0.17 0.16 2.01-2.08 1.99-2.05  * NS 
33, 43 92 101 2.22 2.23 0.23 0.20 2.17-2.27 2.19-2.27  *** NS 
34, 44 101 105 2.43 2.42 0.27 0.25 2.38-2.49 2.37-2.47  *** NS 
35, 45 99 105 2.44 2.46 0.26 0.24 2.39-2.49 2.41-2.51  *** NS 
36, 46 105 101 2.11 2.07 0.17 0.18 2.09-2.15 2.03-2.10  *** NS 
37, 47 106 108 2.01 1.98 0.18 0.19 1.97-2.04 1.94-2.01  NS NS 
 
¤ In tooth numbering, FDI (Fédération Dentaire Internationale) two-digit system (Keiser-Nielsen, 1971) is used 
*p ≤ 0.05; ** p ≤ 0.01; *** p ≤ 0.001; NS, p > 0.05 
 
 Earlier information on normal R/C ratios (also called relative root length or crown-
root index) was available but, due to the inconsistency in methods, comparison of the values 
was impossible. Materials and methods were seldom described in detail or the method was 
useless in a radiographic study, or both. For instance, extracted teeth were measured in some 
studies (Bjorndal et al., 1974; Verhoeven et al., 1979; Carlsen, 1987), and some reference 
points used, like vestibular cemento-enamel junction, may not be adequately recognizable on 
radiographs. Tooth measurements on different kinds of radiographs were performed in other 
studies, but all teeth were assessed in none of them (Lind, 1972; Jakobsson and Lind, 1973; 
Brook and Holt, 1978; Larheim et al., 1984; Carels et al., 1991; Thanyakarn et al., 1992a; 
Schalk-van der Weide et al., 1993; Midtbo and Halse, 1994). Thus, the results of the present 
study are not directly comparable to previous results, although some common tendencies are 
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noticeable. For instance, after excluding R/C ratios of molars that were seldom reported, all 
researchers found smallest R/C ratios (or crown-root index) to be for maxillary central 
incisors. The highest values were recorded for maxillary or mandibular second premolars 
(ratios calculated from the data of Bjorndal et al., 1974; Carlsen, 1987; Midtbo and Halse, 
1994).  
 
11.3. Root-crown ratios of permanent teeth in stem cell transplant recipients (I, IV) 
In the pioneer study (I) on NBL patients (Table 6, page 59), determination of the R/C ratios 
was based on the R/C value obtained from the maxillary central incisors (Lind, 1972). The 
same limit served in classification of all teeth (Section 7.4.1.). All 10 patients who received 
TBI as part of their preparative regimen for SCT had deviations in their R/C ratios. According 
to the three-grade classification of 10 patients, 7, 8, and 9 had mild, severe, or very severe 
aberrations in R/C ratios, respectively. Teeth were differently affected: the same patient had, 
for instance, mild disturbances in some teeth and very severe ones in others. In the TBI 
patients with NBL, 58% of the permanent teeth whose R/C ratios were assessed had 
deviations in the R/C ratios. The non-TBI patients were less affected on the severity scale: 
Mild R/C deviations appeared in 4 of 5 patients, and one of these patients also had severe 
alterations. No aberrations were very severe. The non-TBI patients were less affected also as 
regards percentage of deviant R/C ratios, which was 21%. 
 In the course of the pioneer study it appeared probable that tooth- and perhaps gender-
specific normal R/C ratios should be used in the comparison with the R/C values of SCT 
recipients. This idea served as a foundation for the second study on the R/C ratios of SCT 
recipients (IV). Instead of the severity classification used in Study I, SD-scores, expressing 
deviation from the reference values, were calculated for all teeth.  
 
11.3.1. Root-crown ratios at patient level (IV) 
Altered root development (examples in Figure 10, pages 71-72) occurred in all 52 pediatric 
SCT recipients studied, when R/C ratios outside ±2 SDSs were considered deviating. The 
mean number of affected teeth per patient was 13.9 (range 1-27) with a mean number of 18.2 
(range 1-28) teeth measured. Of 52 patients, 47 (90%) had R/C ratios deviating more than ±3 
SDSs. Some patients had been very young at PRG, and it might have been misleading if 
conclusions concerning these patients (at the patient level) had been based only on a few fully 
developed teeth that could be measured. Therefore, a subgroup of 39 SCT recipients with 
advanced tooth development (more than 50% of their teeth were fully developed) was studied 
separately. Setting the limit at ±2 SDS, 34 of 39 patients (72%) had at least half, and 8 of 39 
patients (21%) had all of their fully developed teeth affected. It is of note that these milder 
alterations of the R/C ratio were very common also in the non-TBI patients. For the 
percentage of affected R/C ratios (outside ±2 SDS) per individual, in reference to TBI and age 
at SCT see Figure 2 in the original publication IV (black and white triangles represent TBI 
and non-TBI patients, respectively).  
 Of these 39 patients, 25 (64%) had more than half of their R/C ratios deviating more 
than ±3 SDSs. TBI patients were more widely affected than non-TBI patients (p < 0.001) 
(Table 13). Using the same variable, the age groups Y, M, and O did not differ significantly, 
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although the R/C ratios in the patients ≤ 5 years at SCT tended to show greater damage. In 
each age group, more TBI than non-TBI patients had R/C ratios outside the ±3 SDS limits in 
more than half their teeth. TBI patients were also more affected when the R/C ratios outside 
±3 SDSs were studied by age group (Table 13). For the percentage of affected R/C ratios 
(outside ±3 SDS) per individual, in reference to TBI and age at SCT see Figure 14.  
 
Table 13. Subgroup of 39 stem cell transplant (SCT) recipients with advanced tooth development: Mean numbers 
of root-crown (R/C) ratios studied and teeth with disturbed R/C ratios in relation to limits of ±3 standard deviation 
scores (SDS). Number (percentage) of patients with more than half their teeth affected is given for different 
groups.  
Group Patients, N 
Mean number 
of R/C ratios 
measured / 
patient 
Mean number 
of R/C ratios 
outside ±3 
SDS / patient 
Significance 
> 50% of R/C 
ratios outside  
±3 SDS;  
N (%), patients  
Significance 
All 39 21.6 12.1  25 (64)  
TBI 29 20.9 14.1 24 (83) 
Non-TBI 10 23.7 6.3 p = 0.001 1 (10) p < 0.001 
       
Y) ≤ 3.0 yrs 11 19.6 10.5 8 (73) 
M) 3.1-5.0 yrs 12 20.2 15.2 10 (83) 
O) ≥ 5.1 yrs 16 24.1 10.9 
Differences 
between age 
groups: NS 7 (44) 
Differences 
between age 
groups: NS 
Y) TBI/non-TBI 8/3 18.1/23.3 13.6/2.0 p = 0.013 8/0 (100/0) p = 0.006 
M) TBI/non-TBI 9/3 19.4/22.3 16.1/12.3 p = 0.306 9/1 (100/33) p = 0.045 
O) TBI/non-TBI 12/4 23.8/25.0 12.9/5.0 p = 0.045 7/0 (58/0) p = 0.088 
Mann-Whitney U and chi-square (Fischers exact) tests for statistical analyses. 
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Figure 14. Percentage of teeth (of all fully developed teeth) with root-crown (R/C) ratios deviating 
more than ±3 standard deviation scores (SDS) in individual patients with advanced tooth development 
(N = 39), in reference to total body irradiation (TBI) and age at stem cell transplantation (SCT). 
According to ±3 SDS limits, 6 of 39 patients (15%) had all of their fully developed teeth affected. 
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11.3.2. Root-crown ratios at tooth level (IV) 
All 945 fully developed permanent teeth of 52 SCT recipients were included in the R/C ratio 
analysis (microdontic teeth and third molars excluded, Table 6, page 59). The mean SDS of 
all fully developed permanent teeth in SCT recipients was 3.4. In teeth exposed to HDC and 
TBI, the mean SDS deviated more than in teeth exposed to HDC only: Mean SDS of R/C 
ratios were 4.0−  and 1.8, respectively (p < 0.001) (Table 14).  
 Mean SDSs at the time of the examination were 3.1, 4.4, and 3.0 in the three age 
groups Y, M, and O, respectively. Group M differed significantly from the others (p < 0.001) 
(Table 14). Especially in the TBI patients were dental roots poorly developed. The difference 
in mean SDSs of R/C ratios between the TBI and non-TBI patients in all age groups was 
highly significant. Furthermore, inside the TBI and non-TBI groups, all age groups differed 
from each other (Table 14). The most seriously affected mean SDSs of R/C ratios were in the 
teeth of the patients who were 3.1 to 5.0 at SCT. The mildest changes were in the teeth of the 
oldest age group if TBI was given, but in the youngest age group if the preparative regimen 
prior to SCT was only HDC (non-TBI) (Table 14; Figure 15). Median SDSs of R/C ratios 
with upper and lower quartiles and minimum and maximum values are shown in Figure 15. 
 
Table 14. Mean standard deviation scores (SDS) of root-crown (R/C) ratios in 945 fully developed permanent 
teeth of 52 patients studied, divided into subgroups according to total body irradiation (TBI) and age at stem cell 
transplantation (SCT). Percentages of teeth with deviating R/C ratios (outside ±2 and ±3 SDSs) are also 
presented.  
Group (N, teeth) Mean SDS (SD)    
R/C outside 
±2 SDS / teeth 
studied (%) 
R/C outside 
±3 SDS / teeth 
studied (%) 
All (945) 3.4 (2.10)   
 77 56 
TBI (674) 4.0 (1.87)    85 68 
Non-TBI (271) 1.8 (1.83)   
 55 25 
TBI / non-TBI p < 0.001    p < 0.001 p < 0.001 
     
Mean SDS (SD) of R/C ratio Age at SCT  
(N, teeth) All TBI Non-TBI 
TBI / 
non-TBI 
R/C outside 
±2 SDS / teeth 
studied (%) 
R/C outside 
±3 SDS / teeth 
studied (%) 
Y) ≤ 3.0 yrs (226) 3.1 (2.69) 
4.3 
(1.81) 
0.3 
(2.14) p < 0.001 71 56 
Sig. Y/M p < 0.001 p = 0.012 p < 0.001  p < 0.001 p < 0.001 
M) 3.1-5.0 yrs (262) 4.4 (1.98) 
5.0 
(1.94) 
3.0 
(1.27) p < 0.001 91 73 
Sig. M/O p < 0.001 p < 0.001 p < 0.001  p < 0.001 p < 0.001 
O) ≥ 5.1 yrs (457) 3.0 (1.60) 
3.3 
(1.58) 
2.0 
(1.22) p < 0.001 72 46 
Sig. O/Y p = 0.180 p < 0.001 p < 0.001  p = 0.788 p = 0.023 
Mann-Whitney U Test was used for statistical analyses. 
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Figure 15. Median standard deviation score (SDS), upper and lower quartiles, and 
minimum/maximum values for root-crown (R/C) ratios of 945 permanent teeth in 52 stem cell 
transplant (SCT) recipients, in relation to age at SCT and total body irradiation (TBI). Each box 
represents interquartile range, containing 50% of the values. Line across box indicates median SDS of 
R/C ratio. Whiskers show highest and lowest SDS values, excluding outliers (circles). N is the number 
of teeth studied in subgroups. Mean values of R/C ratios and significances between groups are in 
Table 14. 
 
 In more than three-quarters (77%) of the teeth assessed, the R/C ratio fell outside the ±2 
SDSs limits, and in more than half (56%) of the teeth it deviated more than ±3 SDSs (Table 
14). Significantly more R/C ratios of permanent teeth in the TBI group than in the non-TBI 
group fell outside ±2 SDSs and ±3 SDSs limits (Table 14).  
 Teeth in the age groups Y and O were equally affected, if the percentage of teeth with 
R/C ratios out of ±2 SDS limits was considered, and were more affected in group Y with ±3 
SDS limits employed (p = 0.023). The highest percentages of R/C ratios outside the ±2 SDSs 
(91%) and ±3 SDSs (73%) appeared in Group M (Table 14). Subdividing the age groups 
further according to TBI revealed the highest percentage of the R/C ratios as outside ±2 SDSs, 
97%, in the teeth of the TBI patients who were 3.1 to 5.0 years at SCT. In each of the three 
age groups Y, M, and O, the number of R/C ratios, deviating more than ±2 SDSs or ±3 SDSs 
was significantly higher in the TBI than in non-TBI groups (p < 0.001) (Figure 16). 
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Figure 16. Percentages of root-crown (R/C) ratios outside ±2 SD- and ±3 SD scores (SDS) in 945 
permanent teeth of 52 stem cell transplant (SCT) recipients. Results are divided according to total 
body irradiation (TBI) and presented for the three age groups (Y: ≤ 3.0 years at SCT; M: 3.1-5.0 years 
at SCT; O: ≥ 5.1 years at SCT). In all comparisons, differences between TBI and non-TBI groups were 
significant (p < 0.001). 
 
11.4. Discussion of root-crown ratios and agreement with previous studies 
11.4.1. Theory and practice of root development  
Tooth development is governed via signal molecules repeatedly functioning throughout tooth 
morphogenesis (Section 1.3.; Figure 2). After crown development is complete, a double-
layered HERS directs root morphogenesis (reviewed by Ten Cate, 1996). Little is known of 
the molecular mechanisms of root development, for instance, how is root length determined, 
or what mechanism makes the apex close. Signaling occurs between epithelial and 
mesenchymal tissues, and mesenchyme probably directs the size, shape, and number of roots. 
Strong Dlx-2 expression in HERS appeared during formation of acellular cementum, 
indicating that Dlx-2 might be involved in the control of epithelial cell differentation in the 
root area, even if its specific role remained unclear (Lezot et al., 2000). Furthermore, after 
detecting Msx2 expression in the root sheath, it was suggested to be involved in root 
morphogenesis (Yamashiro et al., 2003). After all, even if root development probably shares 
signaling molecules and regulatory genes active in crown development, the two processes are 
not equal (Yamashiro et al., 2003). Molecular mechanisms of clinically evident disturbances 
of root development in human teeth following anticancer therapy are obscure. It is likely that 
chemotherapeutic agents, for instance, interfere with the basic mechanisms of root 
development involving epithelial-mesenchymal interactions. However, direct cell toxicity is 
another probable mechanism, at least when cells of HERS are subject to high doses of 
irradiation, CT or both. 
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 All the SCT recipients of the present study had alterations in the root development of 
their permanent teeth. TBI had a clear impairing effect on R/C ratios and on the number of 
injured teeth when compared to effects of treatment with HDC alone. This result differed 
from the radiation effects on tooth agenesis and microdontia, in which the TBI and non-TBI 
groups only occasionally differed from each other. There is no unequivocal answer why root 
development seems to be more vulnerable to TBI than are the initial phases of crown 
development. One possibility is that the molecular processesdiffering at least to some 
extent from those of crown developmentare more easily injured in the root area. Another, 
perhaps more probable explanation is that root development is a long process compared to the 
phases during which the presence or absence of a tooth or the crown size is determined. The 
possibility that TBI affects tooth agenesis or microdontia is diminished when the critical 
time window is narrow. In root development, the vulnerable period is very long, several 
years, as new cells differentiate along with root growth, and for all this time TBI is able to 
disturb root development. The clinical consequences were seen in practice: In all age groups, 
the TBI effect on R/C ratios was significant. Animal experiments (Section 5.1.1.) confirm the 
effect of irradiation (without toxic chemotherapy) on root development in several animal 
species (Burstone, 1950; Bruce, 1950b; Gowgiel, 1961; Donohue and Perreault, 1964). 
 CCT and conditioning therapy prior to SCT, i.e., HDC with or without TBI, were 
responsible for current study patients aberrant root development. When TBI was not included 
in the preparative regimen, fewer teeth were injured, and the damage was less severe. Still, in 
more than half the teeth of the non-TBI patients, R/C ratios deviated from ±2 SDSs. This 
indicates the ability of chemotherapeutic agents, which disturb tooth development in animals 
and in vitro studies (Section 5.1.2.), to disturb tooth development also in SCT recipients 
exposed to anticancer CT. This was a new finding, as in earlier studies on SCT patients 
almost all patients had received TBI, making the separate effect of CT on root development 
impossible to study (Dahllöf et al., 1988; Näsman et al., 1994; Näsman et al., 1997a; Duggal, 
2003). 
 Age at SCT was an important factor as regards consequences of treatment for dental 
roots. Root development begins, or is at its initial phases, between 3 and 5 years in several 
teeth, and if the most intensive treatment occurred at that period, the R/C ratios were severely 
compromised. If TBI preceded SCT at that age (Group M), root development was injured in 
practically all teeth (Figure 16). When environmental insults affect root development at its 
beginning, it remains disturbed ever since, and there seems a considerable possibility that 
these treatment-related disturbances may result in clinically meaningful consequences during 
years to come.  
 
11.4.2. Agreement with previous studies 
Deficient root development has been reported after CCT in several studies. The common 
problem in most of them is their subjective methods, not described at all or not in detail 
(Table 3, pages 49-52). The pioneering work found that 22% of patients had tooth 
abnormalities after CT, but microdontia was also included in this figure (Jaffe et al., 1984). 
Several other reports detected deficient root development in about 10 to 30 % of patients 
(Maguire et al., 1987; Nunn et al., 1991; Näsman et al., 1994, 1997a; Kaste et al., 1997, 
1998). Dental root development was disturbed in all ALL patients < 5 years at diagnosis, and 
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in all ALL patients (children) > 5 years at diagnosis and receiving CRI in addition to CCT 
(Sonis et al., 1990). That study used a rating scale to quantify developmental disturbances of 
teeth in different study groups, but rating criteria were subjective. High disturbance 
percentages (63-84%) were also reported by Rosenberg et al. (1987), who compared length of 
premolars to length of permanent first molars. In the present study, all SCT recipients in the 
non-TBI group had permanent teeth showing deviant R/C ratios. Our number of affected 
patients is higher than presented earlier, although the results of Sonis et al. (1990) were close 
to ours. HDC of the SCT recipients, in addition to CCT, likely led to an increased number of 
patients affected. Another probable explanation is that our objective measurement method 
recognized smaller alterations than did the earlier methods.  
 Dentitions of the SCT recipients were more severely damaged due to treatment than 
were dentitions following CCT. All patients with TBI, and 1 of 3 patients without TBI 
showed disturbances in root development (Dahllöf et al., 1988), and 94% and 95% of the SCT 
patients were affected in two other studies (Näsman et al., 1994, 1997a); these results are in 
good accordance with present results, with all the TBI patients affected. A surprisingly low 
prevalence, 33%, of root hypoplasia appeared in the group of 27 SCT patients (Uderzo et 
al., 1997). Composition of that study group may explain this low figure: some patients were 
old at treatment as regards root growth, and others were still young at the examination, with 
short follow-up periods. In the old patients, alterations of root development were probably 
not seen, as tooth development was (almost) finished by the time of the treatment and, in the 
young ones, root development was only in the beginning, and the results were not yet to be 
detected. 
 Young age at SCT is detrimental to root development (Dahllöf et al., 1988; Näsman et 
al., 1994, 1997a). It has been concluded that the younger the patient at SCT, the more 
detrimental the effects of anticancer therapy on root development (Näsman et al., 1997a). The 
present results do not support this view, because in our SCT group the worst disturbances of 
R/C ratios were in the patients aged 3.1 to 5.0 years at SCT, and patients < 3 years were less 
affected (Table 14; Figures 15 and 16). Several possible reasons exist for this dissimilarity. 
Different distributions of diagnoses in the previous and current studies must have resulted in 
different CCT protocols, with differing toxicity to teeth. The conditioning for SCT in part 
differed: the present study also included non-TBI patients, whereas all patients in the earlier 
report received TBI. This, however, did not explain the differing results concerning the most 
vulnerable age for root development. According to our study, the R/C ratios were always most 
severely affected in the 3.1 to 5-year-olds, no matter whether TBI was included in the 
preparative regimen (Table 14). In addition, direct comparison of results was difficult due to 
differing study methods: Previously, areas of mandibular teeth were measured to calculate 
crown-root ratios (Näsman et al., 1997a), whereas in the current study lengths (heights) of 
roots and crowns of all fully developed permanent teeth were measured for the assessment of 
the R/C ratios.  
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11.5. Conclusions on root-crown ratios 
Healthy population 
1. R/C ratios of the permanent mandibular teeth were larger than were the R/C ratios of the 
corresponding maxillary teeth. 
2. R/C ratios of the permanent central incisors, maxillary lateral incisors, and maxillary first 
and second molars were significantly larger in males than in females. 
 
SCT recipients 
1. Disturbances in root development were evident in all SCT patients.  
2. In 64% (83% of TBI patients and 10% of non-TBI patients) of the 39 SCT recipients with 
advanced tooth development (more than half of the teeth fully developed), the R/C ratios 
in more than 50% of the teeth studied deviated more than ±3 SDSs. 
3. In 21% of the patients, all R/C ratios fell outside ±2 SDSs. All had received TBI. 
4. In 85% of the teeth exposed to TBI, R/C ratios were outside ±2 SDSs. In the non-TBI 
teeth the percentage was 55%. 
5. The mean SDSs of R/C ratios were significantly lower (worse) in those SCT recipients 
whose preparatory regimen included TBI than in the non-TBI patients. 
6. The most seriously affected mean SDSs of R/C ratios were in the teeth of patients who 
were 3.1 to 5.0 years at SCT. 
7. The number of deviating R/C ratios was highest (97%) in teeth exposed to TBI at a patient 
age from 3.1 to 5.0 years. 
 
 
12. Defect Index (I) and Individual Defect Index (thesis) 
Defect Index (DeI) and Individual Defect Index (IDeI) combine tooth agenesis, microdontia, 
and disturbed dental root development into one figure expressing the whole magnitude of the 
damage to the dentition (for details, see Section 7.5.). No effort was made to exclude any 
possible genetic aberrations in tooth development; consequently, they are included in the 
index figures. The only difference between the two indices was in the classification of the R/C 
ratios (Section 7.5.). 
 
12.1. Defect scores calculated with Defect Index and Individual Defect Index 
DeI was created and used in a group of NBL patients (I) to determine overall dental damage. 
The mean DeI score for TBI patients was higher (70, SD 30.3, range 28-117) than for the non-
TBI patients (15.3, SD 9.3, range 4-34) (p < 0.001) when the third molars were included. The 
two groups significantly differed from the healthy test group (1.8, SD 3.9, range 0-15) (p < 
0.001). 
 DeI was tested in a group of 18 healthy adolescents with 464 assessable teeth (I). In 7 
subjects the defect score differed from zero, varying between 1 and 15, with third molars 
included. Without third molars, the DeI ranged from 1 to 8 in 5 subjects, while in 13 the score 
was zero. One individual had peg-shaped maxillary lateral incisors (8 defect points), and one 
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lacked a maxillary second premolar (5 defect points). Three other subjects each scored 1 
point, each of them having one R/C ratio considered mildly disturbed. When IDeI was tested 
in the same group of healthy adolescents, the same defect points 8 and 5 were recorded for the 
two subjects. All others scored zero, as the 3 teeth classified as with mild disturbance in DeI 
were also inside ±2 SDS in IDeI (values were 1.3, 1.8 and 1.7 SDSs). The low DeI and 
IDeI index scores showed that both indices, but especially IDeI, recognized R/C ratios in the 
dentitions tested to be normal. 
 DeI and IDeI were calculated for the group of 55 SCT recipients (third molars 
excluded). DeI gave significantly lower scores than did IDeI (means 30.5 vs. 43.5). This was 
according to expectations, because the classification of R/C ratios in IDeI was changed to a 
more accurate system in which the maximum number of defect points had risen from 3 to 4. 
The two indices arranged the scores of dental disturbancesin proportion to those of other 
patientssimilarly. This is illustrated in the group of 36 SCT recipients with advanced tooth 
development in Figure 17, where the IDeI line rises higher than the DeI line, but the lines rise 
and fall almost in parallel. 
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Figure 17. Comparison of defect scores assessed with Defect Index (DeI) and Individual Defect Index 
(IDeI) in 36 SCT recipients with advanced tooth development (≥ 20 fully developed teeth). Scores for 
tooth agenesis, microdontia, and R/C ratios of permanent teeth (third molars excluded) are combined 
in the indices. Theoretical maximum score is 140. 
 
 Some patients in the study group were so young that only a few teeth could be included 
in the indices, which in the future may markedly rise. For index scores that would be final or 
close to final at patient level, we separated out a subgroup of 36 patients in whom at minimum 
20 teeth of 28 were included in the index (Table 6, page 59). The results regarding IDeI, as 
presented in this thesis, are calculated for this group with advanced tooth development (Table 
15). IDeI scores for individual patients are shown in Table 8 (pages 69-70).  
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 The TBI patients had significantly higher mean IDeI score than did patients with HDC 
only. The highest mean IDeI score was for patients aged 3.1 to 5.0 years at SCT (Group M), 
but difference was not significant when compared to Group Y, also severely affected. In 
Group O, the dental late effects of anticancer therapy were significantly milder. The SCT 
recipients from 2.0 to 4.1 years at SCT most often presented with high IDeI scores (Figure 
18).  
 
Table 15. Mean Individual Defect Index (IDeI) scores and other key figures for the group of 36 stem cell 
transplant (SCT) recipients with advanced tooth development and for subgroups divided according to total body 
irradiation (TBI) and age at SCT (third molars excluded).  
Group Patients, N Mean IDeI score (median) Range of IDeI score  Significance 
All 36 55.1 (52.0) 3-117  
TBI 27 62.9 (59.0) 3-117 
Non-TBI 9 31.9 (29.0) 13-69 
TBI vs. non-TBI:  
p = 0.003 
     
Y) ≤ 3.0 yrs 11 62.3 (71.0) 17-103 Y vs. M: p = 0.387 
M) 3.1-5.0 yrs 10 75.8 (68.0) 43-117 M vs. O: p = 0.001 
O) ≥ 5.1 yrs 15 36.1 (29.0) 3-84 O vs. Y: p = 0.018 
Y) TBI/non-TBI 8/3 75.3 (74.0) / 27.7 (32.0) 40-103 / 17-34 p = 0.012 
M) TBI/non-TBI 8/2 80.8 (79.5) / 56.0 (56.0) 48-117 / 43-69 p = 0.400 
O) TBI/non-TBI 11/4 40.8 (41.0) / 23.8 (25.0) 3-84 / 13-29 p = 0.138 
 
 Composition of the IDeI score differed between age groups Y, M, and O. The agenesis 
score in Group Y was proportionally higher (35%) than in Group M (14%), and made no 
contribution to the IDeI score in Group O (Figure 19A). The microdontia score had its 
greatest proportion in Group M, and the R/C score was almost alone (96%) responsible for the 
IDeI score in Group O, when third molars were excluded. The worst absolute values for R/C 
ratio scores were recorded in those individuals 3.0 to 5.5 years at SCT. All IDeI components 
contributed almost equally in the TBI and non-TBI groups (Figure 19B). Proportions of the 
agenesis, microdontia, and R/C ratio scores were highly variable among individual patients, 
but the proportion of the R/C ratio score did increase with increasing age (Figure 20). Of the 3 
patients (cases 27-29 in Figure 20) with microdontia, 2 were transplanted for a recurrent 
disease. Considering their age at SCT, their microdontia was probably due to the earlier CCT. 
The remaining patient (case 28) had peg-shaped maxillary lateral incisors that could not be 
attributed to anticancer therapy.  
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Figure 18. Individual defect scores (third molars excluded) in 36 stem cell transplant patients, 
according to age at stem cell transplantation (SCT). Different symbols separate patients with and 
without total body irradiation (TBI and non-TBI). 
 
 
 
Figure 19. A.) Proportional contribution of agenesis, microdontia, and root-crown (R/C) ratio scores 
to total Individual Defect Index (IDeI) score in age groups Y (≤ 3.0 years at SCT; N = 11), M (3.1-5.0 
at SCT; N = 10), and O (≥ 5.1 years at SCT; N = 15), and B) in the total body irradiation (TBI; N = 
27) and non-TBI groups (N = 9).  
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Figure 20. The proportional contribution of agenesis, microdontia, and root-crown (R/C) ratio scores 
to the total Individual Defect Index (IDeI) score in the 36 stem cell transplant (SCT) recipients with 
advanced tooth development. Cases 1-11 belong to age group Y (≤ 3.0 years at SCT), 12-21 to age 
group M (3.1-5.0 at SCT), and 22-36 to age group O (≥ 5.1 years at SCT).  
 
12.2. Discussion of defect indices  
Defect points for the indices were subjectively selected, keeping in mind the clinical 
importance of the defect to the patient. There was no doubt about the highest score going to 
tooth agenesis. Microdontia was more difficult. In some cases teeth were very small, 
resembling grains; in other cases their appearance was normal and their size nearly half the 
normal. From the clinical point of view, microdontic teeth of differing sizes should have been 
classified by different scores to increase the clinical accuracy of the indices. However, a 
subjective method was used in microdontia assessment, and separation of different classes 
would have been unreliableas also would have been the measurement of horizontal 
distances in PRGs, which is not considered as reliable as measurement of the vertical 
distances (Rejebian, 1979; McDavid et al., 1985; Larheim and Svanaes, 1986; Welander et al., 
1989). Setting limits for the R/C ratio defect scores was also by clinical judgment. Although 
the classification based on SDSs (IDeI) was easy after the limits were set, no evidence exists 
that these limits, from the clinical point of view, are valid. This will be revealed only by long-
term follow-up.  
 Earlier, on a severity rating scale, the mean severity rating for developmental dental 
disturbances was calculated for groups of ALL patients with various treatment modalities 
(Sonis et al., 1990). That rating scale was based on the number of patients affected and thus 
did not identify the number of teeth affected or severity of disturbances at patient level. The 
scale separated patient groups, and the conclusion was that those groups in which patients 
were < 5 years at diagnosis and received CRI (18 or 24 Gy) had the highest scores in the 
severity rating scale. Although the methods differed, these main findings were confirmed in 
the present study, where irradiation (TBI) and young age at SCT (< 5 years) led to a higher 
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IDeI score (Table 15). Variables used in the severity rating scale (Sonis et al., 1990) and in 
the IDeI score were not identical. On the earlier study, anomalies in root number and the 
presence of enamel hypoplasiaediagnosed as notches on proximal tooth surfaceswere 
checked, whereas the current study ignored them. Scales used to assess root development also 
differed: subjective in the earlier vs. objective in the present study.  
 Defect indices that sum up the late effects of anticancer therapy in the dentition at 
patient level have not been used earlier. Although genetic developmental dental disturbances 
are included in the indices, these probably have a minor effect on ultimate index scores. This 
is assumed because the prevalences of tooth agenesis (8%), peg-shaped maxillary lateral 
incisors (1.3-2.3%) as representing the most common form of microdontia, and short root 
anomaly (1.3%) in a Finnish population are low (Haavikko, 1971; Alvesalo and Portin, 1969; 
Apajalahti et al., 2002) when compared to those of SCT recipients.  
 The current age group division (Y, M, O) was originally based on the schedule of tooth 
development. Calcification of permanent teeth, except the third molars, has usually begun at 3 
years (Logan and Kronfeldt, 1933; Schour and Massler, 1940). Accordingly, our assumption 
was that the proportion of the tooth agenesis score would be highest for patients ≤ 3.0 years at 
SCT. This held true, as shown in Figure 19A for 36 SCT patients with advanced tooth 
development. Occasionally tooth agenesis was also seen later: the maximum age in patients 
with tooth agenesis, excluding third molars, was 4.1 years at SCT and 3.6 years at diagnosis 
(Case 27 in Table 8, pages 69-70). At that age, missing maxillary lateral incisors cannot be 
related to treatment. Absence of a mandibular second premolar may also have had a genetic 
cause. Based on the present study, anticancer therapy initiated after the age 3.5 years was very 
unlikely to have resulted in tooth agenesis (except in third molars).  
 Between the ages of 3 and 5 years, root development starts in the early-developing 
teeth, and crown development is in process in the late-developing teeth. Treatment during this 
period was thought to result in disturbances in both root and crown (microdontia) 
development. Findings of the current study were not so clear-cut as regards microdontia, 
which contributed to the defect score almost equally in age groups Y and M (Figure 19A). If 
microdontia was present after the SCT age of 4.1 years, it could be explained by earlier CCT, 
or was considered genetic. It was concluded that if anticancer therapy was initiated after the 
age of 4, risk for microdontia would be minimal (except in third molars). The proportion of 
the R/C ratio score from Group Y to Group M increased, fulfilling our expectations. 
 In children > 5 years at SCT, we were waiting to see disturbed root development and 
agenesis or microdontia of the third molars. Based on the schedule of tooth development and 
earlier studies on children with cancer, we expected these children to be less affected than 
were younger SCT patients. Our results mainly confirmed our assumptions. The proportion of 
the R/C ratio score of the IDeI increased and was virtually alone responsible for the defect 
score (Figures 19, 20). In patients > 6 years at SCT and > 5 years at diagnosis, the highest 
defect points for the R/C ratio (= 4) were never reached. Usually second premolars, second 
molars, and in a few cases canines scored higher defect points than did the other teeth. 
Microdontia of the third molars was surprisingly infrequent, but agenesis, as expected, was 
common.  
 We had no preconceptions concerning the age at which risk for the most severe 
developmental dental aberrations, as to combined agenesis, microdontia, and R/C ratios, 
would be at its highest. We received no support from the earlier studies, which had not 
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applied individual defect scores. In the present novel result, the highest IDeI scores (= the 
most severe disturbances) appeared for patients aged 2 to 4 years at SCT (Figure 18).  
 
12.3. Conclusions on defect indices  
1. Defect indices enable comparison of the quantity of overall developmental dental defects 
between patient groups and between individuals. 
2. IDeI, in which defect scores of R/C ratios are based on the SDSs, is more objective than 
DeI and this is recommended for studies including R/C ratios. 
3. In all 55 SCT patients, the IDeI score differed from zero, meaning that all patients had 
some developmental dental disturbances. 
4. Individual variation in IDeI score was great (3-117) for the entire study group and for the 
subgroups.  
5. TBI patients had higher mean IDeI scores (62.9) than did non-TBI (HDC) patients (31.9). 
TBI caused the greatest increase in IDeI score in the children ≤ 3.0 years at SCT, when 
compared to non-TBI patients. 
6. Patients who were > 5 years old at SCT had significantly lower (better) mean IDeI scores 
(36.1) than did younger patients. Thus, young age (< 5 years) at SCT was a risk for high 
defect scores. 
7. At the age group level, the highest mean defect score (75.8) was recorded in children from 
3.1 to 5.0 years at SCT.  
8. At an individual level, the highest defect scores were in children aged 2.0 to 4.1 years at 
SCT. 
9. For the total IDeI score, proportions for tooth agenesis, microdontia, and R/C ratio scores 
varied among age groups.  
 
 
13. General notes 
The current studies were focused on the effects of HDC with or without TBI and of age at 
SCT on tooth agenesis, microdontia, and R/C ratios of permanent teeth. One could ask why 
these variables were selected, and if they were the best possible for studying disturbed tooth 
development. In earlier studies, irradiation and age at treatment have been important factors, 
and their selection was evident. Age at SCT was chosen, because the most intensive 
treatment, considered most toxic also to teeth, occurred then. Analysis of the results showed 
that for some children who had a lengthy period between their first anticancer CT and their 
recurrent disease, requiring SCT, age at diagnosis had explained some dental aberrations 
better than did age at SCT. In the whole patient group, however, age at diagnosis and age at 
SCT explained dental defects equally well. Impaired tooth development of our patients in the 
TBI groups separated them from patients in the non-TBI groups in several respects, so this 
variable also appeared a proper choice. 
 Many other dental and medical aspects were not reported. Hypomineralizations, 
manifesting themselves as enamel opacities or hypoplastic aberrations were excluded from the 
defect indices, although they were increased in some studies on children with anticancer 
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therapy (Pajari et al., 1988b; Näsman et al., 1994). Although these decalcifications may result 
from anticancer therapy, it would have been very difficult or impossible to make a distinction 
between etiologies of opaque lesions, as they are common also in healthy children. For 
instance, in Finland, 13 to 19% of children have demarcated hypomineralization lesions 
merely in their permanent first molars (Alaluusua et al., 1996; Hölttä et al., 2001; Leppäniemi 
et al., 2001). Fluorosis, causing hypomineralizations with a cloudy appearance, was not 
included in these figures. Furthermore, in children with a history of anticancer therapy, tooth 
decalcifications may result from compromised oral hygiene due to sensitivity or to ulcerations 
of the oral mucosa, and to the possible change in eating habits during cancer therapy.  
 In the six cases where RT (other than TBI) was delivered to the skull area, we ignored 
the scattered irradiation. In connection with CRI, it has been calculated to be 3 to 6% in 
various oral areas (Pajari et al., 1988a), which means that three patients may have received 
scattered irradiation doses from about 0.4 to 1.4 Gy to some parts of their mouth. When 
compared to the TBI doses of these patients (10-14 Gy), this minor increase was probably of 
little consequence to teeth. The three other irradiation fields (for local metastases) in the skull 
area were even further from the teeth, with hardly any scattered irradiation delivered to the 
dental area. Because deviations from the reference values for absorbed radiation doses occur 
in individual patients and in various intraoral sites during TBI (Bågesund et al., 1998), 
calculation of the exact patient- and site-specific radiation doses for teeth would have been 
impossible. Consequently, we considered it relevant to maintain the reference doses of TBI.  
 The effect of different diagnoses and the required CCT and HDC protocols on tooth 
development would have been an interesting topic for the study. This was not possible, 
however, because age variations in diagnostic groups were great and subgroups were small. 
Differences in toxicity profiles for chemotherapeutic agents have been obvious in animal 
studies (Section 5.1.2.), although no research from the dental point of view has been 
performed on some of them. It is probable that differences in the dental toxicity occur also in 
humans and may have clinical consequences. To confirm this hypothesis, study groups should 
be large enough and adjusted for age.  
 Several other medical variables received no attention in the present study. For instance, 
infections and other morbidity during cancer therapy, other treatment-related late effects like 
hormonal dysfunction, or GVHD in patients with allogeneic SCT were not recorded. Their 
role in tooth development is obscure. However, hair loss, destruction of sweat glands, and 
vertical ridges of nails have been described in GVHD (reviewed by Higman and Vogelsang, 
2004). This is interesting, since disturbances of these ectodermal organs and of teeth often 
occur together in ectodermal dysplasia syndromes (reviewed by Mikkola and Thesleff, 2003) 
(Section 2.1.1.). This may be a clue to GVHD effects on developing teeth, but no studies yet 
confirm or disprove this speculation. 
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14. Concluding remarks 
The current study was focused on developmental dental defects after anticancer therapy and 
SCT in children. A great part of the work was development of study methods, which included 
determination of the R/C ratios of permanent teeth in a healthy population, from their PRGs. 
We believe that the new methods, aiming at objectivity enabled us to notice dental aberrations 
with good accuracy. Our methods are also described in detail, which is the prerequisite for 
repeatability and, possibly, for multi-center studies. 
 
Based on the current study, the following conclusions can be presented: 
1. All SCT patients had developmental defects in their permanent teeth. 
2. Risk for developmental dental defects was highest in children < 5 years at SCT. 
3. TBI led to an increased overall quantity of developmental dental defects, but CT without 
TBI also caused aberrations in teeth of all SCT patients. 
4. Risk for tooth agenesis was very highperhaps 100%in patients ≤ 2.0 years at SCT. 
5. Anticancer therapy initiated after the age of 3.5 years was very unlikely to result in tooth 
agenesis, and no missing teeth, except third molars, were found in patients who were 4 
years or older at the start of CT and 5 years or older at SCT.  
6. If the anticancer therapy was initiated after the age of 4 years, risk for microdontia was 
minimal (except in the third molars).  
7. High defect points resulting from the R/C ratios were found at individual level between 
the SCT ages of about 3 to 5.5 years.  
8. The highest IDeI scores, expressing overall dental damage, were for patients who were 
approximately 2 to 4.5 years at SCT. However, individual variation did occur. 
 
 Our results provide new and detailed information that may help dental professionals in 
couseling children and their guardians after cancer therapy. The data can be utilized in the 
prediction of future developmental dental defects, and they are of aid when dental follow-up 
of the SCT patients is planned. It should be noted, however, that with the changing protocols 
of cancer therapy and the individual differences between the patients, the results obtained 
from one group of patients should not be indiscriminately generalized to others. 
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